Sialyltransferase for production of sialylated oligosaccharides

The newly identified sialic acid transfer enzyme to lactose is solved, and the problem of low production efficiency of sialic acid oligosaccharides in the prior art is achieved efficient and economical production of 3'SL and 3' KDO-lactose effect.

CN118922534APending Publication Date: 2024-11-08INBIOSE NV
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
CN202380029910.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-01-16
Filing Date
2023-03-30
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The prior art is difficult to efficiently and economically produce sialylated oligosaccharides, especially 3'sialylated oligosaccharides and 3'KDO-lactose, and the existing sialylic transferases have stereochemical control and specific bond formation during enzyme synthesis. The challenge.

Method used

Provides a newly identified sialic acid transferase that has alpha-2,3-sialic acid transferase activity against galactose residues of lactose and is similar to the existing amino acid sequence through a specific amino acid sequence for production in cells. 3'sialized oligosaccharides, including 3'SL and/or 3'KDO-lactose, and provide methods for purification of these oligosaccharides.

Benefits of technology

The efficient, time-saving and cost-effective production of 3’siallylated oligosaccharides, especially 3’SL and 3’KDO-lactose, improve yield and purification efficiency, and solve the challenges in the enzyme synthesis process.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005056959300001301
    Figure BDA0005056959300001301
  • Figure BDA0005056959300001311
    Figure BDA0005056959300001311
  • Figure BDA0005056959300001321
    Figure BDA0005056959300001321
Patent Text Reader

Abstract

The invention belongs to the technical field of synthetic biology, metabolic engineering and cell culture. The present invention relates to a newly identified sialyltransferase having an alpha-2, 3-sialyltransferase activity on a galactose residue of lactose. The invention also describes a method for producing a 3 '-sialylated oligosaccharide using any one of the newly identified sialyltransferases and the purification of the 3'-sialylated oligosaccharide The invention also provides a cell for producing the 3 '-sialylated oligosaccharide and the use of the cell in culture or incubation.
Need to check novelty before this filing date? Find Prior Art

Description

Field of the Invention

[0001] The present invention belongs to the technical field of synthetic biology, metabolic engineering and cell culture. The present invention relates to newly identified sialyltransferases, which have α-2,3-sialyltransferase activity on galactose residues of lactose. The present invention also describes a method for producing 3' sialylated oligosaccharides using any of the newly identified sialyltransferases and the purification of the 3' sialylated oligosaccharides. The present invention also provides cells for producing the 3' sialylated oligosaccharides and the use of the cells in culture or incubation. Background Art

[0002] More than 150 structurally distinct human milk oligosaccharides (HMOs) have been identified to date. Although HMOs represent only a small fraction of the total nutritional composition of human milk, the beneficial effects of HMOs on the development of breastfed infants have become apparent over the past few decades.

[0003] Among HMOs, sialylated HMOs (SHMOs) were observed to support several beneficial effects as described in the art. Among the sialylated oligosaccharides in human milk, 3' sialyllactose, 6' sialyllactose, sialyllactose-N-tetraose a, sialyllactose-N-tetraose b, sialyllactose-N-tetraose c and disialyllactose-N-tetraose are the most prevalent members.

[0004] Sialyl oligosaccharides are found to be complex structures and their chemical or (chemo)enzymatic synthesis has proven to be challenging: there are numerous difficulties such as control of stereochemistry, formation of specific linkages, availability of starting materials, etc. Therefore, alternative production methods have been developed, where efforts have been made in the metabolic engineering of microorganisms to produce sialylated oligosaccharides.

[0005] Several sialyltransferases have been identified and characterized to date, from bacterial species (e.g., from Neisseria, Campylobacter, Pasteurella, Helicobacter, and Photobacterium), as well as from mammals and viruses. Sialyltransferases are generally classified into six glycosyltransferase (GT) families based on protein sequence similarity. Sialyltransferases are distinguished by the glycosidic bonds they form, such as sialyltransferases that form α-2,3-, α-2,6-, and α-2,8-bonds. All of these sialyltransferases transfer sialic acid residues from cytidine 5'-monophosphosialic acid (e.g., CMP-NeuNAc) to various acceptor molecules, which are typically galactose (Gal) moieties, N-acetylgalactosamine (GalNAc) moieties, or N-acetylglucosamine (GlcNAc) moieties, or another sialic acid (Sia) moiety. Several bacterial α-2,3-sialyltransferases have been well characterized in the past and have been shown to be suitable for the production of 3' sialyllactose (6'SL). The most commonly used enzyme for microbial 3'SL production is the β-galactoside α-2,3-sialyltransferase from Pasteurella multocida.

[0006] describe SUMMARY OF THE INVENTION

[0008] It is an object of the present invention to provide tools and methods by which sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' sialyllactose (3' SL, Neu5Ac-α2,3-Gal-β1,4-Glc) and / or 3' KDO-lactose can be produced, preferably in an efficient, time-saving and cost-effective manner, and which produce large amounts of the desired oligosaccharides.

[0009] According to the present invention, this object and other objects are achieved by providing newly identified sialyltransferases as described herein, each of which can be used in a method for producing sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL and / or 3' KDO-lactose. In addition, any of the newly identified sialyltransferases can be used in a cell to produce sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL and / or 3' KDO-lactose.

[0010] More specifically, the present invention provides a newly identified sialyltransferase which has α-2,3-sialyltransferase activity towards galactose (Gal) residues of lactose (Gal-β1,4-Glc), and comprises an amino acid sequence that is at least 67.0% identical to any one of the amino acid sequences shown in SEQ ID NO 05, 01, 02, 03, 06, 07 or 08 over a segment of at least 150 amino acid residues, preferably at least 200 amino acid residues, or an amino acid sequence that is at least 85.0% identical to the amino acid sequence shown in SEQ ID NO 04 over a segment of at least 150 amino acid residues, preferably at least 200 amino acid residues, or an amino acid sequence that is at least 60.0% identical to the amino acid sequence shown in SEQ ID NO 12 over a segment of at least 150 amino acid residues, preferably at least 200 amino acid residues. Even more specifically, the present invention provides a newly identified sialyltransferase having α-2,3-sialyltransferase activity towards a galactose (Gal) residue of lactose (Gal-β1,4-Glc) and comprising an amino acid sequence that is at least 80.0% identical to any one of the full-length amino acid sequences shown in SEQ ID NO 05, 04, 12, 01, 02, 03, 06, 07 or 08.

[0011] The present invention also provides methods and cells for producing sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL and / or 3' KDO-lactose. The present invention also provides methods for purifying the sialylated oligosaccharides (preferably 3' sialylated oligosaccharides, more preferably 3' SL and / or 3' KDO-lactose). In addition, the present invention provides a cell that is metabolically engineered with any of the newly identified sialyltransferases described herein and that comprises a pathway for producing the sialylated oligosaccharides (preferably 3' sialylated oligosaccharides, more preferably 3' SL and / or 3' KDO-lactose).

[0012] definition

[0013] The words used in this specification to describe the present invention and its various embodiments should be understood not only in their generally defined meanings, but also include structures, materials or functions specifically defined in this specification beyond the generally defined meanings. Therefore, if an element can be understood to include more than one meaning in the context of this specification, its use in the claims must be understood as general to all possible meanings supported by this specification and the word itself.

[0014] The various aspects and embodiments of the present invention disclosed herein should not only be understood in the order and context specifically described in this specification, but also include any order thereof and any combination thereof. Unless otherwise indicated, each embodiment identified herein may be combined together. All publications, patents and patent applications mentioned in this specification are incorporated herein by reference to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference as a whole.

[0015] As long as the context requires, unless otherwise expressly stated, all words used in the singular will be considered to include the plural form, and vice versa. Unless otherwise specified, all technical and scientific terms used herein generally have the same meaning as those commonly understood by technicians in the technical field to which the present invention belongs. In general, the nomenclature used herein and the experimental procedures in cell culture, molecular genetics, organic chemistry and nucleic acid chemistry and hybridization described herein are those well known and commonly used in the art. Nucleic acid and peptide synthesis are performed using standard techniques. In general, enzyme reactions and purification steps are performed according to manufacturer specifications.

[0016] In this specification, embodiments of the present invention have been disclosed, and although specific terms are employed, the terms are used in a descriptive sense only and not for the purpose of limiting the scope of the invention, which is set forth in the following claims. It must be understood that the illustrated embodiments are set forth for illustrative purposes only and should not be considered to limit the invention. It will be apparent to those skilled in the art that changes, other embodiments, improvements, details, and uses may be made consistent with the letter and spirit of the present disclosure and within the scope of the present disclosure, which is limited only by the claims, which are interpreted in accordance with patent law, including the doctrine of equivalents. In the following claims, reference numerals used to designate claim steps are provided for ease of description only, and are not intended to imply any particular order in which the steps are performed, unless otherwise specifically stated.

[0017] Throughout the application, unless otherwise expressly stated, the features “synthesize”, “synthesized” and “synthesis” are used interchangeably with the features “produce”, “produced” and “production”, respectively. Throughout the application, unless otherwise expressly stated, the expression “capable of… <verb>) and "capable to… <verb>)" is preferably replaced by the active voice of the verb, and vice versa. For example, the expression "can express" is preferably replaced by "express", and vice versa, that is, "express" is preferably replaced by "can express". In this document and its claims, the verbs "include", "have" and "comprise" and their variations are used in their non-limiting sense, meaning that the items following the word are included, but items not specifically mentioned are not excluded. Throughout the application, the verb "include" can be replaced by "consist of..." or "consist of essentially...", and vice versa. In addition, the verb "consist of..." can be replaced by "consist of essentially...", which means that the verbs defined herein are The composition may contain additional components in addition to the specifically identified components, which additional components do not change the unique characteristics of the present invention. In this document and its claims, unless otherwise expressly stated, the verbs "comprise", "have" and "include" and their variations may be replaced by "consisting of" (and variations thereof) or "consisting essentially of" (and variations thereof), and vice versa. In addition, referring to an element by the indefinite article "a" or "an" does not exclude the possibility that more than one element is present, unless the context clearly requires that there is and only one element. Therefore, the indefinite article "a" or "an" generally means "at least one".

[0018] Throughout the application, unless otherwise expressly stated, the articles "a" and "an" are preferably replaced by "at least two / kinds", more preferably by "at least three / kinds", even more preferably by "at least four / kinds", even more preferably by "at least 5 / kinds", even more preferably by "at least 6 / kinds", and most preferably by "at least two / kinds". When used in conjunction with a numerical value (e.g., "about 10") or a range (e.g., "about x to about y"), the word "about" or "approximately" preferably indicates that the value or range is interpreted as being as accurate as the method used for measurement. If no error range is specified, the expression "about" or "approximately" is interpreted as having the same rounding as the given value when used in association with a numerical value. In this document and the claims thereof, unless otherwise stated, the expression "from x to y" (wherein x and y represent numerical values) refers to a numerical range, where x is the lower limit of the range and y is the upper limit of the range. Here, x and y are also included in the range.

[0019] According to the present invention, the term "polynucleotide" generally refers to any polyribonucleotide or polydeoxyribonucleotide that can be unmodified RNA or DNA or modified RNA or DNA. "Polynucleotide" includes but is not limited to single-stranded and double-stranded DNA; DNA that is a mixture of single-stranded and double-stranded regions or single-stranded, double-stranded and triple-stranded regions; single-stranded and double-stranded RNA; and RNA that is a mixture of single-stranded and double-stranded regions; hybrid molecules containing DNA and RNA that can be single-stranded or more usually double-stranded or triple-stranded regions, or a mixture of single-stranded and double-stranded regions. In addition, as used herein, "polynucleotide" refers to a triple-stranded region containing RNA or DNA or both RNA and DNA. The chains in such regions can come from the same molecule or from different molecules. The region can include all of one or more molecules, but more usually only involves regions of some molecules. One of the molecules in the triple helix region is generally an oligonucleotide. As used herein, the term "polynucleotide" also includes DNA or RNA as described above containing one or more modified bases. Therefore, DNA or RNA whose main chain is modified for stability or other reasons is a "polynucleotide" according to the present invention. In addition, DNA or RNA containing unusual bases (e.g., inosine) or modified bases (e.g., tritylated bases) are understood to be covered by the term "polynucleotide". It should be understood that a variety of modifications have been made to DNA and RNA for many applicable purposes known to those skilled in the art. The term "polynucleotide" as used herein encompasses such chemical, enzymatic or metabolically modified forms of polynucleotides, as well as viruses and cells, including chemical forms of DNA and RNA characteristic of, for example, simple and complex cells. The term "polynucleotide" also encompasses short polynucleotides commonly referred to as oligonucleotides.

[0020] "Polypeptide" refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds. "Polypeptide" refers to both short chains (commonly referred to as peptides, oligopeptides and oligomers) and long chains (commonly referred to as proteins). Polypeptides may contain amino acids other than the 20 gene-encoded amino acids. "Polypeptides" include polypeptides modified by natural processes (such as processing and other post-translational modifications) and by chemical modification techniques. Such modifications are fully described in basic textbooks and more detailed monographs as well as in a large number of research documents and are well known to those skilled in the art. The same type of modification may exist in the same or varying degrees at several sites in a given polypeptide. In addition, a given polypeptide may contain multiple types of modifications. Modifications may occur at any position in the polypeptide, including the peptide backbone, amino acid side chains, and the amino or carboxyl termini. Modifications include, for example, acetylation, acylation, ADP ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of pyroglutamic acid, formylation, γ-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, lipid attachment, sulfation, γ-carboxylation of glutamic acid residues, hydroxylation and ADP ribosylation, selenization, transfer RNA-mediated addition of amino acids to proteins, such as arginine acylation, and ubiquitination. Polypeptides can be branched, or cyclic, with or without branches. Circular, branched, and branched cyclic polypeptides can be produced by natural processes after translation, and can also be prepared by complete synthetic methods.

[0021] As used herein, the term "polynucleotide encoding a polypeptide" encompasses a polynucleotide comprising a sequence encoding a polypeptide of the present invention. The term also encompasses a single continuous region or discontinuous regions (e.g., interrupted by integrated phage or insertion sequences or editing) encoding a polypeptide as well as polynucleotides having additional regions that may also contain coding and / or non-coding sequences.

[0022] "Isolated" means altered "by the hand of man" from its natural state, i.e., if it occurs in nature, it is altered or removed from its original environment, or both. For example, a polynucleotide or polypeptide naturally present in a living organism is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated," as the term is used herein. Similarly, the term "synthetic" sequence as used herein means any sequence that has been produced synthetically and is not directly isolated from a natural source. The term "synthetic" as used herein means any sequence that is produced synthetically and is not directly isolated from a natural source.

[0023] "Recombinant" refers to genetically engineered DNA made by transplanting or splicing a gene from one species into the cells of a host organism of a different species. This DNA becomes part of the host's genetic makeup and is replicated.

[0024] As used herein, the terms "recombinant" or "transgenic" or "metabolic engineered" or "genetically engineered" with respect to cells or host cells are used interchangeably and indicate that the cell replicates a heterologous nucleic acid, or expresses a peptide or protein encoded by a heterologous nucleic acid (i.e., a sequence that is "foreign to the cell" or a sequence that is "foreign to the location or environment in the cell"). Such cells are described as transformed with at least one heterologous or exogenous gene, or as transformed by the introduction of at least one heterologous or exogenous gene. Recombinant or metabolically engineered or genetically engineered or transgenic cells may contain genes that are not found in the native (non-recombinant) form of the cell. Recombinant cells may also contain genes found in the native form of the cell, wherein the genes have been modified and reintroduced into the cell by artificial means. The term also encompasses cells containing nucleic acids endogenous to the cell, which have been modified or whose expression or activity has been modified, but the nucleic acid has not been removed from the cell; these modifications include modifications obtained by gene replacement, promoter replacement; site-specific mutations; CrispR; riboswitches; recombineering; ssDNA mutagenesis; transposon mutagenesis and related techniques known to those skilled in the art. Thus, a "recombinant polypeptide" is a polypeptide produced by a recombinant cell. The term also encompasses cells modified by removing endogenous nucleic acids of the cell by common techniques well known to the skilled artisan (eg, knocking out a gene).

[0025] As used herein, a "heterologous sequence" or "heterologous nucleic acid" is a sequence derived from a source that is foreign to a particular cell (e.g., from a different species), or, if from the same source, modified from its original form or position in the genome. Thus, a heterologous nucleic acid operably linked to a promoter is derived from a source different from that of the promoter, or, if from the same source, modified from its original form or position in the genome. A heterologous sequence can be stably introduced into the genome of a host microbial cell, for example, by transfection, transformation, conjugation, or transduction, wherein techniques depending on the cell and the sequence to be introduced can be applied. Various techniques are known to those skilled in the art and are disclosed, for example, in Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989). The term "mutated" or "engineered" cell or microorganism used in the context of the present invention refers to a genetically engineered cell or microorganism.

[0026] Within the context of the present disclosure, the term "endogenous" refers to any polynucleotide, polypeptide or protein sequence that is a natural part of a cell and is present at its natural location in the cell's chromosomes and the control of expression has not been altered compared to the natural control mechanisms that act on its expression. The term "exogenous" refers to any polynucleotide, polypeptide or protein sequence that originates from outside the cell in question and is not derived from a natural part of the cell or is not present at its natural location in the cell's chromosomes or plastids.

[0027] When referring to polynucleotide, gene, nucleic acid, polypeptide or enzyme use, term " heterologous " refers to the polynucleotide, gene, nucleic acid, polypeptide or enzyme from the source outside the host organism species or derived from the source outside the host organism species.On the contrary, " homologous " polynucleotide, gene, nucleic acid, polypeptide or enzyme used herein represent the polynucleotide, gene, nucleic acid, polypeptide or enzyme derived from the host organism species.When referring to gene regulatory sequence or auxiliary nucleic acid sequence (such as promoter, 5 ' untranslated region, 3 ' untranslated region, poly A addition sequence, intron sequence, splice site, ribosome binding site, internal ribosome entry sequence, genome homology region, recombination site etc.) for maintaining or manipulating gene sequence, " heterologous " means that regulatory sequence or auxiliary sequence are not naturally related to the gene juxtaposed in construct, genome, chromosome or episome with regulatory or auxiliary nucleic acid sequence. Thus, a promoter that is operably linked to a gene to which it is not operably linked in nature (i.e., in the genome of a non-genetically engineered organism) is referred to herein as a "heterologous promoter," even though the promoter may be derived from the same species (or in some cases, the same organism) as the gene to which it is linked.

[0028] The term "modified expression" of a gene refers to the expression change compared to the wild-type expression of the gene at any stage of the production process of the desired 3' sialylated oligosaccharide. The modified expression is a lower or higher expression compared to the wild type, wherein the term "higher expression" is also defined as "overexpression" of the gene in the case of an endogenous gene, or "expression" in the case of a heterologous gene not present in a wild-type strain. Lower expression is obtained by means of common well-known techniques of those skilled in the art (e.g., using siRNA, CrispR, CrispRi, riboswitches, recombineering, homologous recombination, ssDNA mutation induction, RNAi, miRNA, asRNA, mutant genes, knockout genes, transposon mutagenesis, etc.), which are used to change genes in a way that the gene produces a functional final product less-able (i.e., statistically significant "weakened ability" compared to a functional wild-type gene) or cannot produce a functional final product (e.g., knockout genes) at all. As used herein, the term "riboswitch" is defined as a portion of a messenger RNA that folds into an intricate structure that blocks expression by interfering with translation. The binding of the effector molecule induces a conformational change, allowing post-transcriptional regulated expression. In addition to altering the gene of interest in a manner to obtain lower expression as described above, lower expression can also be obtained by altering the transcription unit, promoter, untranslated region, ribosome binding site, Shine Dalgarno sequence or transcription terminator. Lower expression or reduced expression can be obtained, for example, by mutating one or more base pairs in the promoter sequence or completely changing the promoter sequence to a constitutive promoter with lower expression intensity compared to the wild type, or an inducible promoter that results in regulated expression, or a repressible promoter that results in regulated expression. Overexpression or expression is obtained by means of common well-known techniques of those skilled in the art (e.g., use of artificial transcription factors, de novo design of promoter sequences, ribosome engineering, introduction or reintroduction of expression modules at euchromatin, use of high copy number plasmids), wherein the gene is part of an "expression cassette", which refers to any sequence in which there are promoter sequences, untranslated region sequences (containing ribosome binding sequences, Shine Dalgarno or Kozak sequences), coding sequences (e.g., sialyltransferase gene sequences), and optionally transcription terminators, and results in expression of a functionally active protein. The expression is constitutive, conditional, regulated or adjustable.

[0029] The term "constitutive expression" is defined as expression that is not regulated by transcription factors other than subunits of RNA polymerase (e.g., bacterial sigma factors, such as s70, s54 or related s factors and yeast mitochondrial RNA polymerase specific factor MTF1, which are co-associated with the RNA polymerase core enzyme) under certain growth conditions. Non-limiting examples of such transcription factors are CRP, LacI, ArcA, Cra, IclR in Escherichia coli (E. coli), or Aft2p, Crz1p, Skn7 in Saccharomyces cerevisiae, or DeoR, GntR, Fur in Bacillus subtilis (B. subtilis). These transcription factors bind to specific sequences and can block or enhance expression under certain growth conditions. RNA polymerase is a catalytic mechanism for synthesizing RNA from a DNA template. RNA polymerase binds to a specific DNA sequence to initiate transcription, for example, via a sigma factor in a prokaryotic host or via MTF1 in yeast. Constitutive expression provides a constant expression level without the need for induction or inhibition.

[0030] The term "regulated expression" is defined as expression regulated under certain growth conditions by transcription factors other than RNA polymerase subunits (e.g., bacterial sigma factors). Examples of such transcription factors are described above. Common expression regulation is achieved by means of inducers, such as, but not limited to, IPTG, arabinose, rhamnose, fucose, allolactose, or pH changes, or temperature changes, or carbon consumption, or substrate or product produced.

[0031] The term "control sequence" refers to a sequence recognized by the cell transcription and translation system, allowing the polynucleotide sequence to be transcribed and translated into a polypeptide. Therefore, such DNA sequences are required for expressing an operably connected coding sequence in a specific host cell, cell or organism. Such control sequences can be, but are not limited to, promoter sequences, ribosome binding sequences, ShineDalgarno sequences, Kozak sequences, transcription terminator sequences. Control sequences suitable for prokaryotes include, for example, promoters, optionally operator sequences and ribosome binding sites. It is known that eukaryotic cells utilize promoters, polyadenylation signals and enhancers. If the DNA of the presequence or secretory leader sequence is expressed as a preprotein that participates in the secretion of the polypeptide, it can be operably connected to the DNA of the polypeptide; if the promoter or enhancer affects the transcription of the coding sequence, it is operably connected to the sequence; or if the ribosome binding site affects the transcription of the coding sequence, it is operably connected to the sequence; or if the ribosome binding site is positioned to promote translation, it is operably connected to the coding sequence. The control sequences may additionally be controlled by external chemicals such as, but not limited to, IPTG, arabinose, lactose, allolactose, rhamnose or fucose via inducible promoters or via genetic circuits that induce or repress transcription or translation of the polynucleotide into a polypeptide.

[0032] Generally, "operably linked" means that the DNA sequences being linked are contiguous and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers need not be contiguous.

[0033] The term "wild type" refers to the generally known genetic or phenotypic condition as it occurs in nature.

[0034] As used herein, the term "modified expression of a protein" refers to i) higher expression or overexpression of an endogenous protein, ii) expression of a heterologous protein, or iii) expression and / or overexpression of a variant protein having higher activity compared to a wild-type (i.e., native in the expression host) protein, iv) reduced expression of an endogenous protein, or v) expression and / or overexpression of a variant protein having reduced activity compared to a wild-type (i.e., native in the expression host) protein. Preferably, the term "modified expression of a protein" as used herein refers to i) higher expression or overexpression of an endogenous protein, ii) expression of a heterologous protein, or iii) expression and / or overexpression of a variant protein having higher activity compared to a wild-type (i.e., native in the expression host) protein.

[0035] The term "altered activity" of a protein relates to a non-native activity of the protein at any stage of the production process of the desired 3' sialylated oligosaccharide. The term "non-native" with respect to the activity of a protein as used herein means that the protein has been modified to have an eliminated, impaired, reduced, delayed, higher, accelerated or improved activity compared to the native activity of the protein. The altered activity of a protein is obtained by altering the expression of the protein, or by the expression of an altered, i.e., mutant form of the protein. The mutant form of a protein can be obtained by expressing a mutant form of a gene encoding the protein (e.g., comprising a deletion, insertion and / or mutation of one or more nucleotides compared to the native gene sequence). The mutant form of a gene can be obtained by techniques well known to those skilled in the art, such as, but not limited to, site-specific mutations; CrispR; riboswitches; recombineering; single-stranded DNA mutagenesis; transposon mutagenesis.

[0036] The term "non-naturally occurring" as used herein in reference to cells that produce 3' sialylated oligosaccharides means that the 3' sialylated oligosaccharides i) are not produced naturally, or ii) are not produced by the cell in the same amount as when produced naturally; and the cell has been genetically engineered to produce said 3' sialylated oligosaccharides or to have a higher yield of said 3' sialylated oligosaccharides.

[0037] As used herein, the term "breast cell" refers generally to mammalian mammary epithelial cells, mammalian mammary epithelial luminal cells or mammalian epithelial alveolar cells or any combination thereof. As used herein, the term "breast cell-like" refers generally to mammalian cells with a phenotype / genotype similar to (or substantially similar to) natural mammalian mammary cells but derived from mammalian non-breast cell sources. Such mammalian mammary cells can be engineered to remove at least one non-required genetic component and / or include at least one mammalian mammary cell typical predetermined genetic construct. Non-limiting examples of mammalian mammary cells may include mammalian mammary epithelial cells, mammalian mammary epithelial luminal cells, mammalian non-breast cells or any combination thereof that exhibit one or more characteristics of cells of mammalian mammary cell lineages. Further non-limiting examples of mammalian mammary cells may include mammalian cells with a phenotype similar to (or substantially similar to) natural mammalian mammary cells, or more specifically mammalian cells similar to (or substantially similar to) the phenotype of natural mammalian mammary epithelial cells. A mammalian cell having a phenotype similar to (or substantially similar to) a native mammalian mammary cell or a mammalian mammary epithelial cell, or exhibiting at least one characteristic similar to (or substantially similar to) a native mammalian mammary cell or a mammalian mammary epithelial cell may include a mammalian cell (e.g., derived from a mammary cell lineage or a non-mammary cell lineage) that naturally or is engineered to be able to express at least one milk component.

[0038] As used herein, the term "non-mammary cell" can generally include any mammalian cell of a non-mammary lineage. In the context of the present invention, a non-mammary cell can be any mammalian cell that can be engineered to express at least one milk component. Non-limiting examples of such non-mammary cells include hepatocytes, blood cells, kidney cells, umbilical cord blood cells, epithelial cells, epidermal cells, muscle cells, fibroblasts, mesenchymal cells, or any combination thereof. In some cases, molecular biology and genome editing techniques can be engineered to eliminate, silence, or attenuate numerous genes simultaneously.

[0039] As used herein, the term "variant" is a polynucleotide or polypeptide that is different from a reference polynucleotide or polypeptide, respectively, but maintains basic properties. A typical variant of a polynucleotide is different from another reference polynucleotide in terms of nucleotide sequence. Changes in the nucleotide sequence of a variant may or may not change the amino acid sequence of a polypeptide encoded by a reference polynucleotide. As discussed below, nucleotide changes may cause amino acid substitutions, additions, deletions, fusions, and truncations in a polypeptide encoded by a reference sequence. A typical variant of a polypeptide is different from another reference polypeptide in terms of amino acid sequence. Typically, the difference is limited, so that the sequence of the reference polypeptide is generally very similar to the sequence of the variant and is identical in many regions. A variant may differ from a reference polypeptide in terms of amino acid sequence by one or more substitutions, additions, deletions in any combination. The amino acid residues substituted or inserted may or may not be residues encoded by a genetic code. A variant of a polynucleotide or polypeptide may be naturally occurring, such as an allelic variant, or it may be a variant not known to be naturally occurring. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques, by direct synthesis, and by other recombinant methods known to those skilled in the art.

[0040] In some embodiments, the present invention contemplates preparing functional variants by modifying the structure of enzymes as used in the present invention. Variants can be produced by amino acid substitution, deletion, addition or a combination thereof. For example, it can be reasonably expected that independent replacement of leucine with isoleucine or valine, independent replacement of aspartic acid with glutamic acid, independent replacement of threonine with serine or similar replacement of amino acids with structurally related amino acids (e.g., conservative mutations) will not have a significant impact on the biological activity of the resulting molecule. Conservative substitutions are substitutions that occur within the amino acid family associated with the side chain. By assessing the ability of the variant polypeptide to react in cells in a manner similar to that of the wild-type polypeptide, it can be easily determined whether the change in the amino acid sequence of the polypeptide of the present invention produces a functional homologue.

[0041] In the case of polynucleotides, "fragment" refers to a clone or any portion of a polynucleotide molecule, particularly a polynucleotide portion that retains the available functional characteristics of a full-length polynucleotide molecule. Useful fragments include oligonucleotides and polynucleotides that can be used for hybridization or amplification techniques or for replication, transcription or translation regulation. "Polynucleotide fragment" refers to any subsequence of a polynucleotide SEQ ID NO, typically comprising or consisting of at least about 9, 10, 11, 12 continuous nucleotides from the polynucleotide SEQ ID NO, such as at least about 30 nucleotides or at least about 50 nucleotides of any polynucleotide sequence provided herein. Exemplary fragments may additionally or alternatively include a region comprising a conserved family domain of a coded polypeptide, a fragment consisting essentially of or consisting of. Exemplary fragments may additionally or alternatively include a fragment comprising a conserved domain of a polypeptide. Therefore, a fragment of a polynucleotide SEQ ID NO preferably refers to a nucleotide sequence comprising or consisting of the polynucleotide SEQ ID NO, wherein no more than about 200, 150, 100, 50 or 25 consecutive nucleotides, preferably no more than about 50 consecutive nucleotides are deleted, and it retains the useful functional characteristics (such as activity) of the full-length polynucleotide molecule, which can be assessed by a skilled person through routine experiments. Alternatively, a fragment of a polynucleotide SEQ ID NO preferably means a nucleotide sequence comprising or consisting of a certain amount of consecutive nucleotides from the polynucleotide SEQ ID NO, and wherein the amount of the consecutive nucleotides is the amount of the polynucleotide SEQ ID NO. At least 50.0%, 60.0%, 70.0%, 80.0%, 81.0%, 82.0%, 83.0%, 84.0%, 85.0%, 86.0%, 87.0%, 88.0%, 89.0%, 90.0%, 91.0%, 92.0%, 93.0%, 94.0%, 95.0%, 95.5%, 96.0%, 96.5%, 97.0%, 97.0%, 98.0%, 99.0%, 100.0%, 101.0%, 102.0%, 103.0%, 104.0%, 105.0%, 106.0%, 107.0%, 108.0%, 109.0%, 110.0%, 111.0%, 112.0%, 113.0%, 114.0%, 115.0%, 116.0%, 117.0%, 118.0%, 119.0%, 120.0%, 121.0%, 122.0%, 123.0%, 124.0%, 125.0%, 126.0%, 127.0%, 128.0%, 129.0%, 130.0%, 131.0%, 132.0%, 133.0%, 134.0%, 135.0%, 136.0%, 137.0%, 138.0%, 139.0%, 140.0%, 141.0%, 142.0%, 143.0%, 144.0%, 145.0%, 146.0%, 147.0%, 148.0%, 149.1%, 15 5%, 98.0%, 98.5%, 99.0%, 99.5%, 100%, preferably at least 80.0%, more preferably at least 85.0%, even more preferably at least 87.0%, even more preferably at least 90.0%, even more preferably at least 95.0%, most preferably at least 97.0%, and which retains the useful functional characteristics (e.g., activity) of the full-length polynucleotide molecule that can be assessed by a skilled person through routine experimentation.Therefore, a fragment of a polynucleotide SEQ ID NO preferably refers to a nucleotide sequence comprising or consisting of the polynucleotide SEQ ID NO, wherein a certain amount of consecutive nucleotides is deleted and wherein the amount does not exceed 50.0%, 40.0%, 30.0% of the full length of the polynucleotide SEQ ID NO, preferably does not exceed 20.0%, 15.0%, 10.0%, 9.0%, 8.0%, 7.0%, 6.0%, 5.0%, 4.5%, 4.0%, 3.5%, 3.0%, 2.5%, 2.0%, 1.5%, 1.0%, 0.5%, more preferably does not exceed 15.0%, even more preferably does not exceed 10.0%, even more preferably does not exceed 5.0%, most preferably does not exceed 2.5%, and wherein the fragment retains the useful functional characteristics (e.g. activity) of the full-length polynucleotide molecule, which can be routinely assessed by a skilled person.

[0042] With respect to polypeptide, "fragment" refers to a subsequence of a polypeptide, which performs at least one biological function of a complete polypeptide in a substantially identical manner or to a similar degree to a complete polypeptide. "Subsequence of a polypeptide" or "a stretch of amino acid residues" as defined herein refers to a sequence of continuous amino acid residues derived from a polypeptide. For example, a polypeptide fragment can include recognizable structural motifs or functional domains, such as a DNA binding site or domain, an activation domain or a domain for protein-protein interactions in conjunction with a DNA promoter region, and can initiate transcription. The size of a fragment can range from as little as 3 amino acid residues to the full length of a complete polypeptide, such as a length of at least about 10 amino acid residues, such as a length of at least about 20 amino acid residues, such as a length of at least about 30 amino acid residues, such as a length of at least about 100 amino acid residues, such as a length of at least about 150 amino acid residues, such as a length of at least about 200 amino acid residues. Thus, a fragment of a polypeptide SEQ ID NO (or UniProt ID) preferably refers to a polypeptide sequence comprising or consisting of said polypeptide SEQ ID NO (or UniProt ID), wherein no more than about 200, 150, 125, 100, 80, 60, 50, 40, 30, 20 or 15 consecutive amino acid residues are deleted, preferably no more than about 100 consecutive amino acid residues are deleted, more preferably no more than about 50 consecutive amino acid residues are deleted, even more preferably no more than about 40 consecutive amino acid residues are deleted, and which performs at least one biological function of the complete polypeptide in substantially the same manner (preferably to a similar or greater extent than the complete polypeptide), as can be routinely assessed by a skilled person. Alternatively, a fragment of a polypeptide SEQ ID NO (or UniProt ID) preferably means comprising or consisting of a certain amount of consecutive amino acid residues from said polypeptide SEQ ID NO (or UniProt ID), and wherein the amount of said consecutive amino acid residues is the same as that of said polypeptide SEQ ID NO (or UniProt ID). %, 98.0%, 99.0%, 100.0%, 101.0%, 102.0%, 103.0%, 104.0%, 105.0%, 106.0%, 107.0%, 108.0%, 109.0%, 110.0%, 111.0%, 112.0%, 113.0%, 114.0%, 115.0%, 116.0%, 117.0%, 118.0%, 119.0%, 120.0%, 121.0%, 122.0%, 123.0%, 124.0%, 125.0%, 126.0%, 127.0%, 128.0%, 129.0%, 130.0%, 131.0%, 132.0%, 133.0%, 134.0%, 135.0%, 136.0%, 137.0%, 138.0%, 139.0%, 140.0%, 141.0%, 142.0%, 143.0%, 144.0%, 145.0%, 146.0%, 147.0%, 148.0%, 149.0%, .0%, 98.5%, 99.0%, 99.5%, 100%, preferably at least 80.0%, more preferably at least 85.0%, even more preferably at least 87.0%, even more preferably at least 90.0%, even more preferably at least 95.0%, most preferably at least 97.0%, and it performs at least one biological function of the intact polypeptide in substantially the same manner as the intact polypeptide, preferably to a similar or greater extent, as can be routinely assessed by a skilled person.Therefore, a fragment of a polypeptide SEQ ID NO (or UniProt ID) preferably refers to a polypeptide sequence comprising or consisting of the polypeptide SEQ ID NO (or UniProt ID), wherein a certain amount of consecutive amino acid residues is deleted, and wherein the amount does not exceed 50.0%, 40.0%, 30.0% of the full length of the polypeptide SEQ ID NO (or UniProt ID), preferably does not exceed 10.0% of the full length of the polypeptide SEQ ID NO (or UniProt ID). %, 15.0%, 10.0%, 9.0%, 8.0%, 7.0%, 6.0%, 5.0%, 4.5%, 4.0%, 3.5%, 3.0%, 2.5%, 2.0%, 1.5%, 1.0%, 0.5%, more preferably no more than 15.0%, even more preferably no more than 10.0%, even more preferably no more than 5.0%, most preferably no more than 2.5% of the full length of the polypeptide (ID), and it performs at least one biological function of the complete polypeptide in essentially the same manner as the complete polypeptide, preferably to a similar or greater extent, as can be routinely assessed by a skilled person.

[0043] Throughout the application, the sequence of a polypeptide may be represented by a SEQ ID NO or, alternatively, by a UniProt ID. Therefore, the terms "polypeptide SEQ ID NO" and "polypeptide UniProt ID" may be used interchangeably unless explicitly stated otherwise.

[0044] A "functional fragment" of a polypeptide has at least one property or activity of the polypeptide from which it is derived, preferably to a similar or greater degree. A functional fragment may, for example, include a functional domain or a conserved domain of a polypeptide. It should be understood that a polypeptide or a fragment thereof may have conservative amino acid substitutions that have substantially no effect on the activity of the polypeptide. Conservative substitutions refer to substitutions of one hydrophobic amino acid for another, or one polar amino acid for another, or one acidic amino acid for another, or one basic amino acid for another, etc. Preferably, conservative substitutions refer to expected combinations such as substitutions of glycine by alanine, and vice versa; substitutions of valine, isoleucine and leucine by methionine, and vice versa; substitutions of aspartic acid by glutamic acid, and vice versa; substitutions of asparagine by glutamine, and vice versa; substitutions of serine by threonine, and vice versa; substitutions of lysine by arginine, and vice versa; substitutions of cysteine ​​by methionine, and vice versa; and substitutions of phenylalanine and tyrosine by tryptophan, and vice versa.

[0045] Homologous sequences as used herein describe those nucleotide sequences that have sequence similarity and encode polypeptides that share at least one functional characteristic (e.g., biochemical activity). More specifically, the term "functional homolog" as used herein describes those polypeptides that have sequence similarity (in other words, homology) and at the same time have at least one functional similarity (e.g., biochemical activity) (Altenhoff et al., PLoS Comput. Biol. 8 (2012) e1002514).

[0046] Homologs can be identified by analyzing nucleotide and polypeptide sequence alignments. For example, a query to a database of nucleotide or polypeptide sequences can identify homologs of the nucleotide or polypeptide of interest. Sequence analysis can involve BLAST, Reciprocal BLAST or PSI-BLAST analysis of a non-redundant database using the amino acid sequence of a reference polypeptide sequence. In some cases, the amino acid sequence is derived from the nucleotide sequence. Typically, those polypeptides in the database that have greater than 40% sequence identity with the polypeptide of interest are candidates for further evaluation of suitability as homologous polypeptides. Amino acid sequence similarity allows conservative amino acid substitutions, such as one hydrophobic residue replacing another or one polar residue replacing another or one acidic amino acid replacing another or one basic amino acid replacing another, etc. Preferably, conservative substitutions refer to expected combinations such as glycine substituted by alanine, and vice versa; valine, isoleucine and leucine substituted by methionine, and vice versa; aspartic acid substituted by glutamic acid, and vice versa; asparagine substituted by glutamine, and vice versa; serine substituted by threonine, and vice versa; lysine substituted by arginine, and vice versa; cysteine ​​substituted by methionine, and vice versa; and phenylalanine and tyrosine substituted by tryptophan, and vice versa. If necessary, such candidates can be manually inspected to narrow the number of candidates that need further evaluation.

[0047] Domains can be assigned by, for example, Pfam (El-Gebali et al., Nucleic Acids Res. 47 (2019) D427-D432), IPR (InterPro domain) (Mitchell et al., Nucleic Acids Res. 47 (2019) D351-D360), protein fingerprint domain (PRINTS) (Attwood et al., Nucleic Acids Res. 31 (2003) 400-402), SUBFAM domain (Gough et al., J. Mol. Biol. 313 (2001) 903-919), TIGRFAM domain (Selengut et al., Nucleic Acids Res. 35 (2007) D260-D264), Conserved Domain Database (CDD) (https: / / www.ncbi.nlm.nih.gov / cdd) (Lu et al., Nucleic Acids Res.48 (2020) D265-D268), PTHR domain (http: / / www.pantherdb.org) (Mi et al., Nucleic Acids. Res.41 (2013) D377-D386; Thomas et al., Genome Research 13 (2003) 2129-2141) or PATRIC identifier or PATRIC DB global family domain (https: / / www.patricbrc.org / ) (Davis et al., Nucleic Acids Res.48 (D1) (2020) D606-D612). Protein or polypeptide sequence information and functional information can be provided by comprehensive resources of protein sequence and annotation data, such as the Universal Protein Resource (UniProt) (www.uniprot.org) (Nucleic Acids Res. 2021, 49 (D1), D480-D489). UniProt contains a specialized and richly included protein database, called the UniProt Knowledgebase (UniProtKB), as well as the UniProt Reference Cluster (UniRef) and the UniProt Archive (UniParc). The UniProt identifier (UniProt ID) is unique for each protein present in the database. Throughout the application, the sequence of the polypeptide is represented by SEQ ID NO or UniProt ID. Unless otherwise stated, the UniProt ID of the described protein corresponds to its sequence version 01 as present in the UniProt database (www.uniprot.org) version 2021_03 and accessed on June 9, 2021.

[0048] InterPro provides functional analysis of proteins by classifying them into families and predicting domains and important sites. To classify proteins in this way, InterPro uses predictive models called signatures, which are provided by several different databases (called member databases) that make up the InterPro consortium. Protein signatures from these member databases are combined into a searchable resource, leveraging their respective strengths to produce a powerful integrated database and diagnostic tool.

[0049] Those skilled in the art will appreciate that the databases used herein include Pfam 32.0 (released in September 2018), CDD v3.17 (released on April 3, 2019), eggnogdb 4.5.1 (released in September 2016), InterPro 82.0 (released on October 8, 2020), and PATRIC 3.6.9 (released in March 2020), and that the content of each database is fixed in each version and does not change. When the content of a particular database changes, that particular database receives a new release version with a new release date. All release versions of each database and their corresponding release dates and the specific content annotated on these specific release dates are available and known to those skilled in the art.

[0050] In the context of two or more nucleic acid or polypeptide sequences, the term "identical" or "percent identity" or "% identity" refers to two or more sequences or subsequences that are identical or have a specified percentage of identical nucleotides or amino acid residues when compared and aligned for maximum correspondence, as measured using a sequence comparison algorithm or by visual inspection. For sequence comparison, one sequence is used as a reference sequence for comparison with a test sequence. When a sequence comparison algorithm is used, the test sequence and the reference sequence are entered into a computer, subsequence coordinates are specified if necessary, and sequence algorithm program parameters are specified. The sequence comparison algorithm then calculates the percent sequence identity of the test sequence relative to the reference sequence based on the specified program parameters. The percent sequence identity can preferably be determined by alignment of the two sequences and identifying the number of positions with identical residues and dividing by the number of residues in the shorter sequence × 100. Percent identity can be calculated globally over the full-length sequence of a given SEQ ID NO (i.e., a reference sequence), thereby generating a global percent identity score. Alternatively, the percent identity of a portion of a reference sequence can be calculated, thereby obtaining a local percent identity score. Partial sequence preferably means at least about 50%, 60%, 70%, 80%, 90% or 95% of the full-length reference sequence. In another preferred embodiment, the partial sequence of a reference polypeptide sequence refers to a section of at least 150 amino acid residues up to the total number of amino acid residues of the reference polypeptide sequence. In another more preferred embodiment, the partial sequence of a reference polypeptide sequence refers to a section of at least 200 amino acid residues up to the total number of amino acid residues of the reference polypeptide sequence. Using the full length of the reference sequence in a local sequence alignment will produce a global percent identity score between the test and reference sequences.

[0051] The percent identity can be determined using different algorithms, such as BLAST and PSI-BLAST (Altschul et al., 1990, J Mol Biol 215:3, 403-410; Altschul et al., 1997, Nucleic Acids Res 25:17, 3389-402), the Clustal Omega method (Sievers et al., 2011, Mol. Syst. Biol. 7:539), the MatGAT method (Campanella et al., 2003, BMC Bioinformatics, 4:29), or EMBOSS Needle.

[0052] As used herein, a polypeptide comprising or consisting of an amino acid sequence having 67.0% or more sequence identity to a stretch of at least 150 amino acid residues of a reference polypeptide sequence is understood to mean that the amino acid sequence has 67.0%, 68.0%, 69.0%, 70.0%, 71.0%, 72.0%, 73.0%, 74.0%, 75.0%, 76.0%, 77.0%, 78.0%, 79.0%, 80.0%, 81.0%, 82.0%, 83.0%, 84.0%, 85.0%, 86.0%, 87.0%, 88.0%, 89.0%, 90.0%, 91.0%, 92.0%, 93.0%, 94.0%, 95.0%, 96.0%, 97.0%, 98.0%, 99.0%, 100.0%, 101.0%, 102.0%, 103.0%, 104.0%, 105.0%, 106.0%, 107.0%, 108.0%, 109.0%, 110.0%, 111.0%, 112.0%, 113.0%, 114.0%, 115.0%, 116.0%, 117.0%, 118.0%, 119.0%, 120.0%, 121.0%, 122.0%, 123.0%, 124.0%, 125 85.0%, 86.0%, 87.0%, 88.0%, 89.0%, 90.0%, 91.0%, 91.50%, 92.00%, 92.50%, 93.00%, 93.50%, 94.00%, 94.50%, 95.00%, 95.50%, 96.00%, 96.50%, 97.00%, 97.50%, 98.00%, 98.50%, 99.00%, 99.50%, 99.60%, 99.70%, 99.80%, 99.90%, 100% sequence identity.

[0053] As used herein, a polypeptide comprising or consisting of an amino acid sequence having 67.0% or more sequence identity to a stretch of at least 200 amino acid residues of a reference polypeptide sequence is understood to mean that the amino acid sequence has 67.0%, 68.0%, 69.0%, 70.0%, 71.0%, 72.0%, 73.0%, 74.0%, 75.0%, 76.0%, 77.0%, 78.0%, 79.0%, 80.0%, 81.0%, 82.0%, 83.0%, 84.0%, 85.0%, 86.0%, 87.0%, 88.0%, 89.0%, 90.0%, 91.0%, 92.0%, 93.0%, 94.0%, 95.0%, 96.0%, 97.0%, 98.0%, 99.0%, 100.0%, 101.0%, 102.0%, 103.0%, 104.0%, 105.0%, 106.0%, 107.0%, 108.0%, 109.0%, 110.0%, 111.0%, 112.0%, 113.0%, 114.0%, 115.0%, 116.0%, 117.0%, 118.0%, 119.0%, 120.0%, 121.0%, 122.0%, 123.0%, 124.0%, 125 85.0%, 86.0%, 87.0%, 88.0%, 89.0%, 90.0%, 91.0%, 91.50%, 92.00%, 92.50%, 93.00%, 93.50%, 94.00%, 94.50%, 95.00%, 95.50%, 96.00%, 96.50%, 97.00%, 97.50%, 98.00%, 98.50%, 99.00%, 99.50%, 99.60%, 99.70%, 99.80%, 99.90%, 100% sequence identity.

[0054] As used herein, a polypeptide comprising or consisting of an amino acid sequence having 55.0% or more sequence identity to the full-length sequence of a reference polypeptide sequence is understood to mean that the amino acid sequence has 55.0%, 56.0%, 57.0%, 58.0%, 59.0%, 60.0%, 61.0%, 62.0%, 63.0%, 64.0%, 65.0%, 66.0%, 67.0%, 68.0%, 69.0%, 70.0%, 71.0%, 72.0%, 73.0%, 74.0%, 75.0%, 76.0%, 77.0%, 78.0%, 79.0%, 80.0%, 81.0%, 82.0%, 83.0%, 84.0%, 85.0%, 86.0%, 87.0%, 88.0%, 89.0%, 90.0%, 91.0%, 92.0%, 93.0%, 94.0%, 95.0%, 96.0%, 97.0%, 98.0%, 99.0%, 100.0%, 101.0%, 102.0%, 103.0%, 104.0%, 105.0%, 106.0%, 107.0%, 108.0%, 109.0%, 110.0%, 111.0%, 112.0%, 113.0%, 114.0%, 115.0%, 116.0%, 117.0%, 118.0%, 119. 0.0%, 81.0%, 82.0%, 83.0%, 84.0%, 85.0%, 86.0%, 87.0%, 88.0%, 89.0%, 90.0%, 91.0%, 91.50%, 92.00%, 92.50%, 93.00%, 93.50%, 94.00%, 94.50%, 95.00%, 95.50%, 96.00%, 96.50%, 97.00%, 97.50%, 98.00%, 98.50%, 99.00%, 99.50%, 99.60%, 99.70%, 99.80%, 99.90%, 100% sequence identity.

[0055] Throughout the application, unless explicitly stated otherwise, a polypeptide comprising or having or consisting of an amino acid sequence having 55.0% or more sequence identity to the full-length amino acid sequence of a reference polypeptide (usually represented by a SEQ ID NO or a UniProt ID) preferably has 55.0%, 60.0%, 65.0%, 70.0%, 75.0%, 80.0%, 85.0%, 90.0%, 91.0%, 92.0%, 93.0%, 94.0%, 95.0%, 96.0%, 97.0%, 98.0%, 99.0%, more preferably at least 60.0%, even more preferably at least 65.0%, even more preferably at least 70.0%, even more preferably at least 80.0%, even more preferably at least 85.0%, even more preferably at least 90.0% sequence identity to the full-length reference sequence. In addition, unless explicitly stated otherwise, a polynucleotide sequence comprises or comprises a nucleotide sequence having 55.0%, 60.0%, 65.0%, 70.0%, 75.0%, 80.0%, 85.0%, 90.0%, 91.0%, 92.0%, 93.0%, 94.0%, 95.0%, 96.0%, 97.0%, 98.0%, 99.0%, more preferably at least 60.0%, even more preferably at least 65.0%, even more preferably at least 70.0%, even more preferably at least 80.0%, even more preferably at least 85.0%, even more preferably at least 90.0% sequence identity to the full-length reference sequence or consists of a nucleotide sequence.

[0056] As used herein, a polypeptide comprising or consisting of an amino acid sequence having 85.0% or more sequence identity to a stretch of at least 150 amino acid residues of a reference polypeptide sequence is understood to mean that the amino acid sequence has 85.0%, 86.0%, 87.0%, 88.0%, 89.0%, 90.0%, 91.0%, 91.50%, 92.00%, 93.00%, 94.00%, 95.00%, 96.00%, 97.00%, 98.00%, 99.00%, 100.00%, 101.00%, 102.00%, 103.00%, 104.00%, 105.00%, 106.00%, 107.00%, 108.00%, 109.00%, 110.00%, 111.00%, 112.00%, 113.00%, 114.00%, 115.00%, 116.00%, 117.00%, 118.00%, 119.00%, 121.00%, 122.00%, 123.00%, 124.00%, 125.00%, 126.00%, 127.00%, 128.00%, 129.00%, 129. %, 92.50%, 93.00%, 93.50%, 94.00%, 94.50%, 95.00%, 95.50%, 96.00%, 96.50%, 97.00%, 97.50%, 98.00%, 98.50%, 99.00%, 99.50%, 99.60%, 99.70%, 99.80%, 99.90%, 100% sequence identity.

[0057] As used herein, a polypeptide comprising or consisting of an amino acid sequence having 85.0% or more sequence identity to a stretch of at least 200 amino acid residues of a reference polypeptide sequence is understood to mean that the amino acid sequence has 85.0%, 86.0%, 87.0%, 88.0%, 89.0%, 90.0%, 91.0%, 91.50%, 92.00%, 93.00%, 94.00%, 95.00%, 96.00%, 97.00%, 98.00%, 99.00%, 100.00%, 101.00%, 102.00%, 103.00%, 104.00%, 105.00%, 106.00%, 107.00%, 108.00%, 109.00%, 110.00%, 111.00%, 112.00%, 113.00%, 114.00%, 115.00%, 116.00%, 117.00%, 118.00%, 119.00%, 121.00%, 122.00%, 123.00%, 124.00%, 125.00%, 126.00%, 127.00%, 128.00%, 129.00%, 130.00%, 131.0 %, 92.50%, 93.00%, 93.50%, 94.00%, 94.50%, 95.00%, 95.50%, 96.00%, 96.50%, 97.00%, 97.50%, 98.00%, 98.50%, 99.00%, 99.50%, 99.60%, 99.70%, 99.80%, 99.90%, 100% sequence identity.

[0058] As used herein, a polypeptide comprising or consisting of an amino acid sequence having 80.0% or more sequence identity to the full-length sequence of a reference polypeptide sequence is understood to mean that the amino acid sequence has 80.0%, 81.0%, 82.0%, 83.0%, 84.0%, 85.0%, 86.0%, 87.0%, 88.0%, 89.0%, 90.0%, 91.0%, 91.5% or more sequence identity to the full-length amino acid sequence of the reference polypeptide sequence. 0%, 92.00%, 92.50%, 93.00%, 93.50%, 94.00%, 94.50%, 95.00%, 95.50%, 96.00%, 96.50%, 97.00%, 97.50%, 98.00%, 98.50%, 99.00%, 99.50%, 99.60%, 99.70%, 99.80%, 99.90%, 100% sequence identity.

[0059] Throughout the application, unless explicitly stated otherwise, a polypeptide comprising or having or consisting of an amino acid sequence having 80.0% or higher sequence identity to the full-length amino acid sequence of a reference polypeptide (usually represented by SEQ ID NO or UniProt ID) preferably has 80.0%, 85.0%, 90.0%, 91.0%, 92.0%, 93.0%, 94.0%, 95.0%, 96.0%, 97.0%, 98.0%, 99.0%, more preferably has at least 85.0%, even more preferably has at least 90.0% sequence identity to the full-length reference sequence. In addition, unless otherwise specifically stated, a polynucleotide sequence comprises or has or consists of a nucleotide sequence having 80.0%, 85.0%, 90.0%, 91.0%, 92.0%, 93.0%, 94.0%, 95.0%, 96.0%, 97.0%, 98.0%, 99.0%, more preferably at least 85.0%, even more preferably at least 90.0% sequence identity with the full-length reference sequence.

[0060] As used herein, a polypeptide comprising or consisting of an amino acid sequence having 60.0% or more sequence identity to a stretch of at least 150 amino acid residues of a reference polypeptide sequence is understood to mean that the amino acid sequence has 60.0%, 61.0%, 62.0%, 63.0%, 64.0%, 65.0%, 66.0%, 67.0%, 68.0%, 69.0%, 70.0%, 71.0%, 72.0%, 73.0%, 74.0%, 75.0%, 76.0%, 77.0%, 78.0%, 79.0%, 80.0%, 81.0%, 82.0%, 83.0%, 84.0%, 85.0%, 86.0%, 87.0%, 88.0%, 89.0%, 90.0%, 91.0%, 92.0%, 93.0%, 94.0%, 95.0%, 96.0%, 97.0%, 98.0%, 99.0%, 100.0%, 101.0%, 102.0%, 103.0%, 104.0%, 105.0%, 106.0%, 107.0%, 108.0%, 109.0%, 110.0%, 111.0%, 112.0%, 113.0%, 114.0%, 115.0%, 116.0%, 117.0%, 118.0%, 119.0%, 120.0%, 121.0%, 122.0%, 123.0%, 124.0%, 125 0%, 82.0%, 83.0%, 84.0%, 85.0%, 86.0%, 87.0%, 88.0%, 89.0%, 90.0%, 91.0%, 91.50%, 92.00%, 92.50%, 93.00%, 93.50%, 94.00%, 94.50%, 95.00%, 95.50%, 96.00%, 96.50%, 97.00%, 97.50%, 98.00%, 98.50%, 99.00%, 99.50%, 99.60%, 99.70%, 99.80%, 99.90%, 100% sequence identity.

[0061] As used herein, a polypeptide comprising or consisting of an amino acid sequence having 60.0% or more sequence identity to a stretch of at least 200 amino acid residues of a reference polypeptide sequence is understood to mean that the amino acid sequence has 60.0%, 61.0%, 62.0%, 63.0%, 64.0%, 65.0%, 66.0%, 67.0%, 68.0%, 69.0%, 70.0%, 71.0%, 72.0%, 73.0%, 74.0%, 75.0%, 76.0%, 77.0%, 78.0%, 79.0%, 80.0%, 81.0%, 82.0%, 83.0%, 84.0%, 85.0%, 86.0%, 87.0%, 88.0%, 89.0%, 90.0%, 91.0%, 92.0%, 93.0%, 94.0%, 95.0%, 96.0%, 97.0%, 98.0%, 99.0%, 100.0%, 101.0%, 102.0%, 103.0%, 104.0%, 105.0%, 106.0%, 107.0%, 108.0%, 109.0%, 110.0%, 111.0%, 112.0%, 113.0%, 114.0%, 115.0%, 116.0%, 117.0%, 118.0%, 119.0%, 120 0%, 82.0%, 83.0%, 84.0%, 85.0%, 86.0%, 87.0%, 88.0%, 89.0%, 90.0%, 91.0%, 91.50%, 92.00%, 92.50%, 93.00%, 93.50%, 94.00%, 94.50%, 95.00%, 95.50%, 96.00%, 96.50%, 97.00%, 97.50%, 98.00%, 98.50%, 99.00%, 99.50%, 99.60%, 99.70%, 99.80%, 99.90%, 100% sequence identity.

[0062] As used herein, a polypeptide comprising or consisting of an amino acid sequence having 45.0% or more sequence identity to the full length of a reference polypeptide sequence is understood to mean that the amino acid sequence has 45.0%, 46.0%, 47.0%, 48.0%, 49.0%, 50.0%, 51.0%, 52.0%, 53.0%, 54.0%, 55.0%, 56.0%, 57.0%, 58.0%, 59.0%, 60.0%, 61.0%, 62.0%, 63.0%, 64.0%, 65.0%, 66.0%, 67.0%, 68.0%, 69.0%, 70.0%, 71.0%, 72.0%, 73.0%, 74.0%, 75.0%, 76.0%, 77.0%, 78.0%, 79.0%, 80.0%, 81.0%, 82.0%, 83.0%, 84.0%, 85.0%, 86.0%, 87.0%, 88.0%, 89.0%, 90.0%, 91.0%, 92.0%, 93.0%, 94.0%, 95.0%, 96.0%, 97.0%, 98.0%, 99.0%, 100.0%, 101.0%, 102.0%, 103.0%, 104.0%, 105.0%, 106.0%, 107.0%, 108.0%, 109.0% 5.0%, 76.0%, 77.0%, 78.0%, 79.0%, 80.0%, 81.0%, 82.0%, 83.0%, 84.0%, 85.0%, 86.0%, 87.0%, 88.0%, 89.0%, 90.0%, 91.0%, 91.50%, 92.00%, 92.50%, 93.00%, 93.50%, 94.00%, 94.50%, 95.00%, 95.50%, 96.00%, 96.50%, 97.00%, 97.50%, 98.00%, 98.50%, 99.00%, 99.50%, 99.60%, 99.70%, 99.80%, 99.90%, 100% sequence identity.

[0063] Throughout this application, unless expressly stated otherwise, a polypeptide comprising or consisting of an amino acid sequence having 45.0% or greater sequence identity to the full-length amino acid sequence of a reference polypeptide (usually represented by a SEQ ID NO or UniProt ID) preferably has 45.0%, 46.0%, 47.0%, 48.0%, 49.0%, 50.0%, 51.0%, 52.0%, 53.0%, 54.0%, 55.0%, 56.0%, 57.0%, 58.0%, 59.0%, 60.0%, 61.0%, 62.0%, 63.0%, 64.0%, 65.0%, 66.0%, 67.0%, 68.0%, 69.0%, 70.0%, 71.0%, 72.0%, 73.0%, 74.0%, 75.0%, 76.0%, 77.0%, 78.0%, 79.0%, 80.0%, 81.0%, 82.0%, 83.0%, 84.0%, 85.0%, 86.0%, 87.0%, 88.0%, 89.0%, 90.0%, %, 76.0%, 77.0%, 78.0%, 79.0%, 80.0%, 85.0%, 90.0%, 91.0%, 92.0%, 93.0%, 94.0%, 95.0%, 96.0%, 97.0%, 98.0%, 99.0%, more preferably having at least 50.0%, more preferably having at least 55.0%, more preferably having at least 60.0%, more preferably having at least 65.0%, more preferably having at least 70.0%, more preferably having at least 75.0%, more preferably having at least 80.0%, more preferably having at least 85.0%, even more preferably having at least 90.0% sequence identity. In addition, unless explicitly stated otherwise, a polynucleotide sequence comprises or comprises a nucleotide sequence having 45.0%, 50.0%, 55.0%, 60.0%, 65.0%, 70.0%, 75.0%, 80.0%, 85.0%, 90.0%, 91.0%, 92.0%, 93.0%, 94.0%, 95.0%, 96.0%, 97.0%, 98.0%, 99.0%, more preferably at least 85.0%, even more preferably at least 90.0% sequence identity to the full-length reference sequence or consists of it.

[0064] For the purposes of the present invention, MatGAT2.01 (Campanella et al., 2003, BMC Bioinformatics 4:29) is used to determine the percent identity. The following default parameters for proteins are used: (1) Gap cost Existence: 12 and Extension: 2; (2) The matrix used is BLOSUM50. In a preferred embodiment, sequence identity is calculated based on the full-length sequence of a given SEQ ID NO (i.e., a reference sequence) or a portion thereof. A portion thereof preferably refers to at least 50%, 60%, 70%, 80%, 90% or 95% of the complete reference sequence.

[0065] The terms "sialic acid", "N-acetylneuraminic acid", "N-acylneuraminic acid", "N-acetylneuraminic acid" are used interchangeably and refer to acidic sugars including, but not limited to, Neu4Ac; Neu5Ac; Neu4,5Ac2; Neu5,7Ac2; Neu5,8Ac2; Neu5,9Ac2; Neu4,5,9Ac3; Neu5,7,9Ac3; Neu5,8,9Ac3; Neu4,5,7,9Ac4; Neu5,7,8,9Ac4; Neu4,5,7,8,9Ac5; Neu5Gc and 2-keto-3-deoxymannose-octulose acid (KDO).

[0066] Neu4Ac is also known as 4-O-acetyl-5-amino-3,5-dideoxy-D-glycero-D-galactosyl-nonan-2-pyranose acid or 4-O-acetylneuraminic acid and has the molecular formula C11H19NO9. Neu5Ac is also known as 5-acetylamino-3,5-dideoxy-D-glycero-D-galacto-nonan-2-pyranose acid, D-glycero-5-acetylamino-3,5-dideoxy-D-galacto-nonan-2-keto-pyranose acid, 5-(acetylamino)-3,5-dideoxy-D-glycero-D-galacto-2-nonanose acid, 5-(acetylamino)-3,5-dideoxy-D-glycero-D-galacto-2-nonanose acid, 5-(acetylamino)-3,5-dideoxy-D-glycero-D-galacto-2-nonanose acid, or 5-(acetylamino)-3,5-dideoxy-D-glycero-D-galacto-nonan-2-nonanose acid and has the molecular formula C11H19NO9. Neu4,5Ac2 is also known as N-acetyl-4-O-acetylneuraminic acid, 4-O-acetyl-N-acetylneuraminic acid, 4-O-acetyl-N-acetylneuraminic acid, 4-acetyl-5-acetylamino-3,5-dideoxy-D-glycero-D-galacto-2-nonanoate, 4-acetyl-5-(acetylamino)-3,5-acetylamino-3,5-dideoxy-D-glycero-D-galacto-2-nonanoate, 4-acetyl-5-acetylamino-3,5-dideoxy-D-glycero-D-galacto-2-nonanoate or 4-acetyl-5-(acetylamino)-3,5-dideoxy-D-glycero-D-galacto-2-nonanoate and has the molecular formula C13H21NO10. Neu5,7Ac2 is also known as 7-O-acetyl-N-acetylneuraminic acid, N-acetyl-7-O-acetylneuraminic acid, 7-O-acetyl-N-acetylneuraminic acid, 7-acetyl-5-acetylamino-3,5-dideoxy-D-glycero-D-galactosyl-2-nonanone acid, 7-acetyl-5-(acetylamino)-3,5-dideoxy-D-glycero-D-galactosyl-2-nonanone acid, 7-acetyl-5-acetylamino-3,5-dideoxy-D-glycero-D-galactosyl-nonanone acid or 7-acetyl-5-(acetylamino)-3,5-dideoxy-D-glycero-D-galactosyl-2-nonanone acid and has a molecular formula of C13H21NO10. Neu5,8Ac2 is also known as 5-n-acetyl-8-o-acetylneuraminic acid and has a molecular formula of C13H21NO10. Neu5,9Ac2 is also known as N-acetyl-9-O-acetylneuraminic acid, 9-anana, 9-O-acetylsialic acid, 9-O-acetyl-N-acetylneuraminic acid, 5-n-acetyl-9-O-acetylneuraminic acid, N,9-O-diacetylneuraminic acid or N,9-O-diacetylneuraminic acid and has the molecular formula C13H21NO10.Neu4,5,9Ac3 is also known as 5-N-acetyl-4,9-di-O-acetylneuraminic acid. Neu5,7,9Ac3 is also known as 5-N-acetyl-7,9-di-O-acetylneuraminic acid. Neu5,8,9Ac3 is also known as 5-N-acetyl-8,9-di-O-acetylneuraminic acid. Neu4,5,7,9Ac4 is also known as 5-N-acetyl-4,7,9-tri-O-acetylneuraminic acid. Neu5,7,8,9Ac4 is also known as 5-N-acetyl-7,8,9-tri-O-acetylneuraminic acid. Neu4,5,7,8,9Ac5 is also known as 5-N-acetyl-4,7,8,9-tetra-O-acetylneuraminic acid. Neu5Gc is also known as N-glycolyl-neuraminic acid, N-glycolylneuraminic acid, N-glycolylneuraminic acid, N-glycolylneuraminic acid, N-glycolylneuraminic acid, N-glycolylneuraminic acid, N-glycolylneuraminic acid, 3,5-dideoxy-5-((hydroxyacetyl)amino)-D-glycero-D-galactosyl-2-nonanone acid, 3,5-dideoxy-5-(ethanolylamino)-D-glycero-D-galactosyl-2-nonopyranone acid, 3,5-dideoxy-5-(ethanolylamino)-D-glycero-D-galactosyl-non-2-pyranone acid, 3,5-dideoxy-5-[(hydroxyacetyl)amino]-D-glycero-D-galactosyl-non-2-pyranone acid, D-glycero-5-glycolylamino-3,5-dideoxy-D-galactosyl Sugar-nona-2-pyranose acid and has the molecular formula C11H19NO10. 2-Keto-3-deoxymanno-octulose acid is also known as KDO, Kdo, kdo, 2-keto-3-deoxy-D-manno-octulose acid, 2-oxo-3-deoxy-D-manno-octulose acid, 3-deoxy-D-manno-2-octulose acid, 3-deoxy-D-manno-octulose acid, 3-deoxy-D-manno-octulose acid, 2-keto- ... Ketone acid, 3-deoxy-D-manno-octyl-2-ketone acid, 3-deoxy-D-manno-octylone acid, 3-deoxy-D-manno-octylone acid, 3-deoxy-D-manno-octylone acid, keto-deoxyoctylone acid, keto-deoxyoctylone acid, (6R)-6-(hydroxymethyl)-1-carboxy-2-deoxy-D-lyxose-pyranose, keto-deoxy-octylone acid and has the molecular formula C8H14O8.

[0067] The term "glycosyltransferase" as used herein refers to an enzyme that is capable of catalyzing the transfer of a sugar moiety of a donor to a specific acceptor to form a glycosidic bond. The donor may be a precursor as defined herein. The classification of glycosyltransferases into different sequence-based families using nucleotide diphosphate sugars, nucleotide monophosphate sugars and sugar phosphates and related proteins has been described (Campbell et al., Biochem. J. 326, 929-939 (1997)) and can be obtained on the CAZy (Carbohydrate Active Enzymes) website (www.cazy.org).

[0068] As used herein, the glycosyltransferase may be selected from a list including but not limited to: fucosyltransferase, sialyltransferase, galactosyltransferase, glucosyltransferase, mannosyltransferase, N-acetylglucosaminyltransferase, N-acetylgalactosaminesaminyltransferase, N-acetylmannosaminesaminyltransferase, xylosyltransferase, glucuronyltransferase, galacturonosyltransferase, glucosaminyltransferase, N-glycolylneuraminic acid transferase, rhamnosyltransferase, N-acetylrhamnosyltransferase, UDP-4-amino-4,6-dideoxy-N-acetyl-β-L-altrosamine aminotransferase, UDP-N-acetylglucosamine enolpyruvyltransferase, and fucosamine transferase.

[0069] Sialyltransferase is a glycosyltransferase that transfers sialic acid (such as Neu5Ac) from a donor (such as CMP-Neu5Ac) to an acceptor. Sialyltransferases include α-2,3-sialyltransferases, α-2,6-sialyltransferases, and α-2,8-sialyltransferases that catalyze the transfer of sialic acid to an acceptor via an α-glycosidic bond. Sialyltransferases can be found in, but are not limited to, GT29, GT42, GT52, GT80, GT97, and GT100 CAZy families.

[0070] As used herein, the term "monosaccharide" refers to a sugar that cannot be broken down into simpler sugars by hydrolysis, is classified as an aldose or ketose, and contains one or more hydroxyl groups per molecule. A monosaccharide is a sugar that contains only one simple sugar.

[0071] The term "phosphorylated monosaccharide" as used herein refers to a phosphorylated monosaccharide. Examples of phosphorylated monosaccharides include, but are not limited to, glucose-1-phosphate, glucose-6-phosphate, glucose-1,6-bisphosphate, galactose-1-phosphate, fructose-6-phosphate, fructose-1,6-bisphosphate, fructose-1-phosphate, glucosamine-1-phosphate, glucosamine-6-phosphate, N-acetylglucosamine-1-phosphate, mannose-1-phosphate, mannose-6-phosphate, or fucose-1-phosphate. Some (but not all) of these phosphorylated monosaccharides are precursors or intermediates for producing activated monosaccharides.

[0072] The terms "activated monosaccharide", "nucleotide activated sugar", "nucleotide-sugar", "activated sugar", "nucleoside" or "nucleotide donor" are used interchangeably herein and refer to the activated form of a monosaccharide. Examples of activated monosaccharides include, but are not limited to, UDP-N-acetylglucosamine (UDP-GlcNAc), UDP-N-acetylgalactosamine (UDP-GalNAc), UDP-N-acetylmannosamine (UDP-ManNAc), UDP-glucose (UDP-Glc), UDP-galactose (UDP-Gal), GDP-mannose (GDP-Man), UDP-glucuronic acid, UDP-galacturonic acid, UDP-2-acetylamino-2,6-dideoxy--L-arabinose-4-hexulose, UDP-2-acetylamino-2,6-dideoxy--L-lyxose-4-hexulose, UDP-N-acetyl-L-rhamnosamine (UDP-L-RhaNAc or UDP-2-acetylamino-2,6-dideoxy-L- Nucleotide-sugar acts as a glycosyl donor in the glycosylation reaction. The glycosylation reaction is a reaction catalyzed by a glycosyltransferase.

[0073] The term "CMP-sialic acid" as used herein refers to nucleotide activated forms of sialic acid, including but not limited to CMP-Neu5Ac, CMP-Neu4Ac, CMP-Neu5Ac9N3, CMP-Neu4,5Ac2, CMP-Neu5,7Ac2, CMP-Neu5,9Ac2, CMP-Neu5,7(8,9)Ac2, CMP-Neu5,7(8,9)Ac2, CMP-N-glycolylneuraminic acid (CMP-Neu5Gc) and CMP-KDO.

[0074] The term "disaccharide" as used herein refers to a sugar polymer containing two simple sugars (i.e., monosaccharides). Examples of disaccharides include lactose (Gal-β1,4-Glc), lactose-N-disaccharide (Gal-β1,3-GlcNAc), N-acetyllactosamine (Gal-β1,4-GlcNAc), LacDiNAc (GalNAc-β1,4-GlcNAc), N-acetylgalactosamine glucosamine (GalNAc-β1,4-Glc), Neu5Ac-α2,3-Gal, Neu5Ac-α2,6-Gal, fucopyranosyl-(1-4)-N-glycolylneuraminic acid (Fuc-(1-4)-Neu5Gc), sucrose (Glc-α1,2-Fru), maltose (Glc-α1,4-Glc), and melibiose (Gal-α1,6-Glc).

[0075] The term "oligosaccharide" as used herein and as generally understood in the prior art refers to a sugar polymer containing a small amount, usually 3 to 20, preferably 3 to 10 simple sugars, i.e., monosaccharides. The oligosaccharides used in the present invention can be a linear structure or can include a branched chain. The bond between two sugar units (e.g., glycosidic bond (glycosidic linkage), galactoside bond, glycosidic bond (glucosidic linkage) etc.) can be expressed as, for example, 1,4, 1→4 or (1-4), and is used interchangeably in this article. For example, the terms "Gal-b1,4-Glc", "Gal-β1,4-Glc", "b-Gal-(1->4)-Glc", "β-Gal-(1->4)-Glc", "Galβ1-4-Glc", "Gal-b(1-4)-Glc", and "Gal-β(1-4)-Glc" have the same meaning, i.e., a β-glycosidic bond connects the carbon-1 of galactose (Gal) to the carbon-4 of glucose (Glc). Each monosaccharide may be in a cyclic form (e.g., a pyranose or furanose form). The linkages between the individual monosaccharide units may include α1->2, α1->3, α1->4, α1->6, α2->1, α2->3, α2->4, α2->6, β1->2, β1->3, β1->4, β1->6, β2->1, β2->3, β2->4, and β2->6. Oligosaccharides may contain both α-glycosidic bonds and β-glycosidic bonds or may contain only α-glycosidic bonds or only β-glycosidic bonds.The term "polysaccharide" refers to a compound composed of monosaccharides linked by a large number, usually more than twenty glycosidic bonds.

[0076] Examples of oligosaccharides include, but are not limited to, Lewis-type antigenic oligosaccharides, mammalian (including human) milk oligosaccharides, O-antigens, enterobacterial common antigens (ECA), glycan chains present in lipopolysaccharide (LPS), oligosaccharide repeating sequences present in capsular polysaccharides, peptidoglycan (PG), amino sugars, antigens of the human ABO blood group system, neutral (uncharged) oligosaccharides, negatively charged oligosaccharides, fucosylated oligosaccharides, sialylated oligosaccharides, oligosaccharides containing N-acetylglucosamine, oligosaccharides containing N-acetyllactosamine, oligosaccharides containing lactose-N-disaccharides, Oligosaccharides, oligosaccharides containing lactose, non-fucosylated neutral (uncharged) oligosaccharides, fucosylated oligosaccharides containing N-acetyllactosamine, non-fucosylated oligosaccharides containing N-acetyllactosamine, fucosylated oligosaccharides containing lactose-N-diose, non-fucosylated oligosaccharides containing lactose-N-diose, negatively charged oligosaccharides containing N-acetyllactosamine, negatively charged oligosaccharides containing lactose-N-diose, animal oligosaccharides, preferably selected from N-glycans and O-glycans and plant oligosaccharides, preferably selected from N-glycans and O-glycans.

[0077] As used herein, "sialylated oligosaccharide" is understood to be an oligosaccharide containing negatively charged sialic acid, i.e., an oligosaccharide having a sialic acid residue. It is acidic. Such sialylated oligosaccharide is a sugar structure comprising at least three monosaccharide subunits connected to each other by glycosidic bonds, wherein at least one of the monosaccharide subunits is a sialic acid residue. The sialylated oligosaccharide may contain more than one sialic acid residue, such as two, three or more. The more than one sialic acid residue may be two, three or more identical sialic acid residues. The more than one sialic acid residue may also be two, three or more different sialic acid residues. Some examples are 3-SL (3'-sialyllactose or 3'SL or Neu5Ac-a2,3-Gal-b1,4-Glc), 3'-sialyllactosamine, 6-SL (6'-sialyllactose, 6'-sialyllactose or 6'SL or Neu5Ac-a2,6-Gal-b1,4-Glc), 3,6-disialyllactose (Neu5Ac-a2,3-(Neu5Ac-a2,6)-Gal-b1,4-Glc), 6,6'-disialyllactose (Neu5Ac-a2,6-Gal-b1,4-(Neu5Ac-a2,6)-Glc), 8,3-disialyllactose (Neu5Ac-a2,8-Neu5Ac-a2,3-Gal-b1,4-Glc), 6'-sialyllactose Glycosamines, oligosaccharides containing 6' sialyllactose (also known as 6' sialyllactose, 6' SL and 6'-SL), SGG hexasaccharide (Neu5Acα-2,3Galβ-1,3GalNacβ-1,3Galα-1,4Galβ-1,4Gal), sialylated tetrasaccharide (Neu5Acα-2,3Galβ-1,4GlcNacβ-1,4GlcNAc), pentasaccharide LSTD (Neu5Acα-2,3Galβ-1,4GlcNacβ-1,3Galβ-1,4Glc), sialylated lactose-N-triose, sialylated lactose-N-tetraose, sialyllactose-N-neotetraose, LSTc (Neu5Ac-α2,6-Gal-β1,4-GlcNAc-β1,3-Gal-β1,4-Glc), monosialyllactose-N-hexaose, disialyllactose-N-hexaose I, monosialyllactose-N-neohexose I, monosialyllactose-N-neohexose II, disialyllactose-N-neohexose, disialyllactose-N-tetraose, disialyllactose-N-hexaose II, sialyllactose-N-tetraose a, disialyllactose-N-hexaose I, sialyllactose Sugar-N-tetraose b, 3'-sialo-3-fucosyllactose, disialyl monofucosyllactose-N-neohexose, monofucosylated monosialyllactose-N-octaose (sialic acid Lea), sialyllactose-N-fucohexose II, disialyl lactose-N-fucopentose II, monofucosylated disialyl lactose-N-tetraose, 3'-KDO-lactose, 3'-KDO- lactosamine, 3'-KDO-6' sialyllactose, 3'KDO-8-sialyllactose, KDO-2,3Galβ-1,3GalNacβ-1,3Galα-1,4Galβ-1,4Gal, KDO-2,3Galβ-1,3GlcNacβ-1,3Galβ-1,4Glc, KDO-2,3Galβ-1,4GlcNacβ-1,3Galβ-1,4Glc, 3'-KDO-3-fucosyllactose and oligosaccharides containing one or more sialic acid residues, including but not limited to: oligosaccharide moieties of gangliosides selected from GM3 (3' sialyllactose, Neu5Acα-2,3Galβ-4Glc) and oligosaccharides containing the following motifs: GM3, GD3 Neu5Acα-2,8Neu5Acα-2,3Galβ-1,4GlcGT3(Neu5Acα-2,8Neu5Acα-2,8Neu5Acα-2,3Galβ-1,4Glc); GM2 GalNAcβ-1,4(Neu5Acα-2,3)Galβ-1,4Glc, GM1 Galβ-1,3GalNAcβ-1,4(Neu5Acα-2,3)Galβ-1,4Glc, GD1a Neu5Acα-2,3Galβ-1,3GalNAcβ-1,4(Neu5Acα-2,3)Galβ-1,4Glc, GT1a Neu5Acα-2,8Neu5Acα-2,3Galβ-1,3GalNAcβ-1,4(Neu5Acα-2,3)Galβ-1,4Glc,GD2 GalNAcβ-1,4(Neu5Acα-2,8Neu5Acα2,3)Galβ-1,4Glc, GT2 GalNAcβ-1,4(Neu5Acα-2,8Neu5Acα-2,8Neu5Acα2,3)Galβ-1,4Glc, GD1b, Galβ-1,3GalNAcβ-1,4(Neu5Acα-2,8Neu5Acα2,3)Galβ-1,4Glc, GT1b Neu5Acα-2,3Galβ-1,3GalNAcβ-1,4(Neu5Acα-2,8Neu5Acα2,3)Galβ-1,4Glc, GQ1b Neu5Acα-2,8Neu5Acα-2,3Galβ-1,3GalNAcβ-1,4(Neu5Acα-2,8Neu5Acα2,3)Galβ-1,4Glc, GT1c Galβ-1,3GalNAcβ-1,4(Neu5Acα-2,8Neu5Acα-2,8Neu5Acα2,3)Galβ-1,4Glc, GQ1c Neu5Acα-2,3Galβ-1,3GalNAcβ-1,4(Neu5Acα-2,8Neu5Acα-2,8Neu5Acα2,3)Galβ-1,4Glc,GP1c Neu5Acα-2,8Neu5Acα-2,3Galβ-1,3GalNAcβ-1,4(Neu5Acα-2,8Neu5Acα-2,8Neu5Acα2,3)Galβ-1,4Glc, GD1a Neu5Acα-2,3Galβ-1,3(Neu5Acα-2,6)GalNAcβ-1,4Galβ-1,4Glc, Fucosyl-GM1 Fucα-1,2Galβ-1,3GalNAcβ-1,4(Neu5Acα-2,3)Galβ-1,4Glc; all of these can be extended to produce the corresponding gangliosides by reacting the above oligosaccharide moieties with ceramide or synthesizing the above oligosaccharides on ceramide.

[0078] As used herein, "3' sialylated oligosaccharide" is understood to be an oligosaccharide containing negatively charged sialic acid, which comprises an oligosaccharide or disaccharide linked to a sialic acid residue α-2,3-glycosidically. It is acidic. Such a sialylated oligosaccharide is a sugar structure comprising at least three monosaccharide subunits linked to each other by glycosidic bonds, wherein at least one of the monosaccharide subunits is an α-2,3-glycosyl linked sialic acid residue. A 3' sialylated oligosaccharide may contain more than one sialic acid residue, such as two, three or more. The more than one sialic acid residue may be two, three or more identical sialic acid residues. The more than one sialic acid residue may also be two, three or more different sialic acid residues. For example, a 3' sialylated oligosaccharide may contain one or more Neu5Ac residues and one or more KDO residues. Some examples are 3-SL (3'-sialyllactose or 3'SL or Neu5Ac-a2,3-Gal-b1,4-Glc), 3'-sialyllactosamine, 3,6-disialyllactose (Neu5Ac-a2,3-(Neu5Ac-a2,6)-Gal-b1,4-Glc), 8,3-disialyllactose (Neu5Ac-a2,8-Neu5Ac-a2,3-Gal-b1,4-Glc), SGG hexasaccharide (Neu5Acα-2,3Galβ-1,3GalNacβ-1, 3Galα-1,4Galβ-1,4Gal), sialylated tetrasaccharide (Neu5Acα-2,3Galβ-1,4GlcNacβ-1,4GlcNAc), pentasaccharide LSTD (Neu5Acα-2,3Galβ-1,4GlcNacβ-1,3Galβ-1,4Glc), 3' sialylated lactose-N-triose, 3' sialylated lactose-N-tetrasaccharide (e.g. Neu5Acα-2,3Galβ-1,3GlcNAcβ-1,3Galβ-1,4Glc(LSTa);KDOα-2,3Galβ-1,3GlcNAcβ-1,3Galβ-1,4Glc), sialyllactose-N-neotetraose, (e.g. Neu5Acα-2,3Galβ-1,4GlcNacβ-1,3Galβ-1,4Glc(LSTd)), monosialyllactose-N-hexaose, disialyllactose-N-hexaose I, monosialyllactose-N-neohexose I, monosialyllactose-N-neohexose II, disialyllactose-N-neohexose, disialyllactose Sialyl lactose-N-tetraose, disialyl lactose-N-hexaose II, sialyl lactose-N-tetraose a, disialyl lactose-N-hexaose I, 3'-sialyl-3-fucosyllactose, disialyl monofucosyllactose-N-neohexaose, monofucosyl monosialyl lactose-N-octaose (sialyl Lea), sialyl lactose-N-fucohexose II, disialyl lactose-N-fucopentose II, monofucosyl disialyl lactose-N-tetraose, 3'-KDO-lactose, 3'-KDO -lactosamine, 3'-KDO-6' sialyllactose, 3'KDO-8-sialyllactose, KDO-2,3Galβ-1,3GalNacβ-1,3Galα-1,4Galβ-1,4Gal, KDO-2,3Galβ-1,3GlcNacβ-1,3Galβ-1,4Glc, KDO-2,3Galβ-1,4GlcNacβ-1,3Galβ-1,4Glc, 3'-KDO-3-fucosyllactose and Oligosaccharides having one or more sialic acid residues, including but not limited to: oligosaccharide moieties of gangliosides selected from GM3 (3' sialyllactose, Neu5Acα-2,3Galβ-4Glc) and oligosaccharides comprising the following: GM3 motif, GD3 (Neu5Acα-2,8Neu5Acα-2,3Galβ-1,4Glc), GT3 (Neu5Acα-2,8Neu5Acα-2,8Neu5Acα-2,3Galβ-1,4Glc);GM2GalNAcβ-1,4(Neu5Acα-2,3)Galβ-1,4Glc, GM1 Galβ-1,3GalNAcβ-1,4(Neu5Acα-2,3)Galβ-1,4Glc, GD1a Neu5Acα-2,3Galβ-1,3GalNAcβ-1,4(Neu5Acα-2,3)Galβ-1,4Glc, GT1a Neu5Acα-2,8Neu5Acα-2,3Galβ-1,3GalNAcβ-1,4(Neu5Acα-2,3)Galβ-1,4Glc, GD2 GalNAcβ-1,4(Neu5Acα-2,8Neu5Acα2,3)Galβ-1,4Glc, GT2 GalNAcβ-1,4(Neu5Acα-2,8Neu5Acα-2,8Neu5Acα2,3)Galβ-1,4Glc, GD1b, Galβ-1,3GalNAcβ-1,4(Neu5Acα-2,8Neu5Acα2,3)Galβ-1,4Glc, GT1b Neu5Acα-2,3Galβ-1,3GalNAcβ-1,4(Neu5Acα-2,8Neu5Acα2,3)Galβ-1,4Glc, GQ1b Neu5Acα-2,8Neu5Acα-2,3Galβ-1,3GalNAcβ-1,4(Neu5Acα-2,8Neu5Acα2,3)Galβ-1,4Gl c, GT1cGalβ-1,3GalNAcβ-1,4(Neu5Acα-2,8Neu5Acα-2,8Neu5Acα2,3)Galβ-1,4Glc, GQ1c Neu5Acα-2,3Galβ-1,3GalNAcβ-1,4(Neu5Acα-2,8Neu5Acα-2,8Neu5Acα2,3)Galβ-1,4Glc,GP1c Neu5Acα-2,8Neu5Acα-2,3Galβ-1,3GalNAcβ-1,4(Neu5Acα-2,8Neu5Acα-2,8Neu5Acα2,3)Galβ-1,4Glc, GD1a Neu5Acα-2,3Galβ-1,3(Neu5Acα-2,6)GalNAcβ-1,4Galβ-1,4Glc, Fucosyl-GM1 Fucα-1,2Galβ-1,3GalNAcβ-1,4(Neu5Acα-2,3)Galβ-1,4Glc; all of these can be expanded to produce the corresponding gangliosides by reacting the above oligosaccharide moieties with ceramide or synthesizing the above oligosaccharides on ceramide. ;

[0079] "Neutral oligosaccharides" or "uncharged oligosaccharides" as used herein and as generally understood in the art are oligosaccharides that do not have a negative charge derived from a carboxylic acid group. Examples of such neutral oligosaccharides are 2'-fucosyllactose (2'FL), 3-fucosyllactose (3FL), 2',3-difucosyllactose (diFL), lacto-N-triose II (LN3), lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), lacto-N-fucopentaose I (LNFP I), lacto-N-neofucopentaose I (LNnFP I), lacto-N-fucopentaose II (LNFP II), lacto-N-fucopentaose III (LNFP III), lacto-N-fucopentaose V (LNFP V), lacto-N-fucopentaose VI, lacto-N-neofucopentaose V (LNnFP V), lacto-N-difucohexaose I (LNFP H), lacto-N-fucopentaose II (LNFP II), lacto-N-fucopentaose III (LNFP III), lacto-N-fucopentaose V (LNFP V), lacto-N-fucopentaose VI, lacto-N-neofucopentaose V (LNnFP V), lacto-N-difucohexaose I (LNFP H), lacto-N-fucopentaose II (LNFP II), lacto-N-fucopentaose III (LNFP III), lacto-N-fucopentaose V (LNFP V), lacto-N-fucopentaose VI (LN I), lactose-N-difucosyllactose II (LNDFH-II), 6'-galactosyl lactose, 3'-galactosyl lactose, lactose-N-hexaose, lactose-N-neohexose, p-lactose-N-hexaose, p-lactose-N-neohexose, fucosyl-lactose-N-hexaose, difucosyl-lactose-N-hexaose, difucosyl-lactose-N-neohexose (LNnDFH II), difucosyl-p-lactose-N-neohexose, trifucosyllactose-N-hexaose, p-lactose-N-fucohexaose and lactose-N-trifucoheptaose.

[0080] Mammalian milk oligosaccharides or MMOs comprise oligosaccharides present in milk found at any stage during lactation, including colostrum from humans (i.e., human milk oligosaccharides or HMOs) and mammals including, but not limited to, cattle (Bos taurus), sheep (Ovis aries), goats (Capra aegagrushircus), Bactrian camels (Camelus bactrianus), horses (Equus feruscaballus), pigs (Sus scropha), dogs (Canis lupusfamiliaris), ezo brown bears (Ursus arctos yesoensis), polar bears (Ursus maritimus), Japanese black bears (Ursus thibetanus japonicus), striped skunks (Mephitis mephitis), Hooded seal (Cystophora cristata), Asian elephant (Elephas maximus), African elephant (Loxodonta africana), Giant anteater (Myrmecophaga tridactyla), True bottlenose dolphin (Tursiops truncates), Arctic minke whale (Balaenoptera acutorostrata), Eugene kangaroo (Macropuseugenii), Red kangaroo (Macropus rufus), Common fox (Trichosurus Vulpecula), Koala (Phascolarctos cinereus), Eastern quoll (Dasyurus viverrinus), Platypus (Ornithorhynchus anatinus).As used herein, "mammalian milk oligosaccharide" or MMO refers to oligosaccharides such as, but not limited to, 3-fucosyllactose, 2'-fucosyllactose, 6-fucosyllactose, 2',3-difucosyllactose, 2',2-difucosyllactose, 3,4-difucosyllactose, 6'-sialyllactose, 3'-sialyllactose, 3,6-disialyllactose, 6,6'-disialyllactose, 6'-s ... Lactose, 8,3-disialyl lactose, 3,6-disialyl lactose-N-tetraose, lactobifucosylatetraose, lactose-N-tetraose, lactose-N-neotetraose, lactose-N-fucopentaose II, lactose-N-fucopentaose I, lactose-N-fucopentaose III, lactose-N-fucopentaose V, lactose-N-fucopentaose VI, sialyllactose-N-tetraose c, sialyllactose-N -tetraose b, sialyllactose-N-tetraose a, lactose-N-difucohexaose I, lactose-N-difucohexaose II, lactose-N-hexaose, lactose-N-neohexaose, p-lactose-N-hexaose, monofucosylmonosialyllactose-N-tetraose c, monofucosyl p-lactose-N-hexaose, monofucosyllactose-N-hexaose III, isofucosylated lactose-N-hexaose Sugar III, isofucosylated lactose-N-hexaose I, sialyllactose-N-hexaose, sialyllactose-N-neohexaose II, difucosyl-p-lactose-N-hexaose, difucosyllactose-N-hexaose, difucosyllactose-N-hexaose a, difucosyllactose-N-hexaose c, galactosylated chitosan, fucosylated oligosaccharides, neutral oligosaccharides and / or sialylated oligosaccharides.As used herein, "mammalian milk oligosaccharides" or MMOs refer to oligosaccharides such as, but not limited to, the following: 3-fucosyllactose, 2'-fucosyllactose, 6-fucosyllactose, 2',3-difucosyllactose, 2',2-difucosyllactose, 3,4-difucosyllactose, 6'-sialyllactose, 3'-sialyllactose, 3,6-disialyllactose, 6,6'-disialyllactose lactose, 8,3-disialyl lactose, 3,6-disialyl lactose-N-tetraose, lactobifucosylatetraose, lactose-N-tetraose, lactose-N-neotetraose, lactose-N-fucopentaose II, lactose-N-fucopentaose I, lactose-N-fucopentaose III, lactose-N-fucopentaose V, lactose-N-fucopentaose VI, sialyllactose-N-tetraose c, sialyllactose- N-tetraose b, sialyllactose-N-tetraose a, lactose-N-difucohexaose I, lactose-N-difucohexaose II, lactose-N-hexaose, lactose-N-neohexaose, p-lactose-N-hexaose, monofucosylmonosialyllactose-N-tetraose c, monofucosyl p-lactose-N-hexaose, monofucosyllactose-N-hexaose III, isofucosylated lactose-N-hexaose Sugar III, isofucosylated lactose-N-hexaose I, sialyllactose-N-hexaose, sialyllactose-N-neohexaose II, difucosyl-p-lactose-N-hexaose, difucosyllactose-N-hexaose, difucosyllactose-N-hexaose a, difucosyllactose-N-hexaose c, galactosylated chitosan, fucosylated oligosaccharides, neutral oligosaccharides and / or sialylated oligosaccharides.As used herein, "mammalian milk oligosaccharides" refer to oligosaccharides such as, but not limited to, the following: 3-fucosyllactose, 2'-fucosyllactose, 6-fucosyllactose, 2',3-difucosyllactose, 2',2-difucosyllactose, 3,4-difucosyllactose, 6'-sialyllactose, 3'-sialyllactose, 3,6-disialyllactose, 6,6'-disialyllactose, 3'-sialyllactose, 3,6-disialyllactose, 6,6'-disialyllactose, 6'-s ... Lactose, 8,3-disialyl lactose, 3,6-disialyl lactose-N-tetraose, lactobifucosylatetraose, lactose-N-tetraose, lactose-N-neotetraose, lactose-N-fucopentaose II, lactose-N-fucopentaose I, lactose-N-fucopentaose III, lactose-N-fucopentaose V, lactose-N-fucopentaose VI, sialyllactose-N-tetraose c, sialyllactose-N -tetraose b, sialyllactose-N-tetraose a, lactose-N-difucohexaose I, lactose-N-difucohexaose II, lactose-N-hexaose, lactose-N-neohexaose, p-lactose-N-hexaose, monofucosylmonosialyllactose-N-tetraose c, monofucosylparalactose-N-hexaose, monofucosyllactose-N-hexaose III, isofucosylated lactose-N-hexaose III, isofucosylated lactose-N-hexaose I, sialyllactose-N-hexaose, sialyllactose-N-neohexaose II, difucosyl-p-lactose-N-hexaose, difucosyllactose-N-hexaose, difucosyllactose-N-hexaose a, difucosyllactose-N-hexaose c, galactosylated chitosan, fucosylated oligosaccharides, neutral oligosaccharides and / or sialylated oligosaccharides.

[0081] As used herein, the terms "α-2,3-sialyltransferase," "α2,3 sialyltransferase," "3-sialyltransferase," "α-2,3-sialyltransferase," "α2,3 sialyltransferase," "3 sialyltransferase," "3-ST," or "3ST," or "a23-ST" are used interchangeably and refer to a glycosyltransferase that catalyzes the transfer of sialic acid from a donor CMP-sialic acid to an acceptor molecule in an α-2,3-linkage. As used herein, the terms "3' sialyllactose", "3'-sialyllactose", "α-2,3-sialyllactose", "α2,3 sialyllactose", "α-2,3-sialyllactose", "α2,3 sialyllactose", "3SL" or "3'SL" are used interchangeably and refer to the product obtained by transferring a sialic acid group from CMP-Neu5Ac to lactose in an α-2,3-linkage by catalysis of α-2,3-sialyltransferase.

[0082] As used herein, the terms "3'-KDO-lactose", "3'KDO-lactose", "3'KDO lactose", "3'KDO-lactose" are used interchangeably and refer to the product obtained by transferring a sialic acid group from CMP-KDO to lactose in an α-2,3-linkage catalyzed by α-2,3-sialyltransferase.

[0083] The terms "LNT II", "LNT-II", "LN3", "lactose-N-triose II", "lactose-N-triose II", "lactose-N-triose", "lactose-N-triose" or "GlcNAcβ1-3Galβ1-4Glc" used in the present invention are used interchangeably. The terms "LNT", "lactose-N-tetraose", "lactose-N-tetraose" or "Galβ1-3GlcNAcβ1-3Galβ1-4Glc" used in the present invention are used interchangeably. The terms "LNnT", "lactose-N-neotetraose", "lactose-N-neotetraose", "neo-LNT" or "Galβ1-4GlcNAcβ1-3Galβ1-4Glc" used in the present invention are used interchangeably.

[0084] The terms "LSTa", "LS-tetrasaccharide a", "sialyl-lactose-N-tetrasaccharide a", "sialyl lactose-N-tetrasaccharide a", or "Neu5Ac-a2,3-Gal-b1,3-GlcNAc-b1,3-Gal-b1,4-Glc" used in the present invention can be used interchangeably. The terms "LSTb", "LS-tetrasaccharide b", "sialyl-lactose-N-tetrasaccharide b", "sialyl lactose-N-tetrasaccharide b", or "Gal-β1,3-(Neu5Ac-α2,6)-GlcNAc-β1,3-Gal-β1,4-Glc" used in the present invention can be used interchangeably. The terms "LSTc", "LS-tetraose c", "sialyl-lactose-N-tetraose c", "sialyl lactose-N-tetraose c", "sialyl lactose-N-neotetraose c" or "Neu5Ac-α2,6-Gal-β1,4-GlcNAc-β1,3-Gal-β1,4-Glc" used in the present invention can be used interchangeably. The terms "LSTd", "LS-tetraose d", "sialyl-lactose-N-tetraose d", "sialyl lactose-N-tetraose d", "sialyl lactose-N-neotetraose d" or "Neu5Ac-α2,3-Gal-β1,4-GlcNAc-β1,3-Gal-β1,4-Glc" used in the present invention can be used interchangeably. The terms "DSLNnT" and "disialyl lactose-N-neotetraose" are used interchangeably to refer to Neu5Ac-α2,6-Gal-β1,4-GlcNAc-β1,3-[Neu5Ac-α2,6]-Gal-β1,4-Glc. The terms "DSLNT", "DS-LNT" and "disialyl lactose-N-tetraose" are used interchangeably to refer to Neu5Ac-α2,3-Gal-β1,3-[Neu5Ac-α2,6]-GlcNAc-β1,3-Gal-β1,4-Glc.

[0085] The term "membrane transporter" as used herein refers to a protein that is part of a cell membrane or interacts with a cell membrane and controls the flow of molecules and information across cells. Therefore, membrane proteins are involved in transport, whether it is input into a cell or output from a cell. Such membrane transporters can be, but are not limited to, transporters driven by PP-bond hydrolysis, β-barrel pores, auxiliary transporters, and phosphotransfer-driven group translocation proteins (Forrest et al., Biochim. Biophys. Acta 1807 (2011) 167-188; Lengeler, J. Mol. Microbiol. Biotechnol. 25 (2015) 79-93; Moraes and Reithmeier, Biochim. Biophys. Acta 1818 (2012), 2687-2706; Saier et al., Nucleic Acids Res. 44 (2016) D372-D379).

[0086] The major facilitator superfamily (MFS) is a superfamily of membrane transporters, which are single-polypeptide secondary carriers with the InterPro domain IPR036259, capable of transporting small solutes in response to chemiosmotic ion gradients (Pao et al., J. Microbiol. Mol. Biol. Rev. 62 (1998) 1-34; Walmsley et al., Trends Biochem. Sci. 23 (1998) 476-481; Wang et al., Jr. Biochim. Biophys. Acta Biomembr. 1862 (2020) 183277; Teelucksingh et al., 202 (2020) e00367-20).

[0087] As used herein, "SET" or "sugar efflux transporter" is part of the MFS superfamily and refers to a membrane protein of the SET family, which is a protein with an InterPRO domain IPR004750 and / or a protein belonging to the eggNOGv5.0.0 family ENOG410XTE9. This protein family is an efflux system for lactose, glucose, aromatic glucosides and galactosides, cellobiose, maltose, α-methyl glucosides, and other sugar compounds. They are found in both Gram-negative and Gram-positive bacteria (Liu et al., Mol. Microbiol. 31 (1999) 1845-1851; Liu et al., J. Biol. Chem. 274 (1999) 22977-22984; Sun and Vanderpool, J. Bacteriol. 193 (2011) 143-153).

[0088] As used herein, the term "siderophore" refers to secondary metabolites of various microorganisms, which are mainly iron ion specific chelators (Neilands, J.Biol.Chem.270 (1995) 26723-26726). Transport proteins are required to export siderophores to the outside of the cell. So far, four superfamilies of membrane proteins have been identified in this process: the main facilitating protein superfamily (MFS); multidrug / oligosaccharide lipid / polysaccharide flippase superfamily (MOP); resistance, nodularity and cell division superfamily (RND); and ABC superfamily (Teelucksingh et al. 202 (2020) e00367-20). In general, genes involved in siderophore export are clustered with siderophore biosynthesis genes. As used herein, the term "siderophore export protein" refers to such transport proteins required for exporting siderophores to the outside of the cell.

[0089] The ATP binding cassette (ABC) superfamily contains both absorption and efflux transport systems, and the members of these two groups are usually loosely clustered together. ATP hydrolysis without protein phosphorylation provides energy for transport. There are dozens of families in the ABC superfamily, and families are generally associated with substrate specificity (Davidson et al., Microbiol. Mol. Biol. Rev. 72 (2008) 317-364; Goffeau et al. (2013). "ABC Transporters". In Lane WJ, Lennarz MD (eds.). Encyclopedia of Biological Chemistry (Second ed.). London: Academic Press. pp. 7-11).

[0090] It will be appreciated by those skilled in the art that for the databases used herein, including EggNOG 5.0.0 (released in November 2018) and InterPro 86.0 (released on June 3, 2021), the content of each database is fixed and does not change in each release version. When the content of a particular database changes, this particular database receives a new release version with a new release date. All release versions of each database and their corresponding release dates and the specific content as marked on these specific release dates are available and known to those skilled in the art.

[0091] The term "pathway for producing sialylated oligosaccharides" as used herein is a biochemical pathway consisting of enzymes and their respective genes, which are involved in the synthesis of sialylated oligosaccharides as defined herein. The pathway for producing sialylated oligosaccharides may include, but is not limited to, pathways involving the synthesis of nucleotide-activated sugars and the transfer of nucleotide-activated sugars to receptors to produce sialylated oligosaccharides of the present invention. An example of such a pathway is the sialylation pathway. Further examples of such a pathway include, but are not limited to, fucosylation, galactosylation, N-acetylglucosaminylation, N-acetylgalactosaminylation, mannosylation, N-acetylmannosaminylation pathways.

[0092] The "sialylation pathway" is a biochemical pathway consisting of at least one enzyme selected from the list comprising: L-glutamine-D-fructose-6-phosphate aminotransferase, phosphoglucosamine mutase, N-acetylglucosamine-6-P deacetylase, N-acylglucosamine 2-epimerase, UDP-N-acetylglucosamine 2-epimerase, N-acetylmannosamine-6-phosphate 2-epimerase, UDP-GlcNAc 2-epimerase / kinase, glucosamine 6-phosphate N-acetyltransferase, N-acetylglucosamine-6-phosphate phosphatase, phosphoacetylglucosamine mutase, N-acetylglucosamine 1-phosphate uridyltransferase, glucosamine-1-phosphate acetyltransferase, Neu5Ac synthase, N-acetylneuraminic acid lyase, N-acylneuraminic acid-9-phosphate synthase, N-acylneuraminic acid-9-phosphatase, sialic acid transporter and CMP-sialic acid synthase, which combine with sialyltransferase to produce α2,3; α2,6 and / or α2,8 sialylated oligosaccharides.

[0093] The terms "pyruvate dehydrogenase," "pyruvate oxidase," "POX," "poxB," and "pyruvate:ubiquinone-8 oxidoreductase" are used interchangeably and refer to an enzyme that catalyzes the oxidative decarboxylation of pyruvate to produce acetate and carbon dioxide.

[0094] The terms "lactate dehydrogenase," "D-lactate dehydrogenase," "ldhA," "hslI," "htpH," "D-LDH," "fermentative lactate dehydrogenase," and "D-specific 2-hydroxyacid dehydrogenase" are used interchangeably and refer to an enzyme that catalyzes the conversion of lactate to pyruvate, producing NADH.

[0095] The term "enabled efflux" means the introduction of solute transport activity on the cytoplasmic membrane and / or cell wall. The transport can be achieved by introducing and / or increasing the expression of a membrane transport protein as described herein. The term "enhanced efflux" means improved solute transport activity on the cytoplasmic membrane and / or cell wall. The transport of solutes on the cytoplasmic membrane and / or cell wall can be enhanced by introducing and / or increasing the expression of a membrane transport protein as described herein. The "expression" of a membrane transport protein is defined as the "overexpression" of the gene encoding the membrane transport protein when it is an endogenous gene, or the "expression" of the gene encoding the membrane transport protein when it is a heterologous gene not present in a wild-type strain or cell.

[0096] The term "purified" refers to a substance that is substantially or substantially free of components that interfere with the activity of biomolecules. For cells, sugars, nucleic acids and polypeptides, the term "purified" refers to a substance that is substantially or substantially free of components that are usually associated with the substances found in the natural state. Typically, as measured by the intensity of the bands on a silver-stained gel or other methods for determining purity, the purified sugars, oligosaccharides, proteins or nucleic acids of the present invention are at least about 50%, 55%, 60%, 65%, 70%, 75%, 80% or 85% pure, usually at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99.0% pure. Purity or homogeneity can be indicated by a variety of methods well known in the art, such as polyacrylamide gel electrophoresis of protein or nucleic acid samples, followed by visualization after staining. For some purposes, high resolution and the use of HPLC or similar methods for purification will be required. For disaccharides and oligosaccharides, purity can be determined using methods such as, but not limited to, thin layer chromatography, gas chromatography, NMR, HPLC, capillary electrophoresis or mass spectrometry. In addition, the terms "contaminants" and "impurities" herein preferably refer to particles, cells, cell components, metabolites, cell debris, proteins, peptides, amino acids, nucleic acids, glycolipids and / or endotoxins that may be present in an aqueous medium such as, for example, a culture or incubation.

[0097] As used herein, the term "clarification" refers to the act of treating an aqueous medium (e.g., a culture or incubation) to remove suspended particles and contaminants from the production process, such as cells, cellular components, insoluble metabolites, and debris that may interfere with the final purification of one or more biological products. Such treatment may be by centrifugation, flocculation, flocculation with optional sonication, gravity filtration, microfiltration, foam separation, or vacuum filtration (e.g., by a Celite® filter). TM The ceramic filter with filter aid is carried out in a conventional manner.

[0098] The term "culture" refers to the culture medium in which cells are cultured or fermented, the cells themselves, and the sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, produced by the cells throughout the culture fluid, i.e., inside the cells (intracellular) as well as outside (extracellular). The terms "culture medium" and "culture medium" used herein are used interchangeably and refer to the culture medium in which cells are cultured.

[0099] The term "incubation" refers to a mixture in which sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, are produced. The mixture may include one or more enzymes, one or more precursors and one or more receptors as defined herein, present in a buffer solution, and incubated at a certain temperature for a certain time, so that the one or more enzymes can use the one or more precursors and one or more receptors in the mixture to catalyze the production of sialylated oligosaccharides, preferably 3' sialylated oligosaccharides. The mixture may also include i) cells obtained after cultivation or incubation, and optionally cell lysis is performed on the cells, ii) a buffer solution or a culture or incubation medium in which cells are cultured or fermented, and iii) sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, produced in the entire culture fluid in the cell (i.e., inside the cell (intracellular) and outside the cell (extracellular)). The incubation may also be a culture as defined herein.

[0100] The terms "reactor" and "incubator" refer to a container filled with a culture or incubation. Examples of reactors and incubators include, but are not limited to, microfluidic devices, well plates, tubes, shake flasks, fermenters, bioreactors, process vessels, cell culture incubators, CO2 incubators.

[0101] As used herein, the term "cell productivity index (CPI)" refers to the mass of sialylated oligosaccharides produced by cells divided by the mass of cells produced in culture.

[0102] The term "precursor" as used herein refers to a substance that is taken up or synthesized by a cell to specifically produce a sialylated oligosaccharide according to the present invention. In this sense, a precursor can be an acceptor as defined herein, but can also be another substance, a metabolite, that is first modified in the cell as part of a biochemical synthetic pathway for sialylated oligosaccharides. The term "precursor" as used herein should also be understood as a chemical compound that participates in a chemical or enzymatic reaction to produce another compound such as an intermediate (as part of a metabolic pathway for sialylated oligosaccharides, preferably 3' sialylated oligosaccharides). The term "precursor" as used herein should also be understood as a donor that is used by a glycosyltransferase to modify an acceptor as defined herein with a sugar moiety in a glycosidic bond as part of a metabolic pathway for sialylated oligosaccharides, preferably 3' sialylated oligosaccharides. Examples of such precursors include receptors as defined herein, and / or dihydroxyacetone, glucosamine, N-acetylglucosamine, N-acetylmannosamine, galactosamine, N-acetylgalactosamine, galactosyl lactose, phosphorylated sugars or sugar phosphates such as, but not limited to, glucose-1-phosphate, galactose-1-phosphate, glucose-6-phosphate, fructose-6-phosphate, fructose-1,6-bisphosphate, mannose-6-phosphate, mannose-1-phosphate, glycerol-3-phosphate, glyceraldehyde-3-phosphate, dihydroxyacetone-phosphate The invention relates to nucleotide activating sugars (e.g., nucleotide diphosphate sugars and nucleotide monophosphate sugars as defined herein, such as UDP-glucose, UDP-galactose, UDP-N-acetylglucosamine, CMP-sialic acid, GDP-mannose, GDP-4-dehydro-6-deoxy-α-D-mannose, GDP-fucose).

[0103] Optionally, the cell is transformed to contain and express a protein encoding a transporter selected from the group consisting of a lactose transporter, an N-acetylneuraminic acid transporter, a fucose transporter, a glucose transporter, a galactose transporter, a transporter for nucleotide-activated sugars, wherein the transporter internalizes the precursor added in the culture medium for the synthesis of the sialylated oligosaccharides of the present invention, preferably 3' sialylated oligosaccharides.

[0104] As used herein, the term "acceptor" refers to a monosaccharide, disaccharide, or oligosaccharide that can be modified by a glycosyltransferase. Examples of such acceptors include glucose, galactose, fructose, glycerol, sialic acid, fucose, mannose, maltose, sucrose, lactose, lacto-N-triose, lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), lacto-N-pentose (LNP), lacto-N-neopentose, p-lactose-N-pentose, p-lactose-N-neopentose, lacto-N-neopentose I, lacto-N-hexose (LNH), lacto-N-neohexose (LNnH), p-lactose-N-neohexose (pLNnH), p-lactose-N-hexose (pLNH), lacto-N-heptose, lacto-N-neoheptose, p-lactose-N-neoheptose, p-lactose-N-heptose, lacto-N-octose (LNO), lacto-N-neooctose, isolactose-N -octose, para-lactose-N-octose, allolactose-N-neooctose, neo-lactose-N-neooctose, para-lactose-N-neooctose, allolactose-N-nonose, neo-lactose-N-nonose, lactose-N-nonose, lactose-N-decose, allolactose-N-decose, neo-lactose-N-decose, lactose-N-neodecose and oligosaccharides containing one or more N-acetyllactosamine units and / or one or more lactose-N-disaccharide units or their oligosaccharides, intermediates in fucosylated and sialylated forms, ceramide, N-acylated sphingosine, glucosylceramide, lactosylceramide, sphingosine, phytosphingosine, sphingosine synthon, peptide backbones with β-GlcNAc-Asn residues, glycoproteins with terminal GlcNAc and Gal residues, immunoglobulins. DETAILED DESCRIPTION OF THE INVENTION

[0106] In a first aspect, the present invention provides a method for producing sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL (Neu5Ac-α2,3-Gal-β1,4-Glc). The method comprises contacting a mixture comprising a donor containing sialic acid residues and an acceptor selected from a list comprising oligosaccharides or disaccharides under conditions where the sialyltransferase catalyzes the transfer of sialic acid residues from a donor to an acceptor, thereby producing the sialylated oligosaccharide. Herein, the sialyltransferase has α-2,3-sialyltransferase activity for galactose (Gal) residues of lactose and comprises an amino acid sequence which is i) at least 67.0% identical to any one of the amino acid sequences shown in SEQ ID NO 05, 01, 02, 03, 06, 07 or 08 over a stretch of at least 150 amino acid residues, preferably at least 200 amino acid residues; ii) at least 85.0% identical to the amino acid sequence shown in SEQ ID NO 04 over a stretch of at least 150 amino acid residues, preferably at least 200 amino acid residues, or iii) at least 60.0% identical to the amino acid sequence shown in SEQ ID NO 12 over a stretch of at least 150 amino acid residues, preferably at least 200 amino acid residues. Preferably, the sialylated oligosaccharide is a 3' sialylated oligosaccharide, more preferably 3' SL, and the acceptor substrate is lactose. In a preferred embodiment, the sialyltransferase also has α-2,3-sialyltransferase activity on galactose (Gal) residues of acceptors other than lactose (eg, lacto-N-tetraose or lacto-N-neotetraose).

[0107] In a preferred aspect, the present invention provides a method for producing 3' sialylated oligosaccharides. The method comprises contacting a mixture comprising a donor containing sialic acid residues and an acceptor selected from a list comprising oligosaccharides or disaccharides under conditions where the sialyltransferase catalyzes the transfer of sialic acid residues from a donor to an acceptor, thereby producing the 3' sialylated oligosaccharides. In this article, the sialyltransferase has α-2,3-sialyltransferase activity for galactose (Gal) residues of lactose and comprises an amino acid sequence that is at least 80.0% identical to any of the full-length amino acid sequences shown in SEQ ID NOs 05, 04, 12, 01, 02, 03, 06, 07 or 08. Preferably, the 3' sialylated oligosaccharides are isolated. In a preferred embodiment, the sialyltransferase also has α-2,3-sialyltransferase activity for galactose (Gal) residues of acceptors other than lactose (e.g., lactose-N-tetraose or lactose-N-neotetraose).

[0108] In a specific embodiment, the present invention provides a method for producing sialylated oligosaccharides (preferably 3' sialylated oligosaccharides, more preferably 3' SL (Neu5Ac-α2,3-Gal-β1,4-Glc)), wherein the method comprises the following steps:

[0109] a) Provide

[0110] i. CMP-sialic acid

[0111] ii. Acceptor, preferably lactose

[0112] iii. a sialyltransferase, wherein the sialyltransferase is a sialyltransferase having α-2,3-sialyltransferase activity towards a galactose (Gal) residue of lactose and comprises an amino acid sequence which i) is at least 67.0% identical to any one of the amino acid sequences shown in SEQ ID NO 05, 01, 02, 03, 06, 07 or 08 over a stretch of at least 150 amino acid residues, preferably at least 200 amino acid residues; ii) is at least 85.0% identical to the amino acid sequence shown in SEQ ID NO 04 over a stretch of at least 150 amino acid residues, preferably at least 200 amino acid residues, or iii) is at least 60.0% identical to the amino acid sequence shown in SEQ ID NO 12 over a stretch of at least 150 amino acid residues, preferably at least 200 amino acid residues.

[0113] b) contacting the sialyltransferase and CMP-sialic acid with the acceptor (preferably lactose) under conditions where the sialyltransferase catalyzes the transfer of sialic acid residues from the CMP-sialic acid to the acceptor, thereby producing sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL (Neu5Ac-α2,3-Gal-β1,4-Glc).

[0114] c) preferably, isolating said produced sialylated oligosaccharides.

[0115] Preferably, the sialyltransferase is any sialyltransferase described herein.

[0116] In a specific embodiment, the present invention provides a method for producing 3' sialylated oligosaccharides, wherein the method comprises the following steps:

[0117] a) Provide

[0118] i. CMP-sialic acid

[0119] ii. Acceptor, preferably lactose

[0120] iii. a sialyltransferase having α-2,3-sialyltransferase activity towards a galactose (Gal) residue of lactose and comprising an amino acid sequence that is at least 80.0% identical to any one of the full-length amino acid sequences set forth in SEQ ID NOs 05, 04, 12, 01, 02, 03, 06, 07 or 08,

[0121] b) contacting the sialyltransferase and CMP-sialic acid with the acceptor (preferably lactose) under conditions where the sialyltransferase catalyzes the transfer of sialic acid residues from the CMP-sialic acid to the acceptor, thereby producing 3' sialylated oligosaccharides,

[0122] c) preferably, isolating said produced 3' sialylated oligosaccharides.

[0123] Preferably, the sialyltransferase is any sialyltransferase described herein.

[0124] In an alternative embodiment, the present invention provides a method wherein a cell extract comprising a sialyltransferase as described herein is contacted with a mixture comprising a donor (comprising a sialic acid residue) and an acceptor (comprising an oligosaccharide or a disaccharide) under conditions where the sialyltransferase catalyzes the transfer of the sialic acid residue from the donor to the acceptor, thereby producing the sialylated oligosaccharide. Preferably, the sialylated oligosaccharide is a 3' sialylated oligosaccharide, more preferably a 3' SL.

[0125] In an alternative embodiment of the method of the invention, the sialylated oligosaccharide is produced in a cell-free system.Preferably, the sialylated oligosaccharide is a 3' sialylated oligosaccharide, more preferably a 3' SL.

[0126] In another aspect, the present invention provides a method for producing sialylated oligosaccharides (preferably 3' sialylated oligosaccharides, more preferably 3' SL (Neu5Ac-α2,3-Gal-β1,4-Glc)), wherein the method comprises the following steps:

[0127] i. providing a cell, preferably a single cell, expressing, preferably heterologously expressing, more preferably overexpressing, even more preferably heterologously overexpressing a sialyltransferase, wherein the sialyltransferase has α-2,3-sialyltransferase activity towards galactose (Gal) residues of lactose and comprises an amino acid sequence which i) is at least 67.0% identical to any one of the amino acid sequences shown in SEQ ID NO 05, 01, 02, 03, 06, 07 or 08 over a stretch of at least 150 amino acid residues, preferably at least 200 amino acid residues, or ii) is at least 85.0% identical to the amino acid sequence shown in SEQ ID NO 04 over a stretch of at least 150 amino acid residues, preferably at least 200 amino acid residues, or iii) is at least 60.0% identical to the amino acid sequence shown in SEQ ID NO 12 over a stretch of at least 150 amino acid residues, preferably at least 200 amino acid residues,

[0128] ii. providing CMP-sialic acid, optionally, said CMP-sialic acid is produced by said cell, and

[0129] iii. providing an oligosaccharide or disaccharide, optionally produced by the cell, and

[0130] iv. culturing and / or incubating said cells under conditions allowing expression of said sialyltransferase (optionally, allowing production of said CMP-sialic acid and / or said oligo- or disaccharide),

[0131] Preferably, said sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL, are isolated from said culture or incubation.

[0132] In another aspect, the present invention provides a method for producing 3' sialylated oligosaccharides, wherein the method comprises the following steps:

[0133] i. providing a cell, preferably a single cell, expressing, preferably heterologously expressing, more preferably overexpressing, even more preferably heterologously overexpressing a sialyltransferase, wherein the sialyltransferase has α-2,3-sialyltransferase activity towards galactose (Gal) residues of lactose and comprises an amino acid sequence that is at least 80.0% identical to any one of the full-length amino acid sequences shown in SEQ ID NO 05, 04, 12, 01, 02, 03, 06, 07 or 08,

[0134] ii. providing CMP-sialic acid, optionally, said CMP-sialic acid is produced by said cell, and

[0135] iii. providing an oligosaccharide or disaccharide, optionally produced by the cell, and

[0136] iv. culturing and / or incubating said cell under conditions: a) allowing expression of said sialyltransferase, optionally allowing production of said CMP-sialic acid and / or said oligosaccharide or disaccharide, and b) wherein said sialyltransferase catalyzes the transfer of a sialic acid residue from said CMP-sialic acid to said acceptor, thereby producing said 3' sialylated oligosaccharide,

[0137] Preferably, said 3' sialylated oligosaccharides are isolated from said culturing or incubation.

[0138] In a specific embodiment of the method of the present invention, the sialylated oligosaccharides are produced by a cell, preferably a single cell, wherein the cell expresses i) a sialyltransferase having α-2,3-sialyltransferase activity towards Gal residues of lactose and comprising an amino acid sequence that i) is at least 67.0% identical to any one of the amino acid sequences shown in SEQ ID NO 05, 01, 02, 03, 06, 07 or 08 over a stretch of at least 150 amino acid residues, preferably at least 200 amino acid residues, ii) is at least 85.0% identical to the amino acid sequence shown in SEQ ID NO 04 over a stretch of at least 150 amino acid residues, preferably at least 200 amino acid residues, iii) is at least 60.0% identical to the amino acid sequence shown in SEQ ID NO 12 over a stretch of at least 150 amino acid residues, preferably at least 200 amino acid residues, or iv) is any sialyltransferase described herein. In a preferred embodiment of the method of the present invention, the 3' sialylated oligosaccharide is produced by a cell, preferably a single cell, wherein the cell expresses i) a sialyltransferase having α-2,3-sialyltransferase activity towards a Gal residue of lactose and comprising an amino acid sequence that is at least 80.0% identical to any one of the full-length amino acid sequences shown in SEQ ID NO 05, 04, 12, 01, 02, 03, 06, 07 or 08, or ii) any sialyltransferase described herein.

[0139] The cell used may be a metabolically engineered cell as described herein, preferably wherein the cell is metabolically engineered to produce the sialylated oligosaccharide. Preferably, the sialylated oligosaccharide is a 3' sialylated oligosaccharide, more preferably a 3' SL. Preferably, the cell is metabolically engineered to produce a 3' sialylated oligosaccharide.

[0140] In preferred embodiments of the methods and / or cells of the invention, the sialyltransferase as described herein comprises an amino acid sequence that is at least 67.0%, at least 70.0%, at least 75.0%, at least 80.0%, at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to any of the amino acid sequences shown in SEQ ID NO 05, 01, 02, 03, 06, 07 or 08 over a stretch of at least 150, at least 160, at least 170, at least 180, at least 190, at least 200, at least 210, at least 220, at least 230, at least 240, at least 250, at least 260, at least 270, at least 280, at least 290 or at least 300 amino acid residues.

[0141] In a more preferred embodiment, the sialyltransferase comprises an amino acid sequence that is at least 55.0%, at least 60.0%, at least 65.0%, at least 70.0%, at least 75.0%, at least 80.0%, at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to any of the full-length amino acid sequences shown in SEQ ID NO 05, 01, 02, 03, 06, 07 or 08.

[0142] In another preferred embodiment of the methods and / or cells of the invention, the sialyltransferase as described herein comprises an amino acid sequence that is at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to the amino acid sequence shown in SEQ ID NO 04 over a stretch of at least 150, at least 160, at least 170, at least 180, at least 190, at least 200, at least 210, at least 220, at least 230, at least 240, at least 250, at least 260, at least 270, at least 280, at least 290 or at least 300 amino acid residues.

[0143] In another more preferred embodiment, the sialyltransferase comprises an amino acid sequence that is at least 80.0%, at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to the full-length amino acid sequence shown in SEQ ID NO 04.

[0144] In another preferred embodiment of the methods and / or cells of the invention, the sialyltransferase described herein comprises an amino acid sequence that is at least 60.0%, at least 65.0%, at least 70.0%, at least 75.0%, at least 80.0%, at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to the full-length amino acid sequence shown in SEQ ID NO 12 over a stretch of at least 150, at least 160, at least 170, at least 180, at least 190, at least 200, at least 210, at least 220, at least 230, at least 240, at least 250, at least 260, at least 270, at least 280, at least 290 or at least 300 amino acid residues.

[0145] In another more preferred embodiment, the sialyltransferase comprises an amino acid sequence that is at least 45.0%, at least 50.0%, at least 55.0%, at least 60.0%, at least 65.0%, at least 70.0%, at least 75.0%, at least 80.0%, at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to the full-length amino acid sequence shown in SEQ ID NO 12.

[0146] Alternatively, the sialyltransferase as described herein comprises an amino acid sequence comprising a fragment of any one of the amino acid sequences shown in SEQ ID NOs 05, 04, 12, 01, 02, 03, 06, 07 or 08, and has α-2,3-sialyltransferase activity towards the Gal residue of lactose.

[0147] Most preferably, the sialyltransferase comprises the amino acid sequence shown in any one of SEQ ID NOs 05, 04, 12, 01, 02, 03, 06, 07 or 08.

[0148] In the context of the present invention, permissive conditions are understood to be conditions related to physical or chemical parameters including, but not limited to, temperature, pH, pressure, osmotic pressure and product / donor / precursor / acceptor concentrations.

[0149] In certain embodiments, permissive conditions may include a temperature range of about 30 + / - 20 degrees Celsius, a pH range of 2.0-10.0, preferably a pH range of 3.0-7.0.

[0150] In another and / or additional preferred embodiment of the methods and / or cells of the invention, the sialic acid residue is selected from at least one of Neu4Ac; Neu5Ac; Neu4,5Ac2; Neu5,7Ac2; Neu5,8Ac2; Neu5,9Ac2; Neu4,5,9Ac3; Neu5,7,9Ac3; Neu5,8,9Ac3; Neu4,5,7,9Ac4; Neu5,7,8,9Ac4; Neu4,5,7,8,9Ac5; Neu5Gc and 2-keto-3-deoxymanno-octulose acid (KDO). In a more preferred embodiment, the sialic acid residue is Neu5Ac. In another more preferred embodiment, the sialic acid residue is KDO.

[0151] In another and / or additional preferred embodiment of the methods and / or cells of the invention, the donor comprising sialic acid residues is CMP-sialic acid. In a more preferred embodiment, the donor comprising sialic acid residues is selected from CMP-Neu5Ac, CMP-Neu4Ac, CMP-Neu5Ac9N3, CMP-Neu4,5Ac2, CMP-Neu5,7Ac2, CMP-Neu5,9Ac2, CMP-Neu5,7(8,9)Ac2, CMP-Neu5,7(8,9)Ac2, CMP-N-glycolylneuraminic acid (CMP-Neu5Gc) and CMP-KDO. In a more preferred embodiment, the donor comprising sialic acid residues is CMP-Neu5Ac. In another more preferred embodiment, the donor comprising sialic acid residues is CMP-KDO.

[0152] Preferably, the sialylated oligosaccharide is a 3' sialylated oligosaccharide, more preferably 3' SL, and the acceptor is lactose. Alternatively, the sialylated oligosaccharide is a 3' sialylated oligosaccharide, the 3' sialylated oligosaccharide is a sugar modified by KDO, more preferably 3' KDO-lactose, and the acceptor is lactose. Alternatively, the sialylated oligosaccharide is a 3' sialylated oligosaccharide, the 3' sialylated oligosaccharide is a mixture of 3' sialyllactose and 3' KDO-lactose, and the acceptor is lactose.

[0153] In one embodiment of the method of the present invention, the culture medium contains at least one carbon source selected from the group consisting of glucose, fructose, sucrose and glycerol.

[0154] In another embodiment of the method of the present invention, the culture or incubation medium contains at least one compound selected from the group consisting of lactose, galactose, glucose, sialic acid, CMP-sialic acid, CMP-Neu5Ac and CMP-KDO.

[0155] Preferably, the sialylated oligosaccharide is recovered from the culture or incubation medium and / or cells or isolated from the culture or incubation as described herein. More preferably, the sialylated oligosaccharide is a 3' sialylated oligosaccharide and the 3' sialylated oligosaccharide is recovered from the culture or incubation medium and / or cells or isolated from the culture or incubation as described herein.

[0156] According to an embodiment of the method of the present invention, the conditions allowing the production of the sialylated oligosaccharides include the use of a culture or incubation medium comprising at least one precursor and / or an acceptor to produce sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, as described herein. Preferably, the culture or incubation medium comprises at least one precursor and / or an acceptor, wherein the precursor is selected from a group comprising monosaccharides, such as galactose, glucose, fucose, sialic acid, GlcNAc, GalNAc; nucleotide activated sugars, such as CMP-sialic acid, CMP-Neu5Ac, CMP-KDO, UDP-Gal, UDP-GlcNAc, GDP-fucose; disaccharides, such as lactose; and oligosaccharides, such as lactose-N-triose (LN3), lactose-N-tetraose (LNT) and lactose-N-neotetraose (LNnT) and / or wherein the acceptor is selected from a group comprising disaccharides (e.g. lactose) and oligosaccharides (e.g. LN3, LNT, LNnT). In a more preferred embodiment of the method of the present invention, the precursor is selected from the list comprising sialic acid, CMP-sialic acid, CMP-KDO, glucose, galactose and UDP-galactose. In another more preferred embodiment of the method of the present invention, the acceptor is lactose.

[0157] According to alternative and / or additional embodiments of the method of the invention, the conditions allowing the production of said sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, comprise adding to the culture or incubation medium at least one precursor and / or acceptor feed for the production of said sialylated oligosaccharides, preferably 3' sialylated oligosaccharides.

[0158] According to an alternative embodiment of the method of the present invention, the conditions allowing the production of said sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, comprise the use of a culture or incubation medium, wherein said culture or incubation medium lacks any precursor and / or acceptor for the production of said sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, and is combined with the further addition of at least one precursor and / or acceptor feed for the production of said sialylated oligosaccharides, preferably 3' sialylated oligosaccharides to said culture or incubation medium.

[0159] According to one embodiment of the method of the invention, the culturing or incubation is comprised in a reactor or incubator as defined herein. The volume of the reactor or incubator ranges from microliter (μL) scale to 10.000 ml. 3 In a preferred embodiment, the volume of the reactor or incubator ranges from 250 mL (milliliters) to 10.000 m 3 (cubic meter).

[0160] In a preferred embodiment, the method for producing sialylated oligosaccharides, preferably 3' sialylated oligosaccharides as described herein comprises at least one of the following steps:

[0161] i) using a culture or incubation medium comprising at least one precursor and / or receptor;

[0162] ii) adding at least one precursor and / or acceptor feed to the culture or incubation medium in the reactor or incubator, wherein the total volume of the reactor or incubator ranges from 250 mL (milliliters) to 10.000 mL (milliliters); 3 (cubic meters), preferably added in a continuous manner, and preferably such that the final volume of the culture or incubation medium does not exceed three times, preferably does not exceed two times, and more preferably is less than two times the volume of the culture or incubation medium before the addition of the precursor and / or acceptor feed;

[0163] iii) adding at least one precursor and / or acceptor feed to the culture or incubation medium in the reactor or incubator, wherein the total volume of the reactor or incubator ranges from 250 mL (milliliters) to 10.000 mL (milliliters); 3 (cubic meters), preferably added in a continuous manner, and preferably the final volume of the culture or incubation medium is not more than three times, preferably not more than two times, more preferably less than two times the volume of the culture or incubation medium before adding the precursor and / or acceptor feed, and the pH value of the precursor and / or acceptor feed is preferably set at 2.0 to 10.0, and the temperature of the precursor and / or acceptor feed is preferably maintained at 20°C to 80°C;

[0164] iv) adding at least one precursor and / or acceptor feed to the culture or incubation medium in a continuous manner via a precursor and / or acceptor feed solution over a period of 1 day, 2 days, 3 days, 4 days, 5 days;

[0165] v) adding at least one precursor and / or receptor feed to the culture or incubation medium in a continuous manner over a period of 1 day, 2 days, 3 days, 4 days, 5 days via a precursor and / or receptor feed solution, wherein, preferably, the pH value of the precursor and / or receptor feed solution is set at 2.0 to 10.0, wherein, preferably, the temperature of the precursor and / or receptor feed solution is maintained at 20° C. to 80° C.;

[0166] The method produces sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL and / or 3' KDO-lactose, at a concentration of at least 50 g / L, preferably at least 75 g / L, more preferably at least 90 g / L, more preferably at least 100 g / L, more preferably at least 125 g / L, more preferably at least 150 g / L, more preferably at least 175 g / L, more preferably at least 200 g / L in the final volume of the culture or incubation. In a more preferred embodiment of the method of the present invention, the precursor is selected from the list comprising sialic acid, CMP-sialic acid, CMP-Neu5Ac, CMP-KDO, glucose, galactose and UDP-galactose. In another more preferred embodiment of the method of the present invention, the acceptor is lactose.

[0167] In another and / or additional preferred embodiment, the method for producing sialylated oligosaccharides, preferably 3' sialylated oligosaccharides as described herein comprises at least one of the following steps:

[0168] i) using a culture or incubation medium comprising at least one precursor and / or receptor;

[0169] ii) adding at least one precursor and / or receptor to the culture or incubation medium in a reactor or incubator in a single pulse or discontinuous (pulsed) manner, wherein the total volume of the reactor or incubator ranges from 250 mL (milliliters) to 10.000 mL (milliliters); 3 (cubic meters), preferably such that the final volume of the culture or incubation medium does not exceed three times, preferably does not exceed two times, more preferably is less than two times the volume of the culture or incubation medium before the addition of the precursor and / or acceptor feed pulse;

[0170] iii) adding at least one precursor and / or acceptor feed to the culture or incubation medium in a reactor or incubator in a single pulse or discontinuous (pulsed) manner, wherein the total volume of the reactor or incubator ranges from 250 mL (milliliters) to 10.000 mL (milliliters); 3 (cubic meters), preferably such that the final volume of the culture or incubation medium does not exceed three times, preferably does not exceed two times, more preferably is less than two times the volume of the culture or incubation medium before the addition of the precursor and / or acceptor feed, and preferably the pH value of the precursor and / or acceptor feed pulse is set at 2.0 to 10.0, and preferably the temperature of the precursor and / or acceptor feed pulse is maintained at 20°C to 80°C;

[0171] iv) adding at least one precursor and / or acceptor feed to the culture or incubation medium in a discontinuous (pulse) manner via a precursor and / or acceptor feed solution over a period of 5 minutes, 10 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 10 hours, 12 hours, 1 day, 2 days, 3 days, 4 days, 5 days;

[0172] v) adding at least one precursor and / or acceptor feed to the culture or incubation medium in a discontinuous (pulsed) manner via a precursor and / or acceptor feed solution over a period of 5 minutes, 10 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 10 hours, 12 hours, 1 day, 2 days, 3 days, 4 days, 5 days, wherein, preferably, the pH value of the precursor and / or acceptor feed solution is set at 2.0 to 10.0, wherein, preferably, the temperature of the precursor and / or acceptor feed solution is maintained at 20° C. to 80° C.;

[0173] The method produces sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL and / or 3' KDO-lactose, at a concentration of at least 50 g / L, preferably at least 75 g / L, more preferably at least 90 g / L, more preferably at least 100 g / L, more preferably at least 125 g / L, more preferably at least 150 g / L, more preferably at least 175 g / L, more preferably at least 200 g / L in the final volume of the culture or incubation. In a more preferred embodiment of the method of the present invention, the precursor is selected from the list comprising sialic acid, CMP-sialic acid, CMP-Neu5Ac, CMP-KDO, glucose, galactose and UDP-galactose. In another more preferred embodiment of the method of the present invention, the acceptor is lactose.

[0174] In another and / or additional preferred embodiment, the method for producing sialylated oligosaccharides, preferably 3' sialylated oligosaccharides as described herein comprises at least one of the following steps:

[0175] i) using a culture or incubation medium comprising at least 50 g, more preferably at least 75 g, more preferably at least 100 g, more preferably at least 120 g, more preferably at least 150 g of precursor per liter of initial reactor or incubator volume, wherein the reactor or incubator volume ranges from 250 mL to 10.000 m 3 (cubic meter);

[0176] ii) adding to the culture or incubation medium in the reactor or incubator at least one precursor feed comprising at least 50 g, more preferably at least 75 g, more preferably at least 100 g, more preferably at least 120 g, more preferably at least 150 g of precursor per liter of initial reactor or incubator volume, wherein the total volume of the reactor or incubator ranges from 250 mL (milliliters) to 10.000 mL (milliliters); 3 (cubic meters), preferably added in a continuous manner, and preferably such that the final volume of the culture or incubation medium does not exceed three times, preferably does not exceed two times, more preferably is less than two times the volume of the culture or incubation medium before the addition of the precursor feed;

[0177] iii) adding at least one precursor feed to the culture or incubation medium in the reactor or incubator, the precursor feed comprising at least 50 g, more preferably at least 75 g, more preferably at least 100 g, more preferably at least 120 g, more preferably at least 150 g of precursor per liter of initial reactor or incubator volume, wherein the total volume of the reactor or incubator ranges from 250 mL (milliliters) to 10.000 mL (milliliters); 3 (cubic meters), preferably added in a continuous manner, and preferably such that the final volume of the culture or incubation medium does not exceed three times, preferably does not exceed two times, more preferably is less than two times the volume of the culture or incubation medium before the addition of the precursor feed, and wherein the pH value of the precursor feed is preferably set at 2.0 to 10.0, and wherein the temperature of the precursor feed is preferably maintained at 20° C. to 80° C.;

[0178] iv) adding at least one precursor feed to the culture or incubation medium in a continuous manner via a precursor feed solution over a period of 1 day, 2 days, 3 days, 4 days, or 5 days;

[0179] v) adding at least one precursor feed to the culture or incubation medium in a continuous manner via a precursor feed solution over a period of 1 day, 2 days, 3 days, 4 days, 5 days, wherein the concentration of the precursor feed solution is 50 g / L, preferably 75 g / L, more preferably 100 g / L, more preferably 125 g / L, more preferably 150 g / L, more preferably 175 g / L, more preferably 200 g / L, more preferably 225 g / L, more preferably 250 g / L, more preferably 275 g / L, more preferably 300 g / L, more preferably 325 g / L, more preferably 350 g / L, more preferably 375 g / L, more preferably 400 g / L, more preferably 450 g / L, more preferably 500 g / L, even more preferably 550 g / L, most preferably 600 g / L; wherein preferably, the pH of the precursor feed solution is set at 2.0 to 10.0, wherein preferably, the temperature of the precursor feed solution is maintained at 20° C. to 80° C.;

[0180] The method produces sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL and / or 3' KDO-lactose, at a concentration of at least 50 g / L, preferably at least 75 g / L, more preferably at least 90 g / L, more preferably at least 100 g / L, more preferably at least 125 g / L, more preferably at least 150 g / L, more preferably at least 175 g / L, more preferably at least 200 g / L in the final volume of the culture or incubation. In a more preferred embodiment of the method of the present invention, the precursor is selected from the list comprising sialic acid, CMP-sialic acid, CMP-Neu5Ac, CMP-KDO, glucose, galactose and UDP-galactose.

[0181] In another and / or additional preferred embodiment, the method for producing sialylated oligosaccharides, preferably 3' sialylated oligosaccharides as described herein comprises at least one of the following steps:

[0182] i) using a culture or incubation medium comprising at least 50 g, more preferably at least 75 g, more preferably at least 100 g, more preferably at least 120 g, more preferably at least 150 g of receptor per liter of initial reactor or incubator volume, wherein the reactor or incubator volume ranges from 250 mL to 10.000 m 3 (cubic meter);

[0183] ii) adding to the culture or incubation medium in the reactor or incubator at least one acceptor feed comprising at least 50 g, more preferably at least 75 g, more preferably at least 100 g, more preferably at least 120 g, more preferably at least 150 g of acceptor per liter of initial reactor or incubator volume, wherein the total volume of the reactor or incubator is from 250 mL (milliliters) to 10.000 mL (milliliters); 3 (cubic meters), preferably added in a continuous manner, and preferably so that the final volume of the culture or incubation medium does not exceed three times, preferably does not exceed two times, more preferably less than two times the volume of the culture or incubation medium before adding the acceptor feed;

[0184] iii) adding to the culture or incubation medium in the reactor or incubator at least one acceptor feed comprising at least 50 grams, more preferably at least 75 grams, more preferably at least 100 grams, more preferably at least 120 grams, more preferably at least 150 grams of acceptor per liter of initial reactor or incubator volume, wherein the total reactor or incubator volume ranges from 250 mL (milliliters) to 10.000 mL (milliliters); 3 (cubic meters), preferably added in a continuous manner, and preferably such that the final volume of the culture or incubation medium does not exceed three times, preferably does not exceed two times, more preferably is less than two times the volume of the culture or incubation medium before the addition of the acceptor feed, and wherein the pH of the acceptor feed is preferably set at 2.0 to 10.0, and wherein the temperature of the acceptor feed is preferably maintained at 20° C. to 80° C.;

[0185] iv) adding at least one acceptor feed to the culture or incubation medium in a continuous manner via an acceptor feed solution over a period of 1 day, 2 days, 3 days, 4 days, or 5 days;

[0186] v) adding at least one acceptor feed to the culture or incubation medium in a continuous manner over a period of 1 day, 2 days, 3 days, 4 days, 5 days via an acceptor feed solution, wherein the concentration of the acceptor feed solution is 50 g / L, preferably 75 g / L, more preferably 100 g / L, more preferably 125 g / L, more preferably 150 g / L, more preferably 175 g / L, more preferably 200 g / L, more preferably 225 g / L, more preferably 250 g / L, more preferably 275 g / L, more preferably 300 g / L, more preferably 325 g / L, more preferably 350 g / L, more preferably 375 g / L, more preferably 400 g / L, more preferably 450 g / L, more preferably 500 g / L, even more preferably 550 g / L, most preferably 600 g / L; wherein preferably, the pH of the acceptor feed solution is set between 2.0 and 10.0, wherein preferably, the temperature of the acceptor feed solution is maintained between 20°C and 80°C;

[0187] The method produces sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL and / or 3' KDO-lactose, at a concentration of at least 50 g / L, preferably at least 75 g / L, more preferably at least 90 g / L, more preferably at least 100 g / L, more preferably at least 125 g / L, more preferably at least 150 g / L, more preferably at least 175 g / L, more preferably at least 200 g / L in the final volume of the culture or incubation. In a more preferred embodiment of the method of the invention, the acceptor is lactose.

[0188] In another and / or additional preferred embodiment, the method for producing sialylated oligosaccharides, preferably 3' sialylated oligosaccharides as described herein comprises at least one of the following steps:

[0189] i) using a culture or incubation medium comprising at least 50 g, more preferably at least 75 g, more preferably at least 100 g, more preferably at least 120 g, more preferably at least 150 g of precursor per liter of initial reactor or incubator volume, wherein the reactor or incubator volume ranges from 250 mL to 10.000 m 3 (cubic meter);

[0190] ii) adding at least one precursor feed to the culture or incubation medium in the reactor or incubator in a single pulse or discontinuous (pulsed) manner, the precursor feed comprising at least 50 g, more preferably at least 75 g, more preferably at least 100 g, more preferably at least 120 g, more preferably at least 150 g of precursor per liter of initial reactor or incubator volume, wherein the total volume of the reactor or incubator ranges from 250 mL (milliliters) to 10.000 mL (milliliters); 3 (cubic meters), preferably such that the final volume of the culture or incubation medium does not exceed three times, preferably does not exceed two times, more preferably is less than two times the volume of the culture or incubation medium before adding the precursor feed pulse;

[0191] iii) adding at least one precursor feed to the culture or incubation medium in the reactor or incubator in a single pulse or discontinuous (pulsed) manner, the precursor feed comprising at least 50 grams, more preferably at least 75 grams, more preferably at least 100 grams, more preferably at least 120 grams, more preferably at least 150 grams of precursor per liter of initial reactor or incubator volume, wherein the total volume of the reactor or incubator ranges from 250 mL (milliliters) to 10.000 mL (milliliters). 3 (cubic meters), preferably such that the final volume of the culture or incubation medium does not exceed three times, preferably does not exceed two times, more preferably is less than two times the volume of the culture or incubation medium before the addition of the precursor feed, and wherein preferably the pH of the precursor feed pulse is set at 2.0 to 10.0, and wherein preferably the temperature of the precursor feed pulse is maintained at 20°C to 80°C;

[0192] iv) adding at least one precursor feed to the culture or incubation medium in a discontinuous (pulse) manner via a precursor feed solution over a period of 5 minutes, 10 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 10 hours, 12 hours, 1 day, 2 days, 3 days, 4 days, 5 days;

[0193] v) adding at least one precursor feed to the culture or incubation medium in a discontinuous (pulsed) manner via a precursor feed solution over a period of 5 minutes, 10 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 10 hours, 12 hours, 1 day, 2 days, 3 days, 4 days, 5 days, wherein the concentration of the precursor feed solution is 50 g / L, preferably 75 g / L, more preferably 100 g / L, more preferably 125 g / L, more preferably 150 g / L, more preferably 175 g / L, more preferably 200 g / L, more preferably 250 g / L Preferably 225 g / L, more preferably 250 g / L, more preferably 275 g / L, more preferably 300 g / L, more preferably 325 g / L, more preferably 350 g / L, more preferably 375 g / L, more preferably 400 g / L, more preferably 450 g / L, more preferably 500 g / L, even more preferably 550 g / L, most preferably 600 g / L; wherein, preferably, the pH value of the precursor feed solution is set at 2.0 to 10.0, and preferably, the temperature of the precursor feed solution is maintained at 20° C. to 80° C.;

[0194] The method produces sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL and / or 3' KDO-lactose, at a concentration of at least 50 g / L, preferably at least 75 g / L, more preferably at least 90 g / L, more preferably at least 100 g / L, more preferably at least 125 g / L, more preferably at least 150 g / L, more preferably at least 175 g / L, more preferably at least 200 g / L in the final volume of the culture or incubation. In a more preferred embodiment of the method of the present invention, the precursor is selected from the list comprising sialic acid, CMP-sialic acid, CMP-Neu5Ac, CMP-KDO, glucose, galactose and UDP-galactose.

[0195] In another and / or additional preferred embodiment, the method for producing sialylated oligosaccharides, preferably 3' sialylated oligosaccharides as described herein comprises at least one of the following steps:

[0196] i) using a culture or incubation medium comprising at least 50 g, more preferably at least 75 g, more preferably at least 100 g, more preferably at least 120 g, more preferably at least 150 g of receptor per liter of initial reactor or incubator volume, wherein the reactor or incubator volume ranges from 250 mL to 10.000 m 3 (cubic meter);

[0197] ii) adding at least one receptor feed to the culture or incubation medium in the reactor or incubator in a single pulse or discontinuous (pulsed) manner, the receptor feed comprising at least 50 grams, more preferably at least 75 grams, more preferably at least 100 grams, more preferably at least 120 grams, more preferably at least 150 grams of receptor per liter of initial reactor or incubator volume, wherein the total volume of the reactor or incubator ranges from 250 mL (milliliters) to 10.000 mL (milliliters); 3 (cubic meters), preferably such that the final volume of the culture or incubation medium does not exceed three times, preferably does not exceed two times, more preferably is less than two times the volume of the culture or incubation medium before adding the acceptor feed pulse;

[0198] iii) adding at least one acceptor feed to the culture or incubation medium in the reactor or incubator in a single pulse or discontinuous (pulsed) manner, the acceptor feed comprising at least 50 grams, more preferably at least 75 grams, more preferably at least 100 grams, more preferably at least 120 grams, more preferably at least 150 grams of acceptor per liter of initial reactor or incubator volume, wherein the total volume of the reactor or incubator ranges from 250 mL (milliliters) to 10.000 mL (milliliters); 3 (cubic meters), preferably such that the final volume of the culture or incubation medium does not exceed three times, preferably does not exceed two times, more preferably is less than two times the volume of the culture or incubation medium before the addition of the acceptor feed, and wherein the pH of the acceptor feed pulse is preferably set at 2.0 to 10.0, and wherein the temperature of the acceptor feed pulse is preferably maintained at 20°C to 80°C;

[0199] iv) adding at least one acceptor feed to the culture or incubation medium in a discontinuous (pulse) manner via an acceptor feed solution over a period of 5 minutes, 10 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 10 hours, 12 hours, 1 day, 2 days, 3 days, 4 days, 5 days;

[0200] v) adding at least one acceptor feed to the culture or incubation medium in a discontinuous (pulse) manner via an acceptor feed solution over a period of 5 minutes, 10 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 10 hours, 12 hours, 1 day, 2 days, 3 days, 4 days, 5 days, wherein the concentration of the acceptor feed solution is 50 g / L, preferably 75 g / L, more preferably 100 g / L, more preferably 125 g / L, more preferably 150 g / L, more preferably 175 g / L, more preferably 200 g / L, more preferably 300 g / L Preferably, the pH value of the acceptor feed solution is set at 2.0 to 10.0, wherein, preferably, the temperature of the acceptor feed solution is maintained at 20°C to 80°C;

[0201] The method produces sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL and / or 3' KDO-lactose, at a concentration of at least 50 g / L, preferably at least 75 g / L, more preferably at least 90 g / L, more preferably at least 100 g / L, more preferably at least 125 g / L, more preferably at least 150 g / L, more preferably at least 175 g / L, more preferably at least 200 g / L in the final volume of the culture or incubation. In a more preferred embodiment of the method of the invention, the acceptor is lactose.

[0202] In a more preferred embodiment, the method for producing sialylated oligosaccharides, preferably 3' sialylated oligosaccharides as described herein comprises at least one of the following steps:

[0203] i) using a culture or incubation medium comprising at least 50 g, more preferably at least 75 g, more preferably at least 100 g, more preferably at least 120 g, more preferably at least 150 g lactose per liter of initial reactor or incubator volume, wherein the reactor or incubator volume ranges from 250 mL to 10.000 m 3 (cubic meter);

[0204] ii) adding a lactose feed comprising at least 50 g, more preferably at least 75 g, more preferably at least 100 g, more preferably at least 120 g, more preferably at least 150 g lactose per liter of initial reactor or incubator volume, wherein the total volume of the reactor or incubator ranges from 250 mL (milliliters) to 10.000 mL (milliliters); 3 (cubic meters), preferably added in a continuous manner, and preferably such that the final volume of the culture or incubation medium does not exceed three times, preferably does not exceed two times, more preferably is less than two times the volume of the culture or incubation medium before adding the lactose feed;

[0205] iii) adding a lactose feed comprising at least 50 g, more preferably at least 75 g, more preferably at least 100 g, more preferably at least 120 g, more preferably at least 150 g lactose per liter of initial reactor or incubator volume, wherein the total volume of the reactor or incubator ranges from 250 mL (milliliters) to 10.000 mL (milliliters); 3 (cubic meters), preferably added in a continuous manner, and preferably such that the final volume of the culture or incubation medium does not exceed three times, preferably does not exceed two times, more preferably is less than two times the volume of the culture or incubation medium before the addition of the lactose feed, and wherein the pH of the lactose feed is preferably set at 2.0 to 10.0, preferably at 3.0 to 7.0, and wherein the temperature of the lactose feed is preferably maintained at 20° C. to 80° C.;

[0206] iv) adding lactose feed to the culture or incubation medium via a feed solution in a continuous manner over a period of 1 day, 2 days, 3 days, 4 days, or 5 days;

[0207] v) adding lactose feed to the culture or incubation medium in a continuous manner via a feed solution over a period of 1 day, 2 days, 3 days, 4 days, 5 days, wherein the concentration of the lactose feed solution is 50 g / L, preferably 75 g / L, more preferably 100 g / L, more preferably 125 g / L, more preferably 150 g / L, more preferably 175 g / L, more preferably 200 g / L, more preferably 225 g / L, more preferably 250 g / L, more preferably 275 g / L, More preferably 300 g / L, more preferably 325 g / L, more preferably 350 g / L, more preferably 375 g / L, more preferably 400 g / L, more preferably 450 g / L, more preferably 500 g / L, even more preferably 550 g / L, most preferably 600 g / L; wherein preferably, the pH of the lactose feed is set at 2.0 to 10.0, preferably at 3.0 to 7.0, and wherein preferably, the temperature of the lactose feed is maintained at 20° C. to 80° C.;

[0208] The method produces sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL and / or 3' KDO-lactose, at a concentration of at least 50 g / L, preferably at least 75 g / L, more preferably at least 90 g / L, more preferably at least 100 g / L, more preferably at least 125 g / L, more preferably at least 150 g / L, more preferably at least 175 g / L, more preferably at least 200 g / L in the final volume of the culture or incubation.

[0209] Preferably, lactose feeding is accomplished by adding lactose at a concentration of at least 5 mM (preferably at a concentration of 30, 40, 50, 60, 70, 80, 90, 100, 150 mM, more preferably at a concentration >300 mM) from the start of the culture or incubation.

[0210] In another embodiment of the method, lactose feeding is accomplished by adding lactose to the culture or incubation medium at a concentration such that a lactose concentration of at least 5 mM, preferably 10 mM or 30 mM, is obtained throughout the production phase of the culture or incubation.

[0211] In another embodiment of the methods described herein, the cells are cultured or incubated for at least about 60, 80, 100, or about 120 hours or in a continuous manner.

[0212] In a preferred embodiment, a carbon source, preferably sucrose, is provided in the culture medium for 3 days or more, preferably up to 7 days; and / or at least 100, advantageously at least 105, more advantageously at least 110, even more advantageously at least 120 grams of sucrose per liter of initial culture volume are provided in the culture medium in a continuous manner, so that the final volume of the culture medium is no more than three times, advantageously no more than two times, more advantageously less than two times the volume of the culture medium before cultivation.

[0213] Preferably, when performing the methods described herein, a first phase of exponential cell growth is provided by adding a carbon source, preferably glucose or sucrose, to the culture medium before lactose is added to the culture medium in the second phase.

[0214] In an alternative preferred embodiment, in the methods described herein, lactose is added together with the carbon substrate during the first phase of exponential growth.

[0215] According to another aspect, the present invention provides a metabolically engineered cell for producing sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL (Neu5Ac-α2,3-Gal-β1,4-Glc), wherein the cell has been metabolically engineered to have, preferably express, more preferably heterologously express, even more preferably overexpress, most preferably heterologously overexpress a sialyltransferase having α-2,3-sialyltransferase activity towards the Gal residue of lactose and comprising an amino acid sequence i) at least 67.0% identical to any one of the amino acid sequences shown in SEQ ID NO 05, 01, 02, 03, 06, 07 or 08 over a stretch of at least 150 amino acid residues, preferably at least 200 amino acid residues, or ii) at least 67.0% identical to any one of the amino acid sequences shown in SEQ ID NO 05, 01, 02, 03, 06, 07 or 08 over a stretch of at least 150 amino acid residues, preferably at least 200 amino acid residues. 04, or iii) at least 60.0% identical to the amino acid sequence shown in SEQ ID NO 12 over a stretch of at least 150 amino acid residues, preferably at least 200 amino acid residues. Preferably, the sialyltransferase used in the cell is a sialyltransferase as described herein.

[0216] In another and / or additional aspect, the present invention provides a metabolically engineered cell for producing 3' sialylated oligosaccharides as described herein, wherein the cell has been metabolically engineered to possess, preferably express, more preferably heterologously express, even more preferably overexpress, most preferably heterologously overexpress a sialyltransferase having α-2,3-sialyltransferase activity towards a Gal residue of lactose and comprising an amino acid sequence that is at least 80.0% identical to any one of the full-length amino acid sequences shown in SEQ ID NO 05, 04, 12, 01, 02, 03, 06, 07 or 08.

[0217] In a preferred embodiment of the cell of the present invention, the sialyltransferase comprises an amino acid sequence that is at least 80.0%, at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to any one of the full-length amino acid sequences shown in SEQ ID NO 05, 04, 12, 01, 02, 03, 06, 07 or 08. In an alternative preferred embodiment of the cell of the present invention, the sialyltransferase comprises an amino acid sequence shown in any one of SEQ ID NO 05, 04, 12, 01, 02, 03, 06, 07 or 08.

[0218] Alternatively or preferably, the cell contains a nucleic acid molecule comprising a polynucleotide sequence encoding any one of the sialyltransferases described herein.

[0219] Provided herein is a metabolically engineered cell comprising a pathway for producing the sialylated oligosaccharide, preferably a 3' sialylated oligosaccharide. Examples of such pathways include, but are not limited to, pathways and / or glycosylation pathways involved in the synthesis of monosaccharides, phosphorylated monosaccharides, nucleotide activated sugars, such as fucosylation, sialylation, galactosylation, N-acetylglucosamination, N-acetylgalactosamination, mannosylation and / or N-acetylmannosamination pathways. The pathway for producing sialylated oligosaccharides preferably comprises at least one sialyltransferase as described herein.

[0220] In preferred embodiments of the methods and / or cells of the invention, the cells comprise one or more monosaccharide synthesis pathways. The monosaccharide synthesis pathways comprise enzymes such as carboxylases, decarboxylases, isomerases, epimerases, reductases, enolases, phosphorylases, carboxykinases, kinases, phosphatases, aldolases, hydrolases, dehydrogenases, enzymes involved in the synthesis of one or more nucleoside triphosphates such as UTP, GTP, ATP and CTP, enzymes involved in the synthesis of any one or more nucleoside monophosphates or diphosphates such as UMP and UDP, and enzymes involved in the synthesis of phosphoenolpyruvate (PEP).

[0221] In another and / or additional preferred embodiment of the method and / or cell of the present invention, the cell comprises one or more phosphorylated monosaccharide synthesis pathways. The phosphorylated monosaccharide synthesis pathways include enzymes involved in the synthesis of one or more monosaccharides, one or more nucleoside monophosphates, diphosphates and / or triphosphates and enzymes involved in the synthesis of phosphoenolpyruvate (PEP), such as but not limited to PEP synthases, carboxylases, decarboxylases, isomerases, epimerases, reductases, enolases, phosphorylases, carboxykinases, kinases, phosphatases, aldolases, hydrolases and dehydrogenases. In another and / or additional preferred embodiment of the method and / or cell of the present invention, the cell comprises one or more pathways for the synthesis of one or more nucleotide activated sugars. The pathway for nucleotide activated sugar synthesis comprises, for example, enzymes, PEP synthase, carboxylase, decarboxylase, isomerase, epimerase, reductase, enolase, phosphorylase, carboxykinase, kinase, phosphatase, aldolase, hydrolase, dehydrogenase, mannose-6-phosphate isomerase, phosphomannose mutase, mannose-1-phosphate guanyl transferase, GDP-mannose 4,6-dehydratase, GDP-L-fucose synthase, L-fucokinase / GDP-fucose pyrophosphorylase, L-glutamine-D-fructose-6-phosphate aminotransferase, glucosamine-6-phosphate deaminase, phosphoglucosamine mutase, N-acetylglucosamine-6-phosphate deacetylase, N-acylglucosamine 2-epimerase, UDP-N-acetylglucosamine 2-epimerase, N-acetylglucosamine-6P 2-epimerase, glucosamine 6-phosphate N-acetyltransferase, N-acetylglucosamine-6-phosphate phosphatase, N-acetylmannosamine-6-phosphate 2-epimerase, N-acetylmannosamine-6-phosphate phosphatase, N-acetylmannosamine kinase, phosphoacetylglucosamine mutase, N-acetylglucosamine-1-phosphate uridyltransferase, glucosamine-1-phosphate acetyltransferase, sialic acid synthase, N-acetylneuraminic acid lyase, N-acylneuraminic acid-9-phosphate synthase, N-acylneuraminic acid-9-phosphatase, CMP-sialic acid synthase, d-arabinose 5-phosphate isomerase, KDO-8P synthase, KDO 8-phosphate phosphatase, CMP-KDO synthase, galactose-1-epimerase, galactokinase, glucokinase, galactose-1-phosphate uridyltransferase, UDP-glucose 4-epimerase, glucose-1-phosphate uridyltransferase and / or phosphoglucomutase.

[0222] The cell may also comprise and express at least one other glycosyltransferase involved in the production of the sialylated oligosaccharides, preferably 3' sialylated oligosaccharides.

[0223] In a preferred embodiment of the methods and / or cells of the invention, the cells are metabolically engineered to comprise a pathway for producing sialylated oligosaccharides as defined herein, preferably for producing 3' sialylated oligosaccharides, more preferably 3' SL and / or 3' KDO-lactose, as defined herein. In an alternative preferred embodiment of the methods and / or cells of the invention, the cells are metabolically engineered to comprise a pathway for producing sialylated oligosaccharides, preferably for producing 3' sialylated oligosaccharides, preferably 3' SL and / or 3' KDO-lactose, as defined herein, and have modified expression or activity of a sialyltransferase of the invention.

[0224] In another preferred embodiment of the method and / or cell of the invention, the cell comprises a recombinant sialyltransferase capable of modifying lactose or another acceptor as defined herein with one or more sialic acid molecules synthesized by any one or more sialic acid synthases, such as Neu5Ac synthase, or by, for example, d-arabinose 5-phosphate isomerase, KDO-8P synthase and KDO 8-phosphate phosphatase expressed in the cell, into sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL and / or 3' KDO-lactose.

[0225] In a preferred embodiment of the methods and / or cells of the invention, the metabolically engineered cell is modified with one or more expression modules.

[0226] The expression module is also referred to as a transcription unit, and includes a polynucleotide for expressing a recombinant gene, which includes a coding gene sequence and an appropriate transcription and / or translation control signal operably connected to the coding gene. The control signal includes a promoter sequence, an untranslated region, a ribosome binding site, and a terminator sequence. The expression module can include elements for expressing a single recombinant gene, but can also include elements for expressing more recombinant genes, or can be organized into an operon structure for integrating and expressing two or more recombinant genes. The polynucleotide can be produced by recombinant DNA technology using techniques well known in the art. Methods for constructing expression modules well known to those skilled in the art include, for example, in vitro recombinant DNA technology, synthetic technology, and in vivo genetic recombination. See, for example, Sambrook et al. (2001) Molecular Cloning: a laboratory manual, 3rd edition, Cold Spring Harbor Laboratory Press, CSH, New York or Current Protocols in Molecular Biology, John Wiley and Sons, NY (1989 and annually updated).

[0227] The expression of each in the expression module can be constitutive, or can be produced by natural or chemical inducers.As used herein, constitutive expression should be understood as the gene expression of continuous transcription in an organism.The expression produced by natural inducers should be understood as the facultative or regulatory expression of genes, which are only expressed under certain natural conditions of the host (such as organisms are in childbirth or lactation), as a response to environmental changes (such as including but not limited to hormones, heat, cold, pH changes, light, oxidation or osmotic stress / signaling), or its expression depends on the developmental stage of the host cell or the position of the cell cycle, including but not limited to apoptosis and autophagy.The expression produced by chemical inducers should be understood as the facultative or regulatory expression of genes, which are only expressed when the genetic circuit perception external chemical substances (such as IPTG, arabinose, lactose, allolactose, rhamnose or fucose) are sensed by inducible promoters or by inducing or suppressing the polynucleotides to be transcribed or translated into polypeptides.

[0228] The expression module can be integrated into the genome of the cell, or can be presented to the cell on a carrier. The carrier can exist in the form of a plasmid, a clay, a phage, a liposome or a virus, and it will be stably transformed / transfected into the metabolic engineering cell. Such carriers include, but are not limited to, chromosomal vectors, episomal vectors and virus-derived vectors, such as vectors derived from bacterial plasmids, phages, transposons, yeast episomes, insertion elements, yeast chromosomal elements, viruses, and vectors derived from their combinations, such as vectors derived from plasmids and phage genetic elements (such as clay and phagemids). These vectors can contain selection markers, such as, but not limited to, antibiotic markers, nutrient deficiency markers, toxin-antitoxin markers, RNA justice / antisense markers. The expression system construct can contain a control region that regulates and causes expression. Generally, any system or carrier suitable for maintaining, breeding or expressing polynucleotides and / or expressing polypeptides in a host can be used for expression in this regard. Suitable DNA sequences can be inserted into expression systems by a variety of well-known conventional techniques, such as, the technology described by Sambrook et al. (see above). For recombinant production, cells can be genetically engineered to incorporate expression systems or portions thereof or polynucleotides of the invention. Polynucleotides can be introduced into cells by methods described in many standard laboratory manuals, such as Davis et al., Basic Methods in Molecular Biology, (1986), and Sambrook et al., 1989, supra.

[0229] As used herein, an expression module includes a polynucleotide for expressing at least one recombinant gene. The recombinant gene is involved in the expression of a polypeptide that is involved in the synthesis of sialylated oligosaccharides, preferably 3' sialylated oligosaccharides such as 3' SL and / or 3' KDO-lactose; or the recombinant gene is connected to other pathways that are not involved in the synthesis of sialylated oligosaccharides in the cell. The recombinant gene encodes an endogenous protein with modified expression or activity, preferably the endogenous protein is overexpressed; or the recombinant gene encodes a heterologous protein that is heterogeneously introduced and expressed (preferably overexpressed) in the modified cell. Endogenous proteins can have modified expression in cells that also express heterologous proteins.

[0230] In preferred embodiments of the methods and / or cells of the invention, the expression of each of said expression modules present in said metabolically engineered cell is constitutive or regulatable as described herein.

[0231] In further embodiments of the methods and / or cells of the invention, the cell is modified in terms of expression or activity of at least one of the sialyltransferases. In preferred embodiments, the sialyltransferase is a cell endogenous protein with modified expression or activity, preferably the endogenous sialyltransferase is overexpressed; or, the sialyltransferase is a heterologous protein heterogeneously introduced and expressed (preferably overexpressed) in the cell. The endogenous sialyltransferase may have modified expression in a cell that also expresses a heterologous sialyltransferase.

[0232] According to a preferred embodiment of the method and / or cell of the present invention, the cell comprises a pathway for producing sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL, which comprises at least one sialyltransferase according to the present invention. According to another preferred embodiment of the method and / or cell of the present invention, the pathway for producing sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL further comprises at least one enzyme selected from the list comprising: L-glutamine-D-fructose-6-phosphate aminotransferase, phosphoglucosamine mutase, N-acetylglucosamine-6-P deacetylase, N-acyl glucosamine 2-epimerase, UDP-N-acetylglucosamine 2-epimerase, N-acetylmannosamine-6-phosphate 2-epimerase, UDP-GlcNAc 2-epimerase / kinase, glucosamine 6-phosphate N-acetyltransferase, N-acetylglucosamine-6-phosphate phosphatase, phosphoacetylglucosamine mutase, N-acetylglucosamine 1-phosphate uridyltransferase, glucosamine-1-phosphate acetyltransferase, Neu5Ac synthase, N-acetylneuraminic acid lyase, N-acylneuraminic acid-9-phosphate synthase, N-acylneuraminic acid-9-phosphatase, sialic acid transporter, and CMP-sialic acid synthase.

[0233] In another and / or additional preferred embodiment of the method and / or cell of the invention, the cell comprises a pathway for producing 3' sialylated oligosaccharides, such as 3' KDO-lactose, comprising at least one sialyltransferase according to the invention. According to another preferred embodiment of the method and / or cell of the invention, the pathway for producing 3' sialylated oligosaccharides, preferably 3' KDO-lactose, further comprises at least one enzyme selected from the list comprising: d-arabinose 5-phosphate isomerase, KDO-8P synthase, KDO 8-phosphate phosphatase and CMP-KDO synthetase.

[0234] In a preferred embodiment, the cell comprises a pathway for producing sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL, wherein the cell expresses at least one enzyme selected from the list comprising: N-acylglucosamine 2-epimerase (as known, for example, from several species including Bacteroides ovatus, Escherichia coli, Homo sapiens, Rattus norvegicus), Neu5Ac synthase, CMP sialic acid synthase (as known, for example, from Neisseria meningitidis), and sialyltransferase according to the invention, wherein the enzyme is as defined herein. N-acetylglucosamine (GlcNAc) may be added to the cell and / or may be provided by an enzyme expressed in the cell or by the cell's machinery. Such GlcNAc-producing cells may express a phosphatase that converts GlcNAc-6-phosphate to GlcNAc, such as, for example, E. coli HAD-like phosphatase genes including aphA, Cof, HisB, OtsB, SurE, Yaed, YcjU, YedP, YfbT, YidA, YigB, YihX, YniC, YqaB, YrbL, AppA, Gph, SerB, YbhA, YbiV, YbjL, Yfb, YieH, YjgL, YjjG, YrfG and YbiU, PsMupP from Pseudomonas putida, ScDOG1 from Saccharomyces cerevisiae, and any one or more of BsAraL from Bacillus subtilis, as described in WO18122225. Preferably, the cell is modified to produce GlcNAc. More preferably, the cell is modified to enhance the production of GlcNAc. The modification may be one or more selected from the group consisting of: knocking out glucosamine-6-phosphate deaminase, N-acetylglucosamine-6-phosphate deacetylase and / or N-acetyl-D-glucosamine kinase, and overexpressing L-glutamine-D-fructose-6-phosphate aminotransferase and / or glucosamine 6-phosphate N-acetyltransferase.

[0235] In alternative and / or additional preferred embodiments, the cell comprises a pathway for producing sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SLs, wherein the cell expresses at least one enzyme selected from the list comprising: UDP-N-acetylglucosamine 2-epimerase (such as enzymes known, for example, from several species including Campylobacter jejuni, Escherichia coli, Neisseria meningitidis, Bacillus subtilis, Citrobacterrodentium), Neu5Ac synthase, CMP sialic acid synthase (such as enzymes known, for example, from Neisseria meningitidis) and sialyltransferases according to the invention, wherein the enzymes are as defined herein. UDP-N-acetylglucosamine (UDP-GlcNAc) can be added to the cell and / or can be provided by an enzyme expressed in the cell or by the metabolism of the cell. Such cells producing UDP-GlcNAc can express an enzyme that converts, for example, GlcNAc to be added to the cell into UDP-GlcNAc. These enzymes can be any one or more enzymes selected from the following list: N-acetyl-D-glucosamine kinase, N-acetylglucosamine-6-phosphate deacetylase, phosphoglucosamine mutase and N-acetylglucosamine-1-phosphate uridyl transferase / glucosamine-1-phosphate acetyl transferase from several species including Homo sapiens and Escherichia coli. Preferably, the cell is modified to produce UDP-GlcNAc. More preferably, the cell is modified to strengthen the generation of UDP-GlcNAc. The modification can be any one or more selected from the following group: knock out N-acetylglucosamine-6-phosphate deacetylase, overexpress L-glutamine-D-fructose-6-phosphate aminotransferase, overexpress phosphoglucosamine mutase and overexpress N-acetylglucosamine-1-phosphate uridyl transferase / glucosamine-1-phosphate acetyl transferase.

[0236] In alternative and / or additional preferred embodiments, the cell comprises a pathway for producing sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SLs, wherein the cell expresses at least one enzyme selected from the list comprising: N-acetylmannosamine-6-phosphate 2-epimerase (such as known, e.g., enzymes from several species including Escherichia coli, Haemophilus influenzae, Enterobacter, Streptomyces); N-acylneuraminic acid-9-phosphate synthetase; N-acylneuraminic acid-9-phosphatase (such as known, e.g., enzymes from Candidatus Magnetomorum sp. HK-1 or Bacteroides thetaiotaomicron); Neu5Ac synthase; CMP sialic acid synthase (such as known, e.g., enzymes from Neisseria meningitidis); and sialyltransferases according to the invention, wherein the enzymes are as defined herein. N-acetyl-D-glucosamine 6-phosphate (GlcNAc-6P) can be added to the cell and / or can be provided by an enzyme expressed in the cell or by cell metabolism. Such cells producing GlcNAc-6P can express an enzyme that converts, for example, GlcN6P to be added to the cell into GlcNAc-6P. The enzyme can be a glucosamine 6-phosphate N-acetyltransferase from several species including saccharomyces cerevisiae, Kluyveromyces lactis, and Homo sapiens. Preferably, the cell is modified to produce GlcNAc-6P. More preferably, the cell is modified to enhance the generation of GlcNAc-6P. The modification can be selected from any one or more of the following groups: knocking out glucosamine-6-phosphate deaminase, N-acetylglucosamine-6-phosphate deacetylase and overexpressing L-glutamine-D-fructose-6-phosphate aminotransferase and / or glucosamine 6-phosphate N-acetyltransferase.

[0237] In alternative and / or additional preferred embodiments, the cell comprises a pathway for producing sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SLs, wherein the cell expresses at least one enzyme selected from the list comprising: a bifunctional UDP-GlcNAc2-epimerase / kinase (such as enzymes known, for example, from several species including Homo sapiens, Rattus norvegicus and Mus musculus), N-acylneuraminic acid-9-phosphate synthetase, N-acylneuraminic acid-9-phosphatase (such as enzymes known, for example, from Candidatus Magnetomorum sp. HK-1 or Bacteroides thetaiotaomicron), Neu5Ac synthase, CMP sialic acid synthase (such as enzymes known, for example, from Neisseria meningitidis) and a sialyltransferase according to the invention, wherein the enzymes are as defined herein. UDP-N-acetylglucosamine may be added to the cell and / or may be provided by an enzyme expressed in the cell or by the metabolism of the cell. Such cells producing UDP-GlcNAc may express an enzyme that converts, for example, GlcNAc to be added to the cell into UDP-GlcNAc. The enzymes can be N-acetyl-D-glucosamine kinase, N-acetylglucosamine-6-phosphate deacetylase, phosphoglucosamine mutase and N-acetylglucosamine-1-phosphate uridyl transferase / glucosamine-1-phosphate acetyl transferase from several species including Homo sapiens and Escherichia coli. Preferably, the cell is modified to produce UDP-GlcNAc. More preferably, the cell is modified to enhance the generation of UDP-GlcNAc. The modification can be selected from any one or more of the following groups: knocking out N-acetylglucosamine-6-phosphate deacetylase, overexpressing L-glutamine-D-fructose-6-phosphate aminotransferase, overexpressing phosphoglucosamine mutase and overexpressing N-acetylglucosamine-1-phosphate uridyl transferase / glucosamine-1-phosphate acetyl transferase.

[0238] In alternative and / or additional preferred embodiments, the cell comprises a pathway for producing 3' sialylated oligosaccharides, preferably 3' KDO-lactose, wherein the cell expresses at least one enzyme selected from the list comprising: d-arabinose 5-phosphate isomerase, KDO-8P synthase, KDO 8-phosphate phosphatase, CMP-KDO synthase from different species such as Escherichia coli, Pseudomonas aeruginosa, Agrobacterium species, and sialyltransferase according to the present invention, wherein the enzyme is as defined herein. Preferably, the cell is capable of making CMP-KDO. More preferably, the cell is modified to produce CMP-KDO. More preferably, the cell is modified to enhance the production of CMP-KDO. The modification may be any one or more selected from the group comprising: overexpression of genes encoding d-arabinose 5-phosphate isomerase, KDO-8P synthase, KDO 8-phosphate phosphatase and / or CMP-KDO synthase.

[0239] Additionally or alternatively, cells used herein are optionally genetically engineered to import precursors and / or receptors into cells by introducing and / or overexpressing a transporter capable of importing corresponding precursors and / or receptors into cells. Such transporters are, for example, membrane proteins belonging to the major facilitator protein superfamily (MFS), the ATP binding cassette (ABC) transporter family, or a PTS system that is involved in absorbing, for example, monosaccharides, disaccharides and / or oligosaccharides.

[0240] Additionally or alternatively, cells used herein are optionally genetically engineered to produce a polyprenol, such as a phosphorylated polyprenol, which can serve as a lipid carrier.

[0241] Additionally or alternatively, the cells used herein are optionally genetically engineered to import lactose into the cells by introducing and / or overexpressing a lactose permease, such as encoded by the lacY gene or the lac12 gene.

[0242] Additionally or alternatively, the cell expresses a membrane protein that is a transporter involved in transporting the compound and / or sialylated oligosaccharides defined in the present invention out of the cell. In the context of the present invention, it is understood that the sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL and / or 3' KDO-lactose are preferably produced intracellularly. The skilled person will further understand that part or substantially all of the sialylated oligosaccharides, preferably 3' sialylated oligosaccharides produced are retained intracellularly and / or excreted outside the cell passively or by active transport.

[0243] In a preferred embodiment of the method and / or cell of the present invention, the cell expresses a membrane transporter or a polypeptide with transport activity, thereby transporting the compound through the outer membrane of the cell wall. In another preferred embodiment of the method and / or cell of the present invention, the cell expresses more than one membrane transporter or a polypeptide with transport activity, thereby transporting the compound to the outer membrane of the cell wall. In a more preferred embodiment of the method and / or cell of the present invention, the cell is modified in terms of the expression or activity of the membrane transporter or the polypeptide with transport activity. The membrane transporter or the polypeptide with transport activity is an endogenous cell protein with modified expression or activity, preferably the endogenous membrane transporter or the polypeptide with transport activity is overexpressed; or the membrane transporter or the polypeptide with transport activity is a heterologous protein introduced and expressed (preferably overexpressed) in the cell. The endogenous membrane transporter or the polypeptide with transport activity can have modified expression in a cell that also expresses a heterologous membrane transporter or a polypeptide with transport activity.

[0244] In a more preferred embodiment of the method and / or cell of the present invention, the membrane transporter or polypeptide having transport activity is selected from a list comprising transporters, transporters driven by PP bond hydrolysis, β-barrel porins, auxiliary transporters, and phosphotransfer-driven group transporters. In an even more preferred embodiment of the method and / or cell of the present invention, the transporters comprise MFS transporters, sugar efflux transporters, and siderophore exporters. In another more preferred embodiment of the method and / or cell of the present invention, the transporters driven by PP bond hydrolysis comprise ABC transporters and siderophore exporters.

[0245] In another preferred embodiment of the method and / or cell of the invention, a membrane transporter or a polypeptide with transport activity controls the flow of said sialylated oligosaccharides on the outer membrane of the cell wall. In an alternative and / or additional preferred embodiment of the method and / or cell of the invention, a membrane transporter or a polypeptide with transport activity controls the flow of one or more precursors for said production of said sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, on the outer membrane of the cell wall.

[0246] In another preferred embodiment of the method and / or cell of the present invention, a membrane transporter or a polypeptide with transport activity provides an improved production of the sialylated oligosaccharide. In an alternative and / or additional preferred embodiment of the method and / or cell of the present invention, a membrane transporter or a polypeptide with transport activity provides an efflux that can be achieved of the sialylated oligosaccharide, preferably a 3' sialylated oligosaccharide. In an alternative and / or additional preferred embodiment of the method and / or cell of the present invention, a membrane transporter or a polypeptide with transport activity provides an enhanced efflux of the sialylated oligosaccharide, preferably a 3' sialylated oligosaccharide.

[0247] Preferably, the cell is transformed to contain at least one nucleic acid sequence encoding a protein selected from the group comprising a lactose transporter, such as LacY or lac12 permease, a glucose transporter, a galactose transporter, a transporter for nucleotide activated sugars (such as a transporter for UDP-GlcNAc), a transporter involved in transporting sialylated oligosaccharides (preferably 3' sialylated oligosaccharides, more preferably 3' SL and / or 3' KDO-lactose) out of the cell.

[0248] In another preferred embodiment of the methods and / or cells of the invention, the cells express a membrane transporter belonging to the MFS transporter family, such as an MdfA polypeptide from the multidrug transporter MdfA family of species including Escherichia coli (UniProt ID P0AEY8), Cronobacter muytjensii (UniProt ID A0A2T7ANQ9), Citrobacter youngae (UniProt ID D4BC23) and Yokenella regensburgei (UniProtID G9Z5F4). In another preferred embodiment of the methods and / or cells of the invention, the cells express a membrane transporter belonging to the sugar efflux transporter family, such as SetA polypeptides from the SetA family of species including Escherichia coli (UniProt ID P31675, sequence version 03 (October 11, 2004)) and Citrobacter koseri (UniProt ID A0A078LM16). In another preferred embodiment of the methods and / or cells of the invention, the cells express a membrane transporter belonging to the siderophore exporter family, such as E. coli entS (UniProt ID P24077, sequence version 02 (November 1, 1997)), K. ascorbata entS (UniProt ID A0A378GQ13) and E. coli iceT (UniProt ID A0A024L207). In another preferred embodiment of the methods and / or cells of the invention, the cells express a membrane transporter belonging to the ABC transporter family, such as oppF from Escherichia coli (UniProt ID P77737), lmrA from Lactococcus lactis subsp. lactis bv. diacetylactis (UniProt ID A0A1V0NEL4) and Blon_2475 from Bifidobacterium longumsubsp. infantis (UniProt ID B7GPD4).In a more preferred embodiment of the methods and / or cells of the invention, the cell expresses more than one membrane transporter selected from the list comprising: a lactose transporter such as LacY or lac12 permease, a fucose transporter, a glucose transporter, a galactose transporter, a transporter for nucleotide activated sugars (e.g. transporters for UDP-GlcNAc, UDP-Gal and / or GDP-Fuc), the MdfA protein from Escherichia coli (UniProt ID P0AEY8), the MdfA protein from Kronospora moginis (UniProt ID DA0A2T7ANQ9), the MdfA protein from Citrobacter youngii (UniProt ID D4BC23), the MdfA protein from Yorkshire rapensis (UniProt ID G9Z5F4), the SetA protein from Escherichia coli (UniProt ID P31675, sequence version 03 (October 11, 2004)), the SetA protein from Citrobacter cohnii (UniProt ID P40696, sequence version 04 (October 11, 2004)), the SetA protein from Citrobacter kohnii (UniProt ID P40697, sequence version 05 (October 11, 2004)), the SetA protein from Citrobacter kohnii (UniProt ID P40698, sequence version 06 (October 11, 2004)), the SetA protein from Citrobacter cohnii (UniProt ID P40696, sequence version 06 (October 11, 2004)), the SetA protein from coli (UniProt ID P24077, sequence version 02 (November 1, 1997)), entS protein from Kluyveromyces ascorbicus (UniProt ID A0A378GQ13), iceT protein from Escherichia coli (UniProt ID A0A024L207), oppF protein from Escherichia coli (UniProt ID P77737), lmrA protein from Lactococcus lactis subsp. lactis var. diacetyllactobacillus (UniProt ID A0A1V0NEL4) and Blon_2475 from Bifidobacterium longum subsp. infantis (UniProt ID B7GPD4).

[0249] Preferably, the cell is transformed to comprise at least one nucleic acid sequence encoding a membrane transporter selected from the group comprising a siderophore exporter, a major facilitator superfamily (MFS) transporter, an ATP-binding cassette (ABC) transporter or a sugar efflux transporter.

[0250] According to another preferred aspect of the method and / or cell of the present invention, the cell is capable of synthesizing N-acetylmannosamine (ManNAc), N-acetylmannosamine-6-phosphate (ManNAc-6-phosphate) and / or phosphoenolpyruvate (PEP).

[0251] In a preferred embodiment, the cell comprises a pathway for producing sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL and / or 3' KDO-lactose, including a pathway for producing ManNAc. ManNAc can be provided by an enzyme expressed in the cell or by a cell mechanism. Such cells producing ManNAc can express N-acyl glucosamine 2-epimerase, such as enzymes known, for example, from several species including Bacteroides ovatus, Escherichia coli, Homo sapiens, Rattus norvegicus, which convert GlcNAc to ManNAc. Alternatively and / or additionally, cells producing ManNAc can express UDP-N-acetylglucosamine 2-epimerase, such as enzymes known, for example, from several species including Campylobacter jejuni, Escherichia coli, Neisseria meningitidis, Bacillus subtilis, Citrobacter rodentium, which convert UDP-GlcNAc to ManNAc. GlcNAc and / or UDP-GlcNAc can be added to the cell and / or provided by an enzyme expressed in the cell or by a cell mechanism as described herein.

[0252] In a more preferred embodiment, the cell is modified to enhance the production of ManNAc. The modification may be any one or more selected from the group consisting of knockout of N-acetylmannosamine kinase and overexpression of N-acetylneuraminic acid lyase.

[0253] In another preferred embodiment, the cell comprises a pathway for producing sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL and / or 3' KDO-lactose, including a pathway for producing ManNAc-6-phosphate. ManNAc-6-phosphate can be provided by an enzyme expressed in the cell or the mechanism of the cell. Such cells producing ManNAc-6-phosphate can express a bifunctional UDP-GlcNAc2-epimerase / kinase, such as enzymes from several species including Homo sapiens, Rattus norvegicus and Mus musculus, which convert UDP-GlcNAc into ManNAc-6-phosphate. Alternatively and / or additionally, cells producing ManNAc-6-phosphate can express N-acetylmannosamine-6-phosphate 2-epimerase, which converts GlcNAc-6-phosphate into ManNAc-6-phosphate. UDP-GlcNAc and / or GlcNAc-6-phosphate can be added to the cell and / or provided by an enzyme expressed in the cell or the mechanism of the cell, as described herein. In a more preferred embodiment, the cell is modified to enhance the production of ManNAc-6-phosphate. The modification may be selected from any one or more of the group consisting of: overexpression of N-acetylglucosamine-6-phosphate deacetylase, overexpression of N-acetyl-D-glucosamine kinase, overexpression of phosphoglucosamine mutase, overexpression of N-acetylglucosamine-1-phosphate uridyl transferase / glucosamine-1-phosphate acetyl transferase.

[0254] According to another embodiment of the method and / or cell of the present invention, the cell is also capable of synthesizing any one or more nucleotide activated sugars. In a preferred embodiment of the method and / or cell of the present invention, the cell is capable of synthesizing one or more nucleotide activated sugars selected from the group consisting of UDP-N-acetylglucosamine (UDP-GlcNAc), UDP-N-acetylgalactosamine (UDP-GalNAc), UDP-N-acetylmannosamine (UDP-ManNAc), UDP-glucose (UDP-Glc), UDP-galactose (UDP-Gal), GDP-mannose (GDP-Man), UDP-glucuronic acid, UDP-galacturonic acid, UDP-2-acetylamino-2,6-dideoxy-L-arabino-4-hexulose, UDP-2-acetylamino-2,6-dideoxy-L-lyxose-4-hexulose, UDP-N-acetyl-L-rhamnosamine (UDP-L-RhaNAc or UDP-2-acetylamino-2,6-dideoxy-L-mannose), dTDP-N-acetylfucosamine, UDP-N -Acetylfucosamine (UDP-L-FucNAc or UDP-2-acetylamino-2,6-dideoxy-L-galactose), UDP-N-acetyl-L-deoxytalosamine (UDP-L-PneNAC or UDP-2-acetylamino-2,6-dideoxy-L-talose), UDP-N-acetylmuramic acid, UDP-N-acetyl-L-quinosamine (UDP-L-QuiNAc or UDP-2-acetylamino-2,6-dideoxy-L -glucose), CMP-sialic acid (e.g. CMP-Neu5Ac, CMP-Neu4Ac, CMP-Neu5Ac9N3, CMP-Neu4,5Ac2, CMP-Neu5,7Ac2, CMP-Neu5,9Ac2, CMP-Neu5,7(8,9)Ac2, CMP-Neu5Gc or CMP-KDO), GDP-fucose (GDP-Fuc), GDP-rhamnose and UDP-xylose. In a more preferred embodiment of the method and / or cell of the present invention, the cell is capable of synthesizing at least one nucleotide-activated sugar CMP-Neu5Ac. In another more preferred embodiment of the method and / or cell of the present invention, the cell is capable of synthesizing at least one nucleotide-activated sugar CMP-KDO. In an even more preferred embodiment of the method and / or cell of the present invention, the cell uses at least one synthesized nucleotide-activated sugar to produce sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL and / or 3' KDO-lactose.

[0255] Cell used herein is optionally through genetic engineering to express the de novo synthesis of UDP-GlcNAc.UDP-GlcNAc can be provided by the enzyme expressed in the cell or the metabolism of the cell.This cell producing UDP-GlcNAc can express the enzyme that for example GlcNAc to be added into the cell is converted into UDP-GlcNAc.These enzymes can be one or more in the list of N-acetyl-D-glucosamine kinase, N-acetylglucosamine-6-phosphate deacetylase, phosphoglucosamine mutase and N-acetylglucosamine-1-phosphate uridyl transferase / glucosamine-1-phosphate acetyl transferase including several species of Homo sapiens and Escherichia coli.Preferably, cell is modified to produce UDP-GlcNAc.More preferably, cell is modified to strengthen the generation of UDP-GlcNAc. The modification may be one or more selected from the group consisting of: knocking out N-acetylglucosamine-6-phosphate deacetylase, overexpressing L-glutamine-D-fructose-6-phosphate aminotransferase, overexpressing phosphoglucosamine mutase, and overexpressing N-acetylglucosamine-1-phosphate uridyltransferase / glucosamine-1-phosphate acetyltransferase.

[0256] In addition or alternatively, the cell used herein is optionally genetically engineered to express the de novo synthesis of CMP-Neu5Ac. CMP-Neu5Ac can be provided by an enzyme expressed in the cell or the metabolism of the cell. This cell producing CMP-Neu5Ac can express an enzyme that converts, for example, sialic acid into CMP-Neu5Ac. The enzyme can be a CMP-sialic acid synthetase, such as N-acylneuraminic acid cytidylic acid transferase from several species including Homo sapiens, Neisseria meningitidis and Pasteurella multocida. Preferably, the cell is modified to produce CMP-Neu5Ac. More preferably, the cell is modified to enhance the production of CMP-Neu5Ac. The modification can be selected from any one or more of the following groups: knocking out N-acetylglucosamine-6-phosphate deacetylase, knocking out glucosamine-6-phosphate deaminase, overexpressing CMP-sialic acid synthetase and overexpressing N-acetyl-D-glucosamine-2-epimerase encoding genes.

[0257] Additionally or alternatively, the cells used herein are optionally genetically engineered to express de novo synthesis of CMP-KDO. CMP-KDO may be provided by an enzyme expressed in the cell or by the metabolism of the cell. Such cells producing CMP-KDO may express an enzyme that converts, for example, KDO to CMP-KDO. The enzyme may be a CMP-KDO synthase, such as 3-deoxy-mannose-octulose acid cytidylyltransferase kdsB from several species including Escherichia coli, Arabidopsis thaliana, Pseudomonas aeruginosa, and Xanthomonas campestris. Preferably, the cells are modified to produce CMP-KDO. More preferably, the cells are modified to enhance the production of CMP-KDO. The modification may be any one or more selected from the group comprising overexpression of d-arabinose 5-phosphate isomerase, KDO-8P synthase, KDO 8-phosphate phosphatase, and / or CMP-KDO synthase encoding genes.

[0258] Additionally or alternatively, the cells used herein are optionally genetically engineered to express the de novo synthesis of GDP-fucose. GDP-fucose can be provided by an enzyme expressed in the cell or by the metabolism of the cell. Such cells producing GDP-fucose can express an enzyme that converts, for example, fucose to be added to the cell into GDP-fucose. Such enzymes can be, for example, bifunctional fucokinase / fucose-1-phosphate guanosine transferase, such as Fkp from Bacteroides fragilis, or a combination of a single fucokinase and a single fucose-1-phosphate guanosine transferase, such as they are known from several species including Homo sapiens, wild boar and Rattus norvegicus. Preferably, the cell is modified to produce GDP-fucose. More preferably, the cell is modified to enhance the production of GDP-fucose. The modification can be any one or more selected from the group comprising: knocking out the gene encoding UDP-glucose:undecaprenyl phosphate glucose-1-phosphotransferase, overexpressing the gene encoding GDP-L-fucose synthase, overexpressing the gene encoding GDP-mannose 4,6-dehydratase, overexpressing the gene encoding mannose-1-phosphate guanosine transferase, overexpressing the gene encoding phosphomannose mutase and overexpressing the gene encoding mannose-6-phosphate isomerase.

[0259] In addition or alternatively, the cell used herein is optionally genetically engineered to express the de novo synthesis of UDP-Gal. UDP-Gal can be provided by an enzyme expressed in the cell or the metabolism of the cell. This cell producing UDP-Gal can express an enzyme that, for example, UDP-glucose is converted into UDP-Gal. This enzyme can be, for example, UDP-glucose-4-epimerase GalE, as known from several species including Homo sapiens, Escherichia coli and Rattus norvegicus. Preferably, the cell is modified to produce UDP-Gal. More preferably, the cell is modified to enhance the generation of UDP-Gal. The modification can be any one or more selected from the following group: knocking out a bifunctional 5'-nucleotidase / UDP-sugar hydrolase encoding gene, knocking out a galactose-1-phosphate uridyl transferase encoding gene and overexpressing a UDP-glucose-4-epimerase encoding gene.

[0260] Additionally or alternatively, the cell used herein is optionally genetically engineered to express the de novo synthesis of UDP-GalNAc.UDP-GalNAc can be synthesized from UDP-GlcNAc by single-step reaction using UDP-N-acetylglucosamine 4-epimerase (such as, for example, wbgU from class Shigella shigelloides, gne from Yersinia enterocolitica or wbpP from O6 serotype Pseudomonas aeruginosa).Preferably, cells are modified to produce UDP-GalNAc.More preferably, cells are modified to enhance the production of UDP-GalNAc.

[0261] Additionally or alternatively, the cell used herein is optionally genetically engineered to express the de novo synthesis of UDP-ManNAc.UDP-ManNAc can be directly synthesized from UDP-GlcNAc by the epimerization reaction performed by UDP-GlcNAc2-epimerase (e.g., cap5P from Staphylococcus aureus, RWE from Escherichia coli, Cps19fK from Streptococcus pneumoniae, and RfbC from Enterococcus).Preferably, the cell is modified to produce UDP-ManNAc.More preferably, the cell is modified to enhance the production of UDP-ManNAc.

[0262] According to another embodiment of the method and / or cell of the invention, the cell expresses at least one additional glycosyltransferase selected from the list comprising fucosyltransferase, sialyltransferase, galactosyltransferase, glucosyltransferase, mannosyltransferase, N-acetylglucosaminyltransferase, N-acetylgalactosaminesaminyltransferase, N-acetylmannosaminesaminyltransferase, xylosyltransferase, glucuronyltransferase, galacturonosyltransferase, glucosaminyltransferase, N-glycolylneuraminyltransferase, rhamnosyltransferase, N-acetylrhamnosyltransferase, UDP-4-amino-4,6-dideoxy-N-acetyl-β-L-altrosamine transaminase, UDP-N-acetylglucosamine enolpyruvyltransferase and fucosamine transferase.

[0263] In a preferred embodiment of the method and / or cell of the invention, the fucosyltransferase is selected from the list comprising α-1,2-fucosyltransferase, α-1,3-fucosyltransferase, α-1,3 / 4-fucosyltransferase, α-1,4-fucosyltransferase and α-1,6-fucosyltransferase.

[0264] In alternative and / or additional embodiments of the methods and / or cells of the invention, the further sialyltransferase is selected from the list comprising α-2,3-sialyltransferase, α-2,6-sialyltransferase and α-2,8-sialyltransferase.

[0265] In alternative and / or additional embodiments of the methods and / or cells of the invention, the galactosyltransferase is selected from the list comprising β-1,3-galactosyltransferase, N-acetylglucosamine β-1,3-galactosyltransferase, β-1,4-galactosyltransferase, N-acetylglucosamine β-1,4-galactosyltransferase, α-1,3-galactosyltransferase and α-1,4-galactosyltransferase.

[0266] In alternative and / or additional embodiments of the methods and / or cells of the invention, the glucosyltransferase is selected from the list comprising α-glucosyltransferase, β-1,2-glucosyltransferase, β-1,3-glucosyltransferase and β-1,4-glucosyltransferase.

[0267] In alternative and / or additional embodiments of the methods and / or cells of the invention, the mannosyltransferase is selected from the list comprising α-1,2-mannosyltransferase, α-1,3-mannosyltransferase and α-1,6-mannosyltransferase.

[0268] In alternative and / or additional embodiments of the methods and / or cells of the invention, the N-acetylglucosaminyltransferase is selected from the list comprising galactoside β-1,3-N-acetylglucosaminyltransferase and β-1,6-N-acetylglucosaminyltransferase.

[0269] In alternative and / or additional embodiments of the methods and / or cells of the invention, the N-acetylgalactosaminyltransferase is selected from the list comprising alpha-1,3-N-acetylgalactosaminyltransferases.

[0270] In further embodiments of the methods and / or cells of the invention, the cell is modified in terms of the expression or activity of at least one of the glycosyltransferases. In preferred embodiments, the glycosyltransferase is a cell endogenous protein with modified expression or activity, preferably the endogenous glycosyltransferase is overexpressed; or the glycosyltransferase is a heterologous protein heterologously introduced and expressed (preferably overexpressed) in the cell. The endogenous glycosyltransferase may have modified expression in a cell that also expresses a heterologous glycosyltransferase.

[0271] According to another and / or alternative preferred embodiment of the method and / or cell of the invention, the cell comprises a fucosylation pathway comprising at least one enzyme selected from the list comprising mannose-6-phosphate isomerase, phosphomannose mutase, mannose-1-phosphate guanylyltransferase, GDP-mannose 4,6-dehydratase, GDP-L-fucose synthase, fucose permease, fucokinase, fucose-1-phosphate guanylyltransferase, fucosyltransferase.

[0272] According to another and / or alternative preferred embodiment of the method and / or cell of the invention, the cell comprises a galactosylation pathway comprising at least one enzyme selected from the list comprising: galactose-1-epimerase, galactokinase, glucokinase, galactose-1-phosphate uridyltransferase, UDP-glucose 4-epimerase, glucose-1-phosphate uridyltransferase, phosphoglucomutase, galactosyltransferase.

[0273] According to another and / or alternative preferred embodiment of the method and / or cell of the invention, the cell comprises an N-acetylglucosaminylation pathway comprising at least one enzyme selected from the list comprising: L-glutamine-D-fructose-6-phosphate aminotransferase, N-acetylglucosamine-6-phosphate deacetylase, phosphoglucosamine mutase, N-acetylglucosamine-1-phosphate uridyltransferase / glucosamine-1-phosphate acetyltransferase, N-acetylglucosamine transferase.

[0274] In alternative and / or additional further embodiments of the methods and / or cells of the invention, the cells are modified in the expression or activity of at least one pyruvate dehydrogenase (e.g. from Escherichia coli, Saccharomyces cerevisiae, Homo sapiens and Rattus norvegicus). In a preferred embodiment, the cells are modified by methods generally known to those skilled in the art to have at least one partially or completely knocked out or mutated pyruvate dehydrogenase encoding gene, resulting in at least one protein with reduced functionality or loss of pyruvate dehydrogenase activity. In a more preferred embodiment, the cells have a completely knocked out poxB encoding gene, resulting in the cell lacking pyruvate dehydrogenase activity.

[0275] In further alternative and / or additional embodiments of the methods and / or cells of the invention, the cells are modified in terms of expression or activity of at least one lactate dehydrogenase (e.g., from Escherichia coli, Saccharomyces cerevisiae, Homo sapiens and Rattus norvegicus). In a preferred embodiment, the cells are modified by methods generally known to those skilled in the art to have at least one partially or completely knocked out or mutated lactate dehydrogenase encoding gene, resulting in at least one protein with reduced functionality or loss of lactate dehydrogenase activity. In a more preferred embodiment, the cells have a completely knocked out ldhA encoding gene, resulting in the cell lacking lactate dehydrogenase activity.

[0276] According to another preferred embodiment of the method and / or cell of the present invention, the cell comprises lower or reduced expression and / or eliminated, impaired, reduced or delayed activity of any one or more of the following proteins, the proteins comprising β-galactosidase, β-galactoside O-acetyltransferase, N-acetylglucosamine-6-phosphate deacetylase, glucosamine-6-phosphate deaminase, N-acetylglucosamine repressor, ribonucleotide monophosphatase, EIICBA-Nag, UDP-glucose: undecaprenol phosphate glucose-1-phosphotransferase, L-fucokinase, L-fucose isomerase, N-acetylneuraminic acid lyase, N-acetylmannosamine kinase, N-acetylmannosamine ly ... -acetylmannosamine-6-phosphate 2-epimerase, EIIAB-Man, EIIC-Man, EIID-Man, ushA, galactose-1-phosphate uridylyltransferase, glucose-1-phosphate adenylyltransferase, glucose-1-phosphatase, ATP-dependent 6-phosphofructokinase isozyme 1, ATP-dependent 6-phosphofructokinase isozyme 2, glucose-6-phosphate isomerase, aerobic respiration control protein, transcription repressor IclR, lon protease, glucose-specific translocase phosphotransferase IIBC component ptsG, glucose-specific translocase phosphotransferase (PTS) enzyme IIBC component malX, enzyme IIA Glc , β-glucoside-specific PTS enzyme II, fructose-specific PTS polyphosphate transfer proteins FruA and FruB, alcohol dehydrogenase, aldehyde dehydrogenase, pyruvate-formate lyase, acetate kinase, phosphate acyltransferase, phosphate acetyltransferase, and pyruvate decarboxylase.

[0277] According to another preferred embodiment of the method and / or cell of the present invention, the cell uses a precursor to synthesize sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL and / or 3' KDO-lactose. Here, the precursor is fed to the cell from the culture or incubation medium. In another preferred embodiment, the cell produces a precursor for synthesizing the sialylated oligosaccharides, preferably 3' sialylated oligosaccharides.

[0278] In a preferred embodiment of the method and / or cell of the invention, the method results in the production of 45 g / L or more, preferably 50 g / L or more, more preferably 60 g / L or more 3' sialylated oligosaccharides. In a more preferred embodiment, the method results in the production of 45 g / L or more, preferably 50 g / L or more, more preferably 60 g / L or more 3' SL. In another more preferred embodiment, the method results in the production of 45 g / L or more, preferably 50 g / L or more, more preferably 60 g / L or more sugar modified with KDO, preferably 3' KDO-lactose.

[0279] In alternative preferred embodiments of the methods and / or cells of the invention, the methods result in the production of 10 g / L or less, preferably 5 g / L or less, more preferably 1 g / L or less, even more preferably 0.5 g / L or less, even more preferably 0.4 g / L or less, even more preferably 0.3 g / L or less, even more preferably 0.2 g / L or less, most preferably 0.1 g / L or less of a sugar modified with KDO, preferably 3'-KDO-lactose.

[0280] In another preferred embodiment of the method and / or cell of the invention, the method results in the production of a sugar mixture comprising a sugar modified with KDO and another sugar, wherein the other sugar is a 3' sialylated oligosaccharide different from KDO-lactose, preferably different from 3'KDO-lactose, preferably the other sugar is 3' SL.

[0281] In another preferred embodiment of the method and / or cell of the invention, the method results in the production of a sugar mixture comprising a sugar modified with KDO and another sugar, wherein the other sugar is a 3' sialylated oligosaccharide without any KDO moiety.

[0282] In another and / or additional preferred embodiment of the methods and / or cells of the invention, the method results in the production of a sugar mixture, wherein the sugar mixture comprises 45 g / L or more, preferably 50 g / L or more, more preferably 60 g / L or more 3' sialylated oligosaccharides (wherein the 3' sialylated oligosaccharides are not KDO-lactose, preferably not 3'KDO-lactose), and 10 g / L or less, preferably 5 g / L or less, more preferably 1 g / L or less, even more preferably 0.5 g / L or less, even more preferably 0.4 g / L or less, even more preferably 0.3 g / L or less, even more preferably 0.2 g / L or less, most preferably 0.1 g / L or less of a sugar modified with KDO, preferably KDO-lactose, more preferably 3'-KDO-lactose. In a more preferred embodiment, the method results in the production of a sugar mixture, wherein the sugar mixture comprises 45 g / L or more, preferably 50 g / L or more, more preferably 60 g / L or more 3'SL and 10 g / L or less, preferably 5 g / L or less, more preferably 1 g / L or less, even more preferably 0.5 g / L or less, even more preferably 0.4 g / L or less, even more preferably 0.3 g / L or less, even more preferably 0.2 g / L or less, most preferably 0.1 g / L or less 3'KDO-lactose.

[0283] According to another preferred embodiment of the method and / or cell of the present invention, the cell produces 90 g / L or more of sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL or 3' KDO-lactose in the whole culture broth and / or the supernatant. In a more preferred embodiment, the sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL or 3' KDO-lactose produced in the whole culture broth and / or the supernatant have a purity of at least 80% (measured based on the total amount of sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL or 3' KDO-lactose and its precursors produced by the cell in the whole culture broth and / or the supernatant, respectively).

[0284] According to another preferred embodiment of the method and / or cell according to the invention, the method results in the production of sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL or 3' KDO-lactose, having a purity equal to or greater than 80% (measured based on the total amount of sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL or 3' KDO-lactose and their precursors). In a more preferred embodiment, the method results in the production of sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL or 3' KDO-lactose, having a purity equal to or greater than 85% (measured based on the total amount of sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL or 3' KDO-lactose and their precursors). In a more preferred embodiment, the method results in the production of sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL or 3' KDO-lactose, having a purity equal to or greater than 90% (measured based on the total amount of sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL or 3' KDO-lactose and their precursors). In another more preferred embodiment, the method results in the production of sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL or 3' KDO-lactose, having a purity equal to or greater than 91%, equal to or greater than 92%, equal to or greater than 93%, equal to or greater than 94%, equal to or greater than 95%, equal to or greater than 96%, equal to or greater than 97%, equal to or greater than 98%, equal to or greater than 99% (measured based on the total amount of sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL or 3' KDO-lactose and their precursors).

[0285] According to another preferred embodiment of the method and / or cell according to the invention, the method results in the production of a mixture comprising sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL, and lactose and sialic acid, wherein the sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL have a purity equal to or greater than 80% (measured according to the total amount of sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL, lactose and sialic acid in the mixture), and wherein the mixture comprises less than 10% lactose and / or less than 5% sialic acid. In a more preferred embodiment, the mixture comprises less than 9% lactose. In an even more preferred embodiment, the mixture comprises less than 8% lactose. In another even more preferred embodiment, the mixture comprises less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1% lactose. In an additional and / or alternative more preferred embodiment, the mixture comprises less than 5% sialic acid. In even more preferred additional and / or alternative more preferred embodiments, the mixture comprises less than 4%, less than 3%, less than 2%, less than 1%, less than 0.5%, less than 0.1% sialic acid.

[0286] According to another preferred embodiment of the method and / or cell according to the invention, the method results in the production of a mixture comprising sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' KDO-lactose, and lactose and sialic acid, wherein the purity of the sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' KDO-lactose is equal to or greater than 80% (measured according to the total amount of sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' KDO-lactose, lactose and sialic acid in the mixture), and wherein the mixture comprises less than 10% lactose and / or less than 5% sialic acid. In a more preferred embodiment, the mixture comprises less than 9% lactose. In an even more preferred embodiment, the mixture comprises less than 8% lactose. In another more preferred embodiment, the mixture comprises less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1% lactose. In an additional and / or alternative more preferred embodiment, the mixture comprises less than 5% sialic acid. In more preferred additional and / or alternative embodiments, the mixture comprises less than 4%, less than 3%, less than 2%, less than 1%, less than 0.5%, less than 0.1% sialic acid.

[0287] According to another preferred embodiment of the method and / or cell of the invention, the method results in the production of a mixture comprising 3'SL and 3'KDO-lactose and lactose and sialic acid, wherein the mixture comprises less than 10% lactose and / or less than 5% sialic acid. In a more preferred embodiment, the mixture comprises less than 9% lactose. In a more preferred embodiment, the mixture comprises less than 8% lactose. In another more preferred embodiment, the mixture comprises less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1% lactose. In an additional and / or alternative more preferred embodiment, the mixture comprises less than 5% sialic acid. In a more preferred additional and / or alternative embodiment, the mixture comprises less than 4%, less than 3%, less than 2%, less than 1%, less than 0.5%, less than 0.1% sialic acid.

[0288] According to another embodiment of the method and / or cell of the invention, the sialylated oligosaccharide is selected from the list comprising milk oligosaccharides, O antigens, oligosaccharide repeats present in capsular polysaccharides, oligosaccharides present in lipopolysaccharides and amino sugars. In a more preferred embodiment, the milk oligosaccharide is a mammalian milk oligosaccharide. In a more preferred embodiment, the milk oligosaccharide is a human milk oligosaccharide.

[0289] According to another embodiment of the method of the present invention and / or cell, the cell is capable of synthesizing a mixture of oligosaccharides. In alternative and / or additional embodiments, the cell is capable of synthesizing a mixture of disaccharides and oligosaccharides, or the cell is capable of synthesizing a mixture of sialic acid, disaccharides and / or oligosaccharides.

[0290] Another aspect of the present invention provides a method and a cell, wherein sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL and / or 3' KDO-lactose are produced in and / or by a cell, the cell being a bacterium, a fungus, a yeast, a plant cell, an animal cell or a protozoan cell. The latter bacterium preferably belongs to the Proteobacteria, or the Firmicutes, or the Cyanobacteria, or the Deinococcus-Thermus, or the Actinobacteria. The latter bacterium belonging to the Proteobacteria preferably belongs to the Enterobacteriaceae, preferably to the species Escherichia coli. The latter bacterium preferably relates to any strain belonging to the species Escherichia coli, such as but not limited to Escherichia coli B, Escherichia coli C, Escherichia coli W, Escherichia coli K12, Escherichia coli Nissle. More specifically, the latter term relates to a cultured Escherichia coli strain (designated as an Escherichia coli K12 strain) that is well adapted to the laboratory environment and, unlike the wild-type strain, has lost the ability to grow in the intestine. Known examples of E. coli K12 strains are K12 wild type, W3110, MG1655, M182, MC1000, MC1060, MC1061, MC4100, JM101, NZN111 and AA200. Therefore, the present invention particularly relates to mutated and / or transformed E. coli cells or strains as described above, wherein the E. coli strain is a K12 strain. More preferably, the E. coli K12 strain is E. coli MG1655. The latter bacteria belonging to the Firmicutes preferably belong to the order Bacilli, preferably the order Lactobacilliales, whose members include, for example, Lactobacillus lactis, Leuconostoc mesenteroides, or the order Bacillales, whose members include, for example, members from the genus Bacillus, such as Bacillus subtilis or Bacillus amyloliquefaciens. The latter bacterium belonging to the Actinobacteria preferably belongs to the Corynebacterium family, whose members include Corynebacterium glutamicum or C.afermentans, or belongs to the Streptomycetaceae family, whose members include Streptomyces griseus or S.fradiae. The latter bacterium belonging to the Proteobacteria preferably belongs to the Vibrio family, whose members include Vibrio natriegens. The latter yeast preferably belongs to the Ascomycota, or the Basidiomycota, or the Deuteromycota, or the Zygomycota.The latter yeast preferably belongs to the genus Saccharomyces (members of which include, for example, S. cerevisiae, S. bayanus, S. boulardii), Zygosaccharomyces, Pichia (members of which include, for example, Pichia pastoris, P. anomala, P. kluyveri), Komagata, Hansenula, Kluyveromyces (members of which include, for example, Kluyveromyces lactis, K. marxianus, K. thermotolerans), Debaromyces, Candida, Schizosaccharomyces, Schwannella, Torulella, Yarrowia (e.g., Yarrowia lipolytica), or Starmerella (e.g., Starmerella bombicola). The latter yeast is preferably selected from Pichia pastoris, Yarrowia lipolytica, Saccharomyces cerevisiae, Kluyveromyces lactis, Hansenula polymorpha, Kluyveromyces marxianus, Pichia methanolica, Pichia stipites, Candida boidinii, Schizosaccharomyces pombe, Schwanniomyces occidentalis, Torulaspora delbrueckii, Zygosaccharomyces rouxii and Zygosaccharomyces bailii. The latter fungi preferably belong to the genus Rhizopus, Dictyostelium, Penicillium, Mucor or Aspergillus. Plant cells include cells of flowering plants and non-flowering plants, as well as algae cells, such as Chlamydomonas, Chlorella, etc. Preferably, the plant is a tobacco, alfalfa, rice, tomato, cotton, rapeseed, soybean, maize or corn plant.The latter animal cells are preferably derived from non-human mammals (e.g., cows, buffaloes, pigs, sheep, mice, rats, primates (e.g., chimpanzees, orangutans, gorillas, monkeys (e.g., Old World, New World), lemurs), dogs, cats, rabbits, horses, cows, goats, bulls, deer, musk deer, bovines, whales, dolphins, hippos, elephants, rhinos, giraffes, zebras, lions, cheetahs, tigers, pandas, red pandas, otters), birds (e.g., chickens, ducks, ostriches, turkeys, pheasants), fish (e.g., swordfish, salmon, tuna, bass, trout, catfish), invertebrates (e.g., lobsters, crabs, shrimps, clams, oysters, mussels, sea urchins), reptiles (e.g., snakes, crocodiles, turtles), amphibians (e.g., frogs) or insects (e.g., flies, nematodes) or are genetically engineered cell lines derived from human cells (excluding embryonic stem cells). The human and non-human mammalian cells are preferably selected from the list comprising epithelial cells such as mammary epithelial cells, embryonic kidney cells (such as HEK293 or HEK 293T cells), fibroblasts, COS cells, Chinese hamster ovary (CHO) cells, murine myeloma cells such as N20, SP2 / 0 or YB2 / 0 cells, NIH-3T3 cells, non-mammary adult stem cells or derivatives thereof (as described in WO21067641), lactocytes derived from mammalian induced pluripotent stem cells (preferably human induced pluripotent stem cells), lactocytes as part of a mammary glandular organ, postpartum mammary epithelial cells, polarized mammary cells (preferably selected from Polarized mammary cells comprising a group of living primary mammary epithelial cells, living mammary myoepithelial cells, living mammary progenitor cells, living immortalized mammary epithelial cells, living immortalized mammary myoepithelial cells, living immortalized mammary progenitor cells), non-mammary adult stem cells or their derivatives (as known to those skilled in the art according to WO2021 / 219634, WO2022 / 054053, WO2021 / 141762, WO2021 / 142241, WO2021 / 067641 and WO2021 / 242866). The latter insect cell is preferably derived from Spodoptera frugiperda, such as Sf9 or Sf21 cells, Bombyx mori, Mamestra brassicae, Trichoplusia ni, such as BTI-TN-5B1-4 cells, or Drosophila melanogaster, such as Drosophila S2 cells. The latter protozoan cell is preferably a Leishmania tarentolae cell.

[0291] More preferably, the cell is selected from the group consisting of prokaryotic cells and eukaryotic cells, preferably selected from the group consisting of yeast cells, bacterial cells, archaeal cells, algae cells and fungal cells as described herein.

[0292] According to another embodiment of the methods and / or cells of the present invention, the cells described herein comprise a nucleic acid molecule comprising a polynucleotide sequence encoding a sialyltransferase as described herein and operably linked to a control sequence recognized by the cell, wherein the sequence is foreign to the cell, the sequence further i) integrated in the genome of the cell and / or ii) presented to the cell on a vector.

[0293] According to another preferred embodiment of the method and / or cell of the invention, the cell comprises an at least partially inactivated catabolic pathway for a selected monosaccharide, disaccharide or oligosaccharide which is involved in the synthesis of sialylated oligosaccharides and / or is required for the synthesis of sialylated oligosaccharides. Preferably, the sialylated oligosaccharides are 3' sialylated oligosaccharides, more preferably 3' SL and / or 3' KDO-lactose.

[0294] Another aspect of the present invention provides an isolated nucleic acid molecule encoding a sialyltransferase, wherein the sialyltransferase has α-2,3-sialyltransferase activity towards galactose (Gal) residues of lactose and comprises an amino acid sequence that is i) at least 67.0% identical to any one of the amino acid sequences shown in SEQ ID NO 05, 01, 02, 03, 06, 07 or 08 over a stretch of at least 150 amino acid residues, preferably at least 200 amino acid residues, ii) at least 85.0% identical to the amino acid sequence shown in SEQ ID NO 04 over a stretch of at least 150 amino acid residues, preferably at least 200 amino acid residues, or iii) at least 60.0% identical to the amino acid sequence shown in SEQ ID NO 12 over a stretch of at least 150 amino acid residues, preferably at least 200 amino acid residues.

[0295] In preferred embodiments, the sialyltransferase encoded by the isolated nucleic acid molecule comprises an amino acid sequence that is at least 67.0%, at least 70.0%, at least 75.0%, at least 80.0%, at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to any of the amino acid sequences set forth in SEQ ID NOs: 05, 01, 02, 03, 06, 07 or 08 over a stretch of at least 150, at least 160, at least 170, at least 180, at least 190, at least 200, at least 210, at least 220, at least 230, at least 240, at least 250, at least 260, at least 270, at least 280, at least 290 or at least 300 amino acid residues.

[0296] In another preferred embodiment, the sialyltransferase encoded by the isolated nucleic acid molecule comprises an amino acid sequence that is at least 55.0%, at least 60.0%, at least 65.0%, at least 70.0%, at least 75.0%, at least 80.0%, at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to any of the full-length amino acid sequences shown in SEQ ID NO 05, 01, 02, 03, 06, 07 or 08.

[0297] In another preferred embodiment, the sialyltransferase encoded by the isolated nucleic acid molecule comprises an amino acid sequence that is at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to the amino acid sequence set forth in SEQ ID NO 04 over a stretch of at least 150, at least 160, at least 170, at least 180, at least 190, at least 200, at least 210, at least 220, at least 230, at least 240, at least 250, at least 260, at least 270, at least 280, at least 290 or at least 300 amino acid residues.

[0298] In another preferred embodiment, the sialyltransferase encoded by the isolated nucleic acid molecule comprises an amino acid sequence that is at least 80.0%, at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to the full-length amino acid sequence shown in SEQ ID NO 04.

[0299] In another preferred embodiment, the sialyltransferase encoded by the isolated nucleic acid molecule comprises an amino acid sequence that is at least 60.0%, at least 65.0%, at least 70.0%, at least 75.0%, at least 80.0%, at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to the amino acid sequence set forth in SEQ ID NO 12 over a stretch of at least 150, at least 160, at least 170, at least 180, at least 190, at least 200, at least 210, at least 220, at least 230, at least 240, at least 250, at least 260, at least 270, at least 280, at least 290 or at least 300 amino acid residues.

[0300] In another preferred embodiment, the sialyltransferase encoded by the isolated nucleic acid molecule comprises an amino acid sequence that is at least 45.0%, at least 50.0%, at least 55.0%, at least 60.0%, at least 65.0%, at least 70.0%, at least 75.0%, at least 80.0%, at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to the full-length amino acid sequence shown in SEQ ID NO 12.

[0301] In another preferred embodiment, the sialyltransferase encoded by the isolated nucleic acid molecule comprises the amino acid sequence shown in any one of SEQ ID NOs 05, 04, 12, 01, 02, 03, 06, 07 or 08.

[0302] Another aspect of the present invention provides an isolated nucleic acid molecule encoding a sialyltransferase, wherein the sialyltransferase has α-2,3-sialyltransferase activity towards a galactose (Gal) residue of lactose and comprises an amino acid sequence that is at least 80.0% identical to any one of the full-length amino acid sequences shown in SEQ ID NO 05, 04, 12, 01, 02, 03, 06, 07 or 08.

[0303] In preferred embodiments, the sialyltransferase encoded by the isolated nucleic acid molecule comprises an amino acid sequence that is at least 80.0%, at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to any of the full-length amino acid sequences set forth in SEQ ID NOs 05, 04, 12, 01, 02, 03, 06, 07 or 08.

[0304] In another preferred embodiment, the sialyltransferase encoded by the isolated nucleic acid molecule comprises the amino acid sequence shown in any one of SEQ ID NOs 05, 04, 12, 01, 02, 03, 06, 07 or 08.

[0305] Another aspect of the present invention provides a vector comprising an isolated nucleic acid molecule encoding a sialyltransferase as described herein.

[0306] Another aspect provides cells stably cultured in a culture medium, wherein the culture medium can be any type of growth medium, including a minimal medium, a complex medium, or a growth medium enriched with certain compounds (such as, but not limited to, vitamins, trace elements, amino acids).

[0307] Microorganism used herein or cell can grow as main carbon source with monosaccharide, disaccharide, oligosaccharide, polysaccharide, polyol, glycerine, complex medium or their mixture.Term " mainly " refers to the most important carbon source of microorganism or cell that is used to produce interested sialylated oligosaccharide, biomass formation, carbonic acid gas and / or byproduct formation (for example acid and / or alcohol, for example acetic acid, lactic acid and / or ethanol), i.e. 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99% of all required carbon derive from above-mentioned carbon source.In one embodiment of the invention, described carbon source is described biological unique carbon source, i.e. 100% of all required carbon derives from above-mentioned carbon source. Common major carbon sources include, but are not limited to, glucose, glycerol, fructose, sucrose, maltose, lactose, arabinose, maltooligosaccharide, maltotriose, sorbitol, xylose, rhamnose, galactose, mannose, methanol, ethanol, trehalose, starch, cellulose, hemicellulose, molasses, corn steep liquor, high fructose syrup, acetate, citrate, lactate and pyruvate. Precursors defined herein as used herein cannot be used as carbon sources for the production of sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, of the present invention.

[0308] According to the present invention, the method described herein preferably comprises the step of isolating the sialylated oligosaccharide, preferably 3' sialylated oligosaccharide of the present invention from the culture or incubation, or the step of recovering the sialylated oligosaccharide, preferably 3' sialylated oligosaccharide, from the culture or incubation medium and / or cells.

[0309] The term "isolated from said culture or incubation" means harvesting, collecting or recovering said sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, from cells and / or their culture or incubation medium.

[0310] Sialyl oligosaccharides, preferably 3' sialylated oligosaccharides, can be separated from the aqueous medium in which the cells are cultured or incubated in a conventional manner. If the sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, are still present in the cells producing the sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, the sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, can be released or extracted from the cells using conventional means, such as cell disruption, use of high pH, ​​heat shock, sonication, French press, homogenization, enzymatic hydrolysis, chemical hydrolysis, solvent hydrolysis, detergent hydrolysis, etc. The culture or incubation medium and / or cell extract can then be further used together or separately to separate the sialylated oligosaccharides, preferably 3' sialylated oligosaccharides.

[0311] This step preferably includes clarifying the sialylated oligosaccharide, preferably 3' sialylated oligosaccharide, to remove suspended particles and pollutants, particularly cells, cell components, insoluble metabolites and fragments produced by culturing or incubating genetically engineered cells. In this step, the sialylated oligosaccharide, preferably 3' sialylated oligosaccharide can be clarified in a conventional manner. Preferably, the sialylated oligosaccharide, preferably 3' sialylated oligosaccharide is clarified by centrifugation, flocculation, decantation and / or filtration. Another step of separating the sialylated oligosaccharide, preferably 3' sialylated oligosaccharide preferably includes removing substantially all final remaining proteins, peptides, amino acids, RNA and DNA and any endotoxins and glycolipids that may interfere with subsequent separation steps from the sialylated oligosaccharide, preferably 3' sialylated oligosaccharide (preferably after its clarification). In this step, remaining proteins and related impurities can be removed in a conventional manner from the sialylated oligosaccharide, preferably 3' sialylated oligosaccharide. Preferably, the sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, are freed from residual proteins, salts, by-products, colors, endotoxins and other related impurities by ultrafiltration, nanofiltration, two-phase partitioning, reverse osmosis, microfiltration, activated carbon or carbon treatment, treatment with non-ionic surfactants, enzymatic digestion, tangential flow high performance filtration, tangential flow ultrafiltration, electrophoresis (e.g. using flat-plate polyacrylamide or sodium dodecyl sulfate-polyacrylamide gel electrophoresis (PAGE)), affinity chromatography (using affinity ligands, including, for example, DEAE-Sepharose, poly-L-lysine and polymyxin-B, endotoxin selective adsorbent matrices), ion exchange chromatography (e.g., but not limited to, cation exchange, anion exchange, mixed bed ion exchange, inside-out ligand attachment), hydrophobic interaction chromatography and / or gel filtration (i.e., size exclusion chromatography), in particular by chromatography, more particularly by ion exchange chromatography or hydrophobic interaction chromatography or ligand exchange chromatography or electrodialysis. With the exception of size exclusion chromatography, the remaining protein and related impurities are retained by the chromatographic medium or selected membrane.

[0312] In a further preferred embodiment, the method described herein also provides for the further purification of the sialylated oligosaccharides of the present invention, preferably 3' sialylated oligosaccharides. The further purification of the sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, can be achieved, for example, by using (activated) charcoal or carbon, nanofiltration, ultrafiltration, electrophoresis, enzyme treatment or ion exchange, temperature regulation, pH regulation or pH regulation with an alkaline or acidic solution to remove any remaining DNA, protein, LPS, endotoxin or other impurities. Alcohols, such as ethanol and aqueous alcohol mixtures can also be used. Another purification step is to achieve by crystallization, evaporation or precipitation of the sialylated oligosaccharides, preferably 3' sialylated oligosaccharides. Another purification step is drying, such as spray drying, freeze drying, spray freeze drying, freeze spray drying, belt drying, belt drying, vacuum belt drying, vacuum belt drying, drum drying, drum drying, vacuum drum drying or vacuum drum drying of the sialylated oligosaccharides, preferably 3' sialylated oligosaccharides produced.

[0313] In an exemplary embodiment, the isolation and purification of sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, is carried out in a process comprising the following steps in any order:

[0314] a) contacting the culture or incubation or a clarified version thereof with a nanofiltration membrane having a molecular weight cut-off (MWCO) of 600-3500 Da to ensure retention of the produced sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, and to allow passage of at least a portion of proteins, salts, by-products, colors and other relevant impurities,

[0315] b) subjecting the retentate from step a) to a diafiltration process using said membrane with an aqueous solution of an inorganic electrolyte and optionally subsequently with pure water to remove excess electrolyte,

[0316] c) and collecting the retentate enriched in said sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, in the form of a salt of a cation from said electrolyte.

[0317] In an alternative exemplary embodiment, the separation and purification of sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, is carried out in a process comprising the following steps in any order: subjecting the culture or incubation or a clarified version thereof to two membrane filtration steps using different membranes, wherein

[0318] - a membrane having a molecular weight cut-off of about 300 to about 500 Daltons, and

[0319] - The other membrane has a molecular weight cut-off of about 600 to about 800 Daltons.

[0320] In an alternative exemplary embodiment, the separation and purification of sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, is carried out by the following steps in any order, the method comprising treating the culture or incubation material or a clarified version thereof with a strong cation exchange resin in H+ form in one step, and treating the culture or incubation material or a clarified version thereof with a weak anion exchange resin in free base form in another step, wherein the steps can be carried out in any order.

[0321] In an alternative exemplary embodiment, the separation and purification of the sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, is carried out in the following manner. The culture or incubation containing the produced sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, biomass, culture medium components and contaminants is applied to the following purification steps:

[0322] i) separating biomass from a culture or incubation,

[0323] ii) cation exchanger treatment to remove positively charged species,

[0324] iii) anion exchanger treatment to remove negatively charged species,

[0325] iv) a nanofiltration step and / or an electrodialysis step,

[0326] A purified solution containing the produced sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, is provided, with a purity greater than or equal to 80%. Optionally, the purified solution is dried by any one or more drying steps selected from the list consisting of spray drying, freeze drying, spray freeze drying, freeze spray drying, strip drying, belt drying, vacuum strip drying, vacuum belt drying, drum drying, drum drying, vacuum drum drying or vacuum drum drying.

[0327] In alternative exemplary embodiments, the separation and purification of sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, is carried out in a process comprising the following steps in any order: enzymatic treatment of the culture or incubation; removal of biomass from the culture or incubation; ultrafiltration; nanofiltration; and a column chromatography step. Preferably, the column chromatography is a single column or multiple columns. Further preferably, the column chromatography step is a simulated moving bed chromatography. The simulated moving bed chromatography preferably comprises i) at least 4 columns, at least one of which comprises a weak or strong cation exchange resin; and / or ii) four zones I, II, III and IV with different flow rates; and / or iii) an eluent comprising water; and / or iv) an operating temperature of 15 degrees Celsius to 60 degrees Celsius.

[0328] In a specific embodiment, the present invention provides sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, produced by drying into a powder by any one or more drying steps selected from the list comprising spray drying, freeze drying, spray freeze drying, freeze spray drying, strip drying, belt drying, vacuum strip drying, vacuum belt drying, drum drying, drum drying, vacuum drum drying or vacuum drum drying, wherein the dry powder contains <15%-wt. of water, preferably <10%-wt. of water, more preferably <7%-wt. of water, and most preferably <5%-wt. of water.

[0329] Another aspect of the present invention provides the use of a sialyltransferase for producing sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL, the sialyltransferase having α-2,3-sialyltransferase activity towards galactose (Gal) residues of lactose and comprising an amino acid sequence, which:

[0330] - is at least 67.0%, at least 70.0%, at least 75.0%, at least 80.0%, at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to any of the amino acid sequences set forth in SEQ ID NOs 05, 01, 02, 03, 06, 07 or 08 over a stretch of at least 150, at least 160, at least 170, at least 180, at least 190, at least 200, at least 210, at least 220, at least 230, at least 240, at least 250, at least 260, at least 270, at least 280, at least 290 or at least 300 amino acid residues,

[0331] - is at least 55.0%, at least 60.0%, at least 65.0%, at least 70.0%, at least 75.0%, at least 80.0%, at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to any of the full-length amino acid sequences set forth in SEQ ID NOs 05, 01, 02, 03, 06, 07 or 08,

[0332] - is at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to the amino acid sequence set forth in SEQ ID NO 04 over a stretch of at least 150, at least 160, at least 170, at least 180, at least 190, at least 200, at least 210, at least 220, at least 230, at least 240, at least 250, at least 260, at least 270, at least 280, at least 290 or at least 300 amino acid residues,

[0333] - is at least 80.0%, at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to the full-length amino acid sequence of SEQ ID NO 04,

[0334] - is at least 60.0%, at least 65.0%, at least 70.0%, at least 75.0%, at least 80.0%, at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to the amino acid sequence of SEQ ID NO 12 over a stretch of at least 150, at least 160, at least 170, at least 180, at least 190, at least 200, at least 210, at least 220, at least 230, at least 240, at least 250, at least 260, at least 270, at least 280, at least 290 or at least 300 amino acid residues,

[0335] - is at least 45.0%, at least 50.0%, at least 55.0%, at least 60.0%, at least 65.0%, at least 70.0%, at least 75.0%, at least 80.0%, at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to the full-length amino acid sequence of SEQ ID NO 12, or

[0336] - as shown in any one of SEQ ID NO 05, 04, 12, 01, 02, 03, 06, 07 or 08.

[0337] Another aspect of the present invention provides the use of a sialyltransferase for producing 3' sialylated oligosaccharides, preferably 3' SL or 3' KDO-lactose, the sialyltransferase having α-2,3-sialyltransferase activity towards a galactose (Gal) residue of lactose and comprising an amino acid sequence, which:

[0338] - is at least 80.0%, at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to any of the full-length amino acid sequences set forth in SEQ ID NOs 05, 04, 12, 01, 02, 03, 06, 07 or 08, or

[0339] - as shown in any one of SEQ ID NO 05, 04, 12, 01, 02, 03, 06, 07 or 08.

[0340] Another aspect of the invention provides the use of a cell as described herein for producing sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL and / or 3' KDO-lactose.

[0341] Another aspect of the present invention provides i) the use of the method described herein for producing sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL and / or 3' KDO-lactose, ii) the use of the isolated nucleic acid molecule described herein for producing sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL and / or 3' KDO-lactose, or iii) the use of the vector described herein for producing sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL and / or 3' KDO-lactose.

[0342] In addition, the present invention also relates to sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, obtained by the method of the present invention. The sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, can be used to make preparations as food additives, prebiotics, symbiotics, for supplementing infant food, adult food, young animal feed, adult animal feed, or as therapeutic or pharmaceutically active compounds or for cosmetic applications. In a preferred embodiment, the preparation comprises at least one sialylated oligosaccharide, preferably 3' sialylated oligosaccharide, more preferably 3' SL and / or 3' KDO-lactose, which can be obtained by the method described herein, preferably obtained by the method described herein. In another preferred embodiment, a preparation is provided, which also includes at least one probiotic microorganism. In another preferred embodiment of the present invention, the preparation is a nutritional composition. In a more preferred embodiment, the preparation is a pharmaceutical preparation, a dietary supplement, a dairy beverage or an infant formula.

[0343] Utilizing the novel method, sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, can be easily and efficiently provided without the need for complex, time-consuming and costly synthetic processes.

[0344] To identify the sialylated oligosaccharides of the invention produced as described herein, preferably 3' sialylated oligosaccharides, the monosaccharide or monomer building blocks (e.g. monosaccharide or polysaccharide unit composition), the anomeric configuration of the side chains, the presence and position of substituents, the degree of polymerization / molecular weight and the mode of linkage can be identified by standard methods known in the art (e.g. methylation analysis, reductive cleavage, hydrolysis, GC-MS (gas chromatography-mass spectrometry), MALDI-MS (matrix-assisted laser desorption / ionization-mass spectrometry), ESI-MS (electrospray ionization-mass spectrometry), HPLC (high performance liquid chromatography with ultraviolet or refractive index detection), HPAEC-PAD (high performance anion exchange chromatography with pulsed amperometric detection), CE (capillary electrophoresis), IR (infrared) / Raman spectroscopy and NMR (nuclear magnetic resonance) spectroscopy techniques). The crystal structure can be solved using, for example, solid-state NMR, FT-IR (Fourier transform infrared spectroscopy) and WAXS (wide angle X-ray scattering). The degree of polymerization (DP), DP distribution and polydispersity can be determined, for example, by viscometry and SEC (SEC-HPLC, high performance size exclusion chromatography). To identify the monomeric components of sialylated oligosaccharides (preferably 3' sialylated oligosaccharides), methods such as acid-catalyzed hydrolysis, HPLC (high performance liquid chromatography) or GLC (gas-liquid chromatography) (after conversion to alditol acetate) can be used. To determine glycosidic bonds, sialylated oligosaccharides (preferably 3' sialylated oligosaccharides) are methylated in DMSO with methyl iodide and a strong base, hydrolyzed, reduced to partially methylated alditols, acetylated to methylated alditol acetates, and analyzed by GLC / MS (gas-liquid chromatography coupled to mass spectrometry). To determine the glycan sequence, partial depolymerization is performed using acids or enzymes to determine the structure. To identify the anomeric configuration, the sialylated oligosaccharide (preferably the 3' sialylated oligosaccharide) is subjected to enzymatic analysis, for example, by contacting it with an enzyme specific for a particular type of linkage (eg, β-galactosidase or α-glucosidase, etc.), and the product can be analyzed using NMR.

[0345] The isolated and preferably also purified sialylated oligosaccharides (preferably 3' sialylated oligosaccharides) as described herein are incorporated into food (e.g., human food or feed), dietary supplements, pharmaceutical ingredients, cosmetic ingredients or medicaments. In some embodiments, the sialylated oligosaccharides (preferably 3' sialylated oligosaccharides) are mixed with one or more ingredients suitable for food, feed, dietary supplements, pharmaceutical ingredients, cosmetic ingredients or medicaments.

[0346] In some embodiments, the dietary supplement comprises at least one prebiotic ingredient and / or at least one probiotic ingredient.

[0347] "Prebiotics" are substances that promote the growth of microorganisms that are beneficial to the host, particularly microorganisms in the gastrointestinal tract. In some embodiments, dietary supplements provide a variety of prebiotics, including 3' sialylated oligosaccharides, which are prebiotics produced and / or purified by the methods disclosed in this specification to promote the growth of one or more beneficial microorganisms. Examples of prebiotic ingredients of dietary supplements include other prebiotic molecules (e.g., HMOs) and plant polysaccharides (e.g., inulin, pectin, b-glucans, and xylooligosaccharides). "Probiotic" products typically contain live microorganisms that replace or increase the gastrointestinal microbiota, thereby benefiting the recipient. Examples of such microorganisms include Lactobacillus species (e.g., Lactobacillus acidophilus and Lactobacillus bulgaricus), Bifidobacterium species (e.g., Bifidobacterium animalis, Bifidobacterium longum, and Bifidobacterium infantis (e.g., Bi-26)), and Saccharomyces boulardii. In some embodiments, sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, produced and / or purified by the methods of this specification are administered orally in combination with such microorganisms.

[0348] Examples of other ingredients of dietary supplements include oligosaccharides (e.g., 2'-fucosyllactose, 3-fucosyllactose, 6'-sialyllactose), disaccharides (e.g., lactose), monosaccharides (e.g., glucose, galactose, L-fucose, sialic acid, glucosamine, and N-acetylglucosamine), thickeners (e.g., gum arabic), acidity regulators (e.g., trisodium citrate), water, skim milk, and flavorings.

[0349] In some embodiments, sialylated oligosaccharides (preferably 3' sialylated oligosaccharides) are incorporated into human infant foods (e.g., infant formula). Infant formula is typically a manufactured food for feeding infants as a complete or partial substitute for human breast milk. In some embodiments, infant formula is sold in powder form and prepared by mixing with water for feeding to infants in bottles or cups. The composition of infant formula is typically designed to roughly simulate human breast milk. In some embodiments, sialylated oligosaccharides (preferably 3' sialylated oligosaccharides) produced and / or purified by the methods of the present specification are included in infant formula to provide nutritional benefits similar to those provided by oligosaccharides in human breast milk. In some embodiments, sialylated oligosaccharides (preferably 3' sialylated oligosaccharides) are mixed with one or more ingredients of infant formula. Examples of infant formula ingredients include skim milk, a carbohydrate source (e.g., lactose), a protein source (e.g., whey protein concentrate and casein), a fat source (e.g., vegetable oils, such as palm oil, high oleic safflower oil, rapeseed oil, coconut oil and / or sunflower oil; and fish oil), vitamins (e.g., vitamins A, Bb, B12, C and D), minerals (e.g., potassium citrate, calcium citrate, magnesium chloride, sodium chloride, sodium citrate and calcium phosphate) and possibly human milk oligosaccharides (HMO). Such HMOs can include, for example, DiFL, lacto-N-triose II, LNT, LNnT, lacto-N-fucopentaose I, lacto-N-neofucopentaose, lacto-N-fucopentaose II, lacto-N-fucopentaose III, lacto-N-fucopentaose V, lacto-N-neofucopentaose V, lacto-N-difucohexaose I, lacto-N-difucohexaose II, 6'-galactosyl lactose, 3'-galactosyl lactose, lacto-N-hexaose, and lacto-N-neohexaose.

[0350] In some embodiments, the one or more infant formula ingredients include skim milk, a carbohydrate source, a protein source, a fat source, and / or vitamins and minerals.

[0351] In some embodiments, one or more infant formula ingredients include lactose, whey protein concentrate, and / or high oleic safflower oil.

[0352] In some embodiments, the concentration of sialylated oligosaccharides (preferably 3' sialylated oligosaccharides) in the infant formula is about the same as the concentration of sialylated oligosaccharides (preferably 3' sialylated oligosaccharides) typically present in human breast milk.

[0353] In some embodiments, sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, are incorporated into a feed formulation, wherein the feed is selected from the list comprising: pet food, animal milk replacer, veterinary product, veterinary feed supplement, nutritional supplement, post-weaning feed or starter feed.

[0354] As shown in the Examples herein, the methods and cells of the invention preferably provide at least one of the following further surprising advantages when using a sialyltransferase as described herein, compared to a method or cell using the same setup or enzyme or genetic background but without using a sialyltransferase as described herein:

[0355] - a higher titer (g / L) of sialylated oligosaccharides, preferably 3' sialylated oligosaccharides,

[0356] - a higher purity (g / L) of sialylated oligosaccharides, preferably 3' sialylated oligosaccharides,

[0357] - the purity (g / L) of sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, is equal to or greater than 80%, preferably equal to or greater than 85%, more preferably equal to or greater than 90%, even more preferably equal to or greater than 91%, even more preferably equal to or greater than 92%, even more preferably equal to or greater than 93%, even more preferably equal to or greater than 94%, even more preferably equal to or greater than 95%, even more preferably equal to or greater than 96%, even more preferably equal to or greater than 97%, even more preferably equal to or greater than 98%, even more preferably equal to or greater than 99%,

[0358] - higher lactose conversion, resulting in lower lactose concentration (g / L lactose) at the end of fermentation,

[0359] - lower sialic acid formation (g / L),

[0360] - a higher production rate r (grams of sialylated oligosaccharides / L / h, preferably grams of 3' sialylated oligosaccharides / L / h),

[0361] - a higher cell performance index CPI (grams of sialylated oligosaccharides / grams of X, preferably grams of 3' sialylated oligosaccharides / grams of X),

[0362] - a higher specific production rate Qp (grams of sialylated oligosaccharides / grams of X / h, preferably grams of 3'-sialylated oligosaccharides / grams of X / h),

[0363] - a higher yield Y for the carbon source used (grams of sialylated oligosaccharides / grams of carbon source used, preferably grams of 3'-sialylated oligosaccharides / grams of carbon source used),

[0364] - a higher yield Ys on sucrose (grams of sialylated oligosaccharides / grams of sucrose, preferably grams of 3'-sialylated oligosaccharides / grams of sucrose),

[0365] - a higher uptake / conversion rate Q of the carbon source used (grams of carbon source / grams of X / h),

[0366] - Higher sucrose uptake / conversion rate Qs (grams of sucrose / grams of X / h),

[0367] - higher lactose conversion / consumption rate rs (grams of lactose / h),

[0368] - higher secretion or excretion or extracellular transport of sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, and / or

[0369] -Higher growth rate of production host.

[0370] Unless otherwise defined, all technical and scientific terms used herein generally have the same meanings as those of ordinary skill in the art to which the invention belongs. Generally, the nomenclature used herein and the laboratory procedures in cell culture, molecular genetics, organic chemistry and nucleic acid chemistry and hybridization described above and below are well known and commonly used in the art. Standard techniques are used for nucleic acid and peptide synthesis. Generally, purification steps are carried out according to the instructions of the manufacturer.

[0371] Specific embodiments and examples may bring further advantages.It goes without saying that the features mentioned above and those still to be explained below can be used not only in the respectively specified combination but also in other combinations or alone, without departing from the scope of the present invention.

[0372] In addition, the present invention relates to the following specific embodiments:

[0373] 1. A method for producing sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL (Neu5Ac-α2,3-Gal-β1,4-Glc), the method comprising: contacting a sialyltransferase with a mixture comprising a donor (comprising a sialic acid residue) and an acceptor (selected from a list comprising an oligosaccharide or a disaccharide) under conditions where the sialyltransferase catalyzes the transfer of the sialic acid residue from the donor to the acceptor, thereby producing the sialylated oligosaccharide, preferably 3' sialylated oligosaccharide, more preferably 3' SL, wherein the sialyltransferase has α-2,3-sialyltransferase activity towards a galactose (Gal) residue of lactose, and comprising:

[0374] - an amino acid sequence that is at least 67.0% identical to any of the amino acid sequences shown in SEQ ID NOs 05, 01, 02, 03, 06, 07 or 08 over a stretch of at least 150 amino acid residues, preferably at least 200 amino acid residues,

[0375] - an amino acid sequence that is at least 85.0% identical to the amino acid sequence shown in SEQ ID NO 04 over a stretch of at least 150 amino acid residues, preferably at least 200 amino acid residues, or

[0376] - an amino acid sequence that is at least 60.0% identical to the amino acid sequence shown in SEQ ID NO 12 over a stretch of at least 150 amino acid residues, preferably at least 200 amino acid residues.

[0377] 2. The method according to embodiment 1, wherein the sialylated oligosaccharide is 3'SL and the acceptor is lactose.

[0378] 3. A method for producing sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL (Neu5Ac-α2,3-Gal-β1,4-Glc), the method comprising the following steps:

[0379] a) Provide

[0380] i. CMP-sialic acid,

[0381] ii. an acceptor, preferably lactose, and

[0382] iii. A sialyltransferase, wherein the sialyltransferase has α-2,3-sialyltransferase activity towards a galactose (Gal) residue of lactose, and comprises:

[0383] - an amino acid sequence that is at least 67.0% identical to any of the amino acid sequences shown in SEQ ID NOs 05, 01, 02, 03, 06, 07 or 08 over a stretch of at least 150 amino acid residues, preferably at least 200 amino acid residues,

[0384] - an amino acid sequence that is at least 85.0% identical to the amino acid sequence shown in SEQ ID NO 04 over a stretch of at least 150 amino acid residues, preferably at least 200 amino acid residues, or

[0385] - an amino acid sequence that is at least 60.0% identical to the amino acid sequence shown in SEQ ID NO 12 over a stretch of at least 150 amino acid residues, preferably at least 200 amino acid residues,

[0386] b) contacting the sialyltransferase and CMP-sialic acid with the acceptor (preferably lactose) under conditions where the sialyltransferase catalyzes the transfer of sialic acid residues from the CMP-sialic acid to the acceptor, thereby producing sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL (Neu5Ac-α2,3-Gal-β1,4-Glc),

[0387] c) preferably, isolating said produced sialylated oligosaccharides.

[0388] 4. A method according to any of the preceding embodiments, comprising: contacting a cell extract comprising the sialyltransferase with a mixture comprising a donor (comprising sialic acid residues) and an acceptor (comprising oligosaccharides or disaccharides) under conditions where the sialyltransferase catalyzes the transfer of sialic acid residues from the donor to the acceptor, thereby producing the sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SLs.

[0389] 5. The method according to any of the preceding embodiments, wherein the sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SLs are produced in a cell-free system.

[0390] 6. A method for producing sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL (Neu5Ac-α2,3-Gal-β1,4-Glc), the method comprising the following steps:

[0391] i. providing a cell, preferably a single cell, expressing, preferably heterologously expressing, more preferably overexpressing, even more preferably heterologously overexpressing a sialyltransferase, wherein the sialyltransferase has α-2,3-sialyltransferase activity towards a galactose (Gal) residue of lactose, and comprising:

[0392] - an amino acid sequence that is at least 67.0% identical to any of the amino acid sequences shown in SEQ ID NOs 05, 01, 02, 03, 06, 07 or 08 over a stretch of at least 150 amino acid residues, preferably at least 200 amino acid residues,

[0393] - an amino acid sequence that is at least 85.0% identical to the amino acid sequence shown in SEQ ID NO 04 over a stretch of at least 150 amino acid residues, preferably at least 200 amino acid residues, or

[0394] - an amino acid sequence that is at least 60.0% identical to the amino acid sequence shown in SEQ ID NO 12 over a stretch of at least 150 amino acid residues, preferably at least 200 amino acid residues,

[0395] ii. providing CMP-sialic acid, optionally, said CMP-sialic acid is produced by said cell, and

[0396] iii. providing an oligosaccharide or disaccharide, optionally produced by the cell, and

[0397] iv. culturing and / or incubating said cells under conditions allowing expression of said sialyltransferase (optionally, allowing production of said CMP-sialic acid and / or said oligo- or disaccharide),

[0398] v. Preferably, said sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SLs are isolated from said culture or incubation.

[0399] 7. The method according to embodiment 6, wherein the cell is a metabolically engineered cell, preferably wherein the cell is metabolically engineered for production of said sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SLs.

[0400] 8. The method according to any one of the preceding embodiments, wherein the sialyltransferase comprises:

[0401] an amino acid sequence that is at least 67.0%, at least 70.0%, at least 75.0%, at least 80.0%, at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to any of the amino acid sequences set forth in SEQ ID NOs 05, 01, 02, 03, 06, 07 or 08 over a stretch of at least 150, at least 160, at least 170, at least 180, at least 190, at least 200, at least 210, at least 220, at least 230, at least 240, at least 250, at least 260, at least 270, at least 280, at least 290 or at least 300 amino acid residues,

[0402] - an amino acid sequence that is at least 55.0%, at least 60.0%, at least 65.0%, at least 70.0%, at least 75.0%, at least 80.0%, at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to any of the full-length amino acid sequences set forth in SEQ ID NOs 05, 01, 02, 03, 06, 07 or 08,

[0403] an amino acid sequence that is at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to the amino acid sequence shown in SEQ ID NO 04 over a stretch of at least 150, at least 160, at least 170, at least 180, at least 190, at least 200, at least 210, at least 220, at least 230, at least 240, at least 250, at least 260, at least 270, at least 280, at least 290 or at least 300 amino acid residues,

[0404] - an amino acid sequence that is at least 80.0%, at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to the full-length amino acid sequence of SEQ ID NO 04,

[0405] an amino acid sequence that is at least 60.0%, at least 65.0%, at least 70.0%, at least 75.0%, at least 80.0%, at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to the amino acid sequence of SEQ ID NO 12 over a stretch of at least 150, at least 160, at least 170, at least 180, at least 190, at least 200, at least 210, at least 220, at least 230, at least 240, at least 250, at least 260, at least 270, at least 280, at least 290 or at least 300 amino acid residues,

[0406] - an amino acid sequence that is at least 45.0%, at least 50.0%, at least 55.0%, at least 60.0%, at least 65.0%, at least 70.0%, at least 75.0%, at least 80.0%, at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to the full-length amino acid sequence of SEQ ID NO 12, or

[0407] - an amino acid sequence as shown in any one of SEQ ID NOs 05, 04, 12, 01, 02, 03, 06, 07 or 08.

[0408] 9. The method according to any one of embodiments 6 to 8, wherein the culture medium contains at least one carbon source selected from the group consisting of glucose, fructose, sucrose and glycerol.

[0409] 10. The method according to any of the preceding embodiments, wherein the culture or incubation medium contains at least one compound selected from the group consisting of lactose, galactose, glucose, sialic acid and CMP-sialic acid.

[0410] 11. The method according to any of the preceding embodiments, wherein the sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SLs are recovered from the culture or incubation medium and / or cells.

[0411] 12. The method according to any of the preceding embodiments, comprising:

[0412] i) using a culture or incubation medium comprising at least one precursor and / or receptor for producing said sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL, and / or

[0413] ii) adding to the culture or incubation medium at least one precursor and / or acceptor feed for producing said sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SLs,

[0414] Preferably, the precursor is selected from the list comprising sialic acid, CMP-sialic acid, glucose, galactose and UDP-galactose,

[0415] Preferably the acceptor is lactose.

[0416] 13. The method according to any of the preceding embodiments, comprising at least one of the following steps:

[0417] i) using a culture or incubation medium comprising at least one precursor and / or receptor;

[0418] ii) adding at least one precursor and / or acceptor feed to the culture or incubation medium in the reactor or incubator, wherein the total volume of the reactor or incubator ranges from 250 mL to 10.000 mL 3 (cubic meters), preferably added in a continuous manner, and preferably such that the final volume of the culture or incubation medium does not exceed three times, preferably does not exceed two times, and more preferably is less than two times the volume of the culture or incubation medium before the addition of the precursor and / or acceptor feed;

[0419] iii) adding at least one precursor and / or acceptor feed to the culture or incubation medium in the reactor or incubator, wherein the total volume of the reactor or incubator ranges from 250 mL to 10.000 mL 3 (cubic meters), preferably added in a continuous manner, and preferably the final volume of the culture or incubation medium is not more than three times, preferably not more than two times, more preferably less than two times the volume of the culture or incubation medium before adding the precursor and / or acceptor feed, and the pH value of the precursor and / or acceptor feed is preferably set at 2.0 to 10.0, and the temperature of the precursor and / or acceptor feed is preferably maintained at 20°C to 80°C;

[0420] iv) adding at least one precursor and / or acceptor feed to the culture or incubation medium in a continuous manner via a precursor and / or acceptor feed solution over a period of 1 day, 2 days, 3 days, 4 days, 5 days;

[0421] v) adding at least one precursor and / or receptor feed to the culture or incubation medium in a continuous manner over a period of 1 day, 2 days, 3 days, 4 days, 5 days via a precursor and / or receptor feed solution, wherein the concentration of the precursor and / or receptor feed solution is 50 g / L, preferably 75 g / L, more preferably 100 g / L, more preferably 125 g / L, more preferably 150 g / L, more preferably 175 g / L, more preferably 200 g / L, more preferably 225 g / L, more preferably 250 g / L , more preferably 275 g / L, more preferably 300 g / L, more preferably 325 g / L, more preferably 350 g / L, more preferably 375 g / L, more preferably 400 g / L, more preferably 450 g / L, more preferably 500 g / L, even more preferably, 550 g / L, most preferably 600 g / L; wherein preferably, the pH of the precursor and / or acceptor feed solution is set at 2.0 to 10.0, wherein preferably, the temperature of the precursor and / or acceptor feed solution is maintained at 20°C to 80°C;

[0422] The method produces the sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL, in a concentration of at least 50 g / L, preferably at least 75 g / L, more preferably at least 90 g / L, more preferably at least 100 g / L, more preferably at least 125 g / L, more preferably at least 150 g / L, more preferably at least 175 g / L, more preferably at least 200 g / L in the final volume of the culture or incubation.

[0423] Wherein preferably, the precursor is selected from the list comprising sialic acid, CMP-sialic acid, glucose, galactose and UDP-galactose, and wherein preferably the acceptor is lactose.

[0424] 14. The method according to any one of embodiments 1 to 12, comprising at least one of the following steps:

[0425] i) using a culture or incubation medium comprising at least 50 g, more preferably at least 75 g, more preferably at least 100 g, more preferably at least 120 g, more preferably at least 150 g of precursor per liter of initial reactor or incubator volume, wherein the reactor or incubator volume ranges from 250 mL to 10.000 m 3 (cubic meter);

[0426] ii) using a culture or incubation medium comprising at least 50 g, more preferably at least 75 g, more preferably at least 100 g, more preferably at least 120 g, more preferably at least 150 g of receptor per liter of initial reactor or incubator volume, wherein the reactor or incubator volume ranges from 250 mL to 10.000 mL 3 (cubic meter);

[0427] iii) adding a precursor feed to the culture or incubation medium in the reactor or incubator, the precursor feed comprising at least 50 g, more preferably at least 75 g, more preferably at least 100 g, more preferably at least 120 g, more preferably at least 150 g of precursor per liter of initial reactor or incubator volume, wherein the reactor or incubator volume ranges from 250 mL to 10.000 mL 3 (cubic meters), preferably added in a continuous manner, and preferably such that the final volume of the culture or incubation medium does not exceed three times, preferably does not exceed two times, more preferably is less than two times the volume of the culture or incubation medium before the addition of the precursor feed;

[0428] iv) adding a receptor feed to the culture or incubation medium in the reactor or incubator, the receptor feed comprising at least 50 grams, more preferably at least 75 grams, more preferably at least 100 grams, more preferably at least 120 grams, more preferably at least 150 grams of receptor per liter of initial reactor or incubator volume, wherein the reactor or incubator volume ranges from 250 mL to 10.000 mL 3 (cubic meters), preferably added in a continuous manner, and preferably so that the final volume of the culture or incubation medium does not exceed three times, preferably does not exceed two times, more preferably less than two times the volume of the culture or incubation medium before adding the acceptor feed;

[0429] v) adding a precursor feed to the culture or incubation medium, the precursor feed comprising at least 50 g, more preferably at least 75 g, more preferably at least 100 g, more preferably at least 120 g, more preferably at least 150 g of precursor per liter of initial reactor or incubator volume, wherein the total reactor or incubator volume ranges from 250 mL to 10.000 mL 3 (cubic meters), preferably added in a continuous manner, and preferably such that the final volume of the culture or incubation medium does not exceed three times, preferably does not exceed two times, more preferably is less than two times the volume of the culture or incubation medium before the addition of the precursor feed, and wherein the pH of the precursor feed is preferably set at 2.0 to 10.0, and wherein the temperature of the precursor feed is preferably maintained at 20° C. to 80° C.;

[0430] vi) adding a receptor feed to the culture or incubation medium, the receptor feed comprising at least 50 grams, more preferably at least 75 grams, more preferably at least 100 grams, more preferably at least 120 grams, more preferably at least 150 grams of receptor per liter of initial reactor or incubator volume, wherein the total reactor or incubator volume ranges from 250 mL to 10.000 m 3 (cubic meters), preferably added in a continuous manner, and preferably the final volume of the culture or incubation medium is not more than three times, preferably not more than two times, more preferably less than two times the volume of the culture or incubation medium before adding the acceptor feed, and the pH value of the acceptor feed is preferably set at 2.0 to 10.0, and the temperature of the acceptor feed is preferably maintained at 20°C to 80°C;

[0431] vii) adding precursor and / or acceptor feed to the culture or incubation medium in a continuous manner via a precursor and / or acceptor feed solution over 1 day, 2 days, 3 days, 4 days, 5 days;

[0432] viii) adding a precursor feed to the culture or incubation medium in a continuous manner over a period of 1 day, 2 days, 3 days, 4 days, 5 days via a precursor feed solution, wherein the concentration of the precursor feed solution is 50 g / L, preferably 75 g / L, more preferably 100 g / L, more preferably 125 g / L, more preferably 150 g / L, more preferably 175 g / L, more preferably 200 g / L, more preferably 225 g / L, more preferably 250 g / L, more preferably 275 g / L, more preferably 300 g / L, more preferably 325 g / L, more preferably 350 g / L, more preferably 375 g / L, more preferably 400 g / L, more preferably 450 g / L, more preferably 500 g / L, even more preferably 550 g / L, most preferably 600 g / L; wherein, preferably, the pH value of the precursor feed solution is set at 2.0 to 10.0, and preferably, the temperature of the precursor feed solution is maintained at 20° C. to 80° C.;

[0433] ix) adding acceptor feed to the culture or incubation medium in a continuous manner over a period of 1 day, 2 days, 3 days, 4 days, 5 days via an acceptor feed solution, wherein the concentration of the acceptor feed solution is 50 g / L, preferably 75 g / L, more preferably 100 g / L, more preferably 125 g / L, more preferably 150 g / L, more preferably 175 g / L, more preferably 200 g / L, more preferably 225 g / L, more preferably 250 g / L, more preferably 275 g / L, more preferably 300 g / L, more preferably 325 g / L, more preferably 350 g / L, more preferably 375 g / L, more preferably 400 g / L, more preferably 450 g / L, more preferably 500 g / L, even more preferably 550 g / L, most preferably 600 g / L; wherein, preferably, the pH of the acceptor feed solution is set at 2.0 to 10.0, and preferably, the temperature of the acceptor feed solution is maintained at 20° C. to 80° C.;

[0434] The method produces the sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL, in a concentration of at least 50 g / L, preferably at least 75 g / L, more preferably at least 90 g / L, more preferably at least 100 g / L, more preferably at least 125 g / L, more preferably at least 150 g / L, more preferably at least 175 g / L, more preferably at least 200 g / L in the final volume of the culture or incubation.

[0435] Wherein preferably the precursor is selected from the list comprising sialic acid, CMP-sialic acid, glucose, galactose and UDP-galactose, and preferably the acceptor is lactose.

[0436] 15. A metabolically engineered cell for producing sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL (Neu5Ac-α2,3-Gal-β1,4-Glc), wherein the cell has been metabolically engineered to have, preferably express, a sialyltransferase, wherein the sialyltransferase has α-2,3-sialyltransferase activity towards galactose (Gal) residues of lactose and comprises:

[0437] - an amino acid sequence that is at least 67.0% identical to any of the amino acid sequences shown in SEQ ID NOs 05, 01, 02, 03, 06, 07 or 08 over a stretch of at least 150 amino acid residues, preferably at least 200 amino acid residues,

[0438] - an amino acid sequence that is at least 85.0% identical to the amino acid sequence shown in SEQ ID NO 04 over a stretch of at least 150 amino acid residues, preferably at least 200 amino acid residues, or

[0439] - an amino acid sequence that is at least 60.0% identical to the amino acid sequence shown in SEQ ID NO 12 over a stretch of at least 150 amino acid residues, preferably at least 200 amino acid residues.

[0440] 16. The cell according to embodiment 15, wherein the sialyltransferase comprises:

[0441] an amino acid sequence that is at least 67.0%, at least 70.0%, at least 75.0%, at least 80.0%, at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to any of the amino acid sequences set forth in SEQ ID NOs 05, 01, 02, 03, 06, 07 or 08 over a stretch of at least 150, at least 160, at least 170, at least 180, at least 190, at least 200, at least 210, at least 220, at least 230, at least 240, at least 250, at least 260, at least 270, at least 280, at least 290 or at least 300 amino acid residues,

[0442] - an amino acid sequence that is at least 55.0%, at least 60.0%, at least 65.0%, at least 70.0%, at least 75.0%, at least 80.0%, at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to any of the full-length amino acid sequences set forth in SEQ ID NOs 05, 01, 02, 03, 06, 07 or 08,

[0443] an amino acid sequence that is at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to the amino acid sequence shown in SEQ ID NO 04 over a stretch of at least 150, at least 160, at least 170, at least 180, at least 190, at least 200, at least 210, at least 220, at least 230, at least 240, at least 250, at least 260, at least 270, at least 280, at least 290 or at least 300 amino acid residues,

[0444] - an amino acid sequence that is at least 80.0%, at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to the full-length amino acid sequence of SEQ ID NO 04,

[0445] an amino acid sequence that is at least 60.0%, at least 65.0%, at least 70.0%, at least 75.0%, at least 80.0%, at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to the amino acid sequence of SEQ ID NO 12 over a stretch of at least 150, at least 160, at least 170, at least 180, at least 190, at least 200, at least 210, at least 220, at least 230, at least 240, at least 250, at least 260, at least 270, at least 280, at least 290 or at least 300 amino acid residues,

[0446] - an amino acid sequence that is at least 45.0%, at least 50.0%, at least 55.0%, at least 60.0%, at least 65.0%, at least 70.0%, at least 75.0%, at least 80.0%, at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to the full-length amino acid sequence of SEQ ID NO 12, or

[0447] - an amino acid sequence as shown in any one of SEQ ID NOs 05, 04, 12, 01, 02, 03, 06, 07 or 08.

[0448] 17. The cell according to any one of embodiments 15 or 16, wherein the cell contains a nucleic acid molecule comprising a polynucleotide sequence encoding the sialyltransferase.

[0449] 18. The cell according to any one of embodiments 15 to 17, wherein the cell is a bacterium, a fungus, a yeast, a plant cell, an animal cell or a protozoan cell,

[0450] - preferably, the bacterium is an Escherichia coli strain, more preferably, the Escherichia coli strain is a K-12 strain, even more preferably, the Escherichia coli K-12 strain is Escherichia coli MG1655,

[0451] - preferably, the fungus belongs to a genus selected from the group comprising Rhizopus, Myxomyces, Penicillium, Mucor or Aspergillus,

[0452] - preferably, the yeast belongs to a genus selected from the group comprising Saccharomyces, Zygosaccharomyces, Pichia, Komagata, Hansenula, Yarrowia, Stamosaccharomyces, Kluyveromyces or Debaryomyces,

[0453] - preferably, the plant cell is an algae cell or is derived from a tobacco, alfalfa, rice, tomato, cotton, rapeseed, soybean, maize or corn plant,

[0454] -Preferably, the animal cell is derived from a non-human mammal, bird, fish, invertebrate, reptile, amphibian or insect, or is a genetically engineered cell line derived from a human cell other than an embryonic stem cell. More preferably, the human and non-human mammal cell is an epithelial cell, embryonic kidney cell, fibroblast, COS cell, Chinese hamster ovary (CHO) cell, mouse myeloma cell, NIH-3T3 cell, non-mammary adult stem cell or a derivative thereof. More preferably, the insect cell is derived from Spodoptera frugiperda, Bombyx mori, Spodoptera brassicae, Trichoplusia ni or Drosophila melanogaster.

[0455] - Preferably, the protozoan cell is a Leishmania cell.

[0456] 19. The cell according to any one of embodiments 15 to 18, wherein the cell is selected from the group consisting of prokaryotic cells and eukaryotic cells, preferably selected from the group consisting of yeast cells, bacterial cells, archaeal cells, algae cells and fungal cells.

[0457] 20. A cell according to any one of embodiments 15 to 19, wherein the cell comprises a nucleic acid molecule comprising a polynucleotide sequence encoding the sialyltransferase and operably linked to a control sequence recognized by the cell, wherein the sequence is foreign to the cell, the sequence further i) integrated in the genome of the cell and / or ii) presented to the cell on a vector.

[0458] 21. The cell according to any one of embodiments 15 to 20, wherein the cell comprises an at least partially inactivated catabolic pathway for selected mono-, di- or oligosaccharides involved in and / or requiring the synthesis of sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SLs.

[0459] 22. An isolated nucleic acid molecule encoding a sialyltransferase, wherein the sialyltransferase has alpha-2,3-sialyltransferase activity towards a galactose (Gal) residue of lactose, and comprising:

[0460] - an amino acid sequence that is at least 67.0% identical to any of the amino acid sequences shown in SEQ ID NOs 05, 01, 02, 03, 06, 07 or 08 over a stretch of at least 150 amino acid residues, preferably at least 200 amino acid residues,

[0461] - an amino acid sequence that is at least 85.0% identical to the amino acid sequence shown in SEQ ID NO 04 over a stretch of at least 150 amino acid residues, preferably at least 200 amino acid residues, or

[0462] - an amino acid sequence that is at least 60.0% identical to the amino acid sequence shown in SEQ ID NO 12 over a stretch of at least 150 amino acid residues, preferably at least 200 amino acid residues.

[0463] 23. The isolated nucleic acid molecule of embodiment 22, wherein the sialyltransferase comprises:

[0464] an amino acid sequence that is at least 67.0%, at least 70.0%, at least 75.0%, at least 80.0%, at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to any of the amino acid sequences set forth in SEQ ID NOs 05, 01, 02, 03, 06, 07 or 08 over a stretch of at least 150, at least 160, at least 170, at least 180, at least 190, at least 200, at least 210, at least 220, at least 230, at least 240, at least 250, at least 260, at least 270, at least 280, at least 290 or at least 300 amino acid residues,

[0465] - an amino acid sequence that is at least 55.0%, at least 60.0%, at least 65.0%, at least 70.0%, at least 75.0%, at least 80.0%, at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to any of the full-length amino acid sequences set forth in SEQ ID NOs 05, 01, 02, 03, 06, 07 or 08,

[0466] an amino acid sequence that is at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to the amino acid sequence shown in SEQ ID NO 04 over a stretch of at least 150, at least 160, at least 170, at least 180, at least 190, at least 200, at least 210, at least 220, at least 230, at least 240, at least 250, at least 260, at least 270, at least 280, at least 290 or at least 300 amino acid residues,

[0467] - an amino acid sequence that is at least 80.0%, at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to the full-length amino acid sequence of SEQ ID NO 04,

[0468] an amino acid sequence that is at least 60.0%, at least 65.0%, at least 70.0%, at least 75.0%, at least 80.0%, at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to the amino acid sequence of SEQ ID NO 12 over a stretch of at least 150, at least 160, at least 170, at least 180, at least 190, at least 200, at least 210, at least 220, at least 230, at least 240, at least 250, at least 260, at least 270, at least 280, at least 290 or at least 300 amino acid residues,

[0469] - an amino acid sequence that is at least 45.0%, at least 50.0%, at least 55.0%, at least 60.0%, at least 65.0%, at least 70.0%, at least 75.0%, at least 80.0%, at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to the full-length amino acid sequence of SEQ ID NO 12, or

[0470] - an amino acid sequence as shown in any one of SEQ ID NOs 05, 04, 12, 01, 02, 03, 06, 07 or 08.

[0471] 24. A vector comprising the nucleic acid molecule of any one of embodiments 22 or 23.

[0472] 25. Use of a sialyltransferase for producing sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL, the sialyltransferase having α-2,3-sialyltransferase activity towards galactose (Gal) residues of lactose, and comprising:

[0473] an amino acid sequence that is at least 67.0%, at least 70.0%, at least 75.0%, at least 80.0%, at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to any of the amino acid sequences set forth in SEQ ID NOs 05, 01, 02, 03, 06, 07 or 08 over a stretch of at least 150, at least 160, at least 170, at least 180, at least 190, at least 200, at least 210, at least 220, at least 230, at least 240, at least 250, at least 260, at least 270, at least 280, at least 290 or at least 300 amino acid residues,

[0474] - an amino acid sequence that is at least 55.0%, at least 60.0%, at least 65.0%, at least 70.0%, at least 75.0%, at least 80.0%, at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to any of the full-length amino acid sequences set forth in SEQ ID NOs 05, 01, 02, 03, 06, 07 or 08,

[0475] an amino acid sequence that is at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to the amino acid sequence shown in SEQ ID NO 04 over a stretch of at least 150, at least 160, at least 170, at least 180, at least 190, at least 200, at least 210, at least 220, at least 230, at least 240, at least 250, at least 260, at least 270, at least 280, at least 290 or at least 300 amino acid residues,

[0476] - an amino acid sequence that is at least 80.0%, at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to the full-length amino acid sequence of SEQ ID NO 04,

[0477] an amino acid sequence that is at least 60.0%, at least 65.0%, at least 70.0%, at least 75.0%, at least 80.0%, at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to the amino acid sequence of SEQ ID NO 12 over a stretch of at least 150, at least 160, at least 170, at least 180, at least 190, at least 200, at least 210, at least 220, at least 230, at least 240, at least 250, at least 260, at least 270, at least 280, at least 290 or at least 300 amino acid residues,

[0478] - an amino acid sequence that is at least 45.0%, at least 50.0%, at least 55.0%, at least 60.0%, at least 65.0%, at least 70.0%, at least 75.0%, at least 80.0%, at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to the full-length amino acid sequence of SEQ ID NO 12, or

[0479] - an amino acid sequence as shown in any one of SEQ ID NOs 05, 04, 12, 01, 02, 03, 06, 07 or 08.

[0480] 26. Use of a cell according to any one of embodiments 15 to 21 for producing sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL.

[0481] 27. Use of the method according to any one of embodiments 1 to 14 for producing sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SLs.

[0482] 28. Use of the isolated nucleic acid molecule according to any one of embodiments 22 or 23 for producing sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SLs.

[0483] 29. Use of the vector according to embodiment 24 for producing sialylated oligosaccharides, preferably 3' sialylated oligosaccharides, more preferably 3' SL.

[0484] In addition, the present invention relates to the following preferred embodiments:

[0485] 1. A method for producing 3' sialylated oligosaccharides, the method comprising: contacting a sialyltransferase with a mixture comprising a donor and an acceptor under conditions where the sialyltransferase catalyzes the transfer of sialic acid residues from the donor to the acceptor, the donor comprising sialic acid residues, the acceptor being selected from a list comprising oligosaccharides or disaccharides, thereby producing the 3' sialylated oligosaccharides, wherein the sialyltransferase has α-2,3-sialyltransferase activity towards galactose (Gal) residues of lactose and comprises an amino acid sequence that is at least 80.0% identical to any one of the full-length amino acid sequences shown in SEQ ID NOs 05, 04, 12, 01, 02, 03, 06, 07 or 08,

[0486] Preferably, the produced 3' sialylated oligosaccharides are isolated.

[0487] 2. The method according to preferred embodiment 1, comprising: contacting a cell extract containing the sialyltransferase with a mixture containing a donor (containing sialic acid residues) and an acceptor (containing oligosaccharides or disaccharides) under conditions where the sialyltransferase catalyzes the transfer of sialic acid residues from the donor to the acceptor, thereby producing the 3' sialylated oligosaccharide.

[0488] 3. The method according to any one of the preferred embodiments 1 or 2, wherein the 3' sialylated oligosaccharides are produced in a cell-free system.

[0489] 4. A method for producing 3' sialylated oligosaccharides, the method comprising the following steps:

[0490] i. providing a cell, preferably a single cell, which expresses, preferably heterologously expresses, more preferably overexpresses, even more preferably heterologously overexpresses a sialyltransferase, wherein the sialyltransferase has α-2,3-sialyltransferase activity towards galactose (Gal) residues of lactose and comprises an amino acid sequence that is at least 80.0% identical to any one of the full-length amino acid sequences shown in SEQ ID NOs 05, 04, 12, 01, 02, 03, 06, 07 or 08,

[0491] ii. providing CMP-sialic acid, optionally said CMP-sialic acid is produced by said cell, and

[0492] iii. providing an oligosaccharide or disaccharide, optionally produced by the cell, and

[0493] iv. culturing and / or incubating said cell under conditions: a) allowing expression of said sialyltransferase, optionally allowing production of said CMP-sialic acid and / or said oligosaccharide or disaccharide, and b) wherein said sialyltransferase catalyzes the trans...

Claims

1. A method for producing 3' sialylated oligosaccharides, the method comprising: contacting a sialyltransferase with a mixture comprising a donor comprising a sialic acid residue and an acceptor selected from a list comprising an oligosaccharide or a disaccharide under conditions where the sialyltransferase catalyzes the transfer of a sialic acid residue from the donor to the acceptor, thereby producing the 3' sialylated oligosaccharide, wherein the sialyltransferase has α-2,3-sialyltransferase activity towards galactose (Gal) residues of lactose and comprises an amino acid sequence that is at least 80.0% identical to any one of the full-length amino acid sequences set forth in SEQ ID NOs 05, 04, 12, 01, 02, 03, 06, 07 or 08, Preferably, the produced 3' sialylated oligosaccharides are isolated.

2. The method according to claim 1, comprising: The cell extract containing the sialyltransferase is contacted with a mixture containing a donor containing a sialic acid residue and an acceptor containing an oligosaccharide or disaccharide under conditions where the sialyltransferase catalyzes the transfer of the sialic acid residue from the donor to the acceptor, thereby producing the 3' sialylated oligosaccharide.

3. The method according to any one of claims 1 or 2, wherein the 3' sialylated oligosaccharides are produced in a cell-free system.

4. A method for producing 3' sialylated oligosaccharides, the method comprising the following steps: i. providing a cell, preferably a single cell, which expresses, preferably heterologously expresses, more preferably overexpresses, even more preferably heterologously overexpresses a sialyltransferase, wherein the sialyltransferase has α-2,3-sialyltransferase activity towards galactose (Gal) residues of lactose and comprises an amino acid sequence that is at least 80.0% identical to any one of the full-length amino acid sequences shown in SEQ ID NOs 05, 04, 12, 01, 02, 03, 06, 07 or 08, ii. providing CMP-sialic acid, optionally said CMP-sialic acid is produced by said cell, and iii. providing an oligosaccharide or disaccharide, optionally produced by the cell, and iv. culturing and / or incubating said cell under conditions: a) allowing expression of said sialyltransferase, optionally allowing production of said CMP-sialic acid and / or said oligosaccharide or disaccharide, and b) wherein said sialyltransferase catalyzes the transfer of a sialic acid residue from said CMP-sialic acid to said acceptor, thereby producing said 3' sialylated oligosaccharide, v. Preferably, said 3' sialylated oligosaccharides are isolated from said culturing or incubation.

5. The method according to claim 4, wherein the cell is a metabolically engineered cell, preferably wherein the cell is metabolically engineered for the production of the 3' sialylated oligosaccharide.

6. A method according to any one of the preceding claims, wherein the sialic acid residue is selected from at least one of Neu4Ac; Neu5Ac; Neu4,5Ac2; Neu5,7Ac2; Neu5,8Ac2; Neu5,9Ac2; Neu4,5,9Ac3; Neu5,7,9Ac3; Neu5,8,9Ac3; Neu4,5,7,9Ac4; Neu5,7,8,9Ac4; Neu4,5,7,8,9Ac5; Neu5Gc and 2-keto-3-deoxymannooctolonic acid (KDO).

7. The method according to any one of the preceding claims, wherein the donor comprising sialic acid residues is CMP-sialic acid, preferably selected from CMP-Neu5Ac, CMP-Neu4Ac, CMP-Neu5Ac9N3, CMP-Neu4,5Ac2, CMP-Neu5,7Ac2, CMP-Neu5,9Ac2, CMP-Neu5,7(8,9)Ac2, CMP-Neu5,7(8,9)Ac2, CMP-N-glycolylneuraminic acid (CMP-Neu5Gc) and CMP-KDO.

8. The method according to any one of the preceding claims, wherein the 3' sialylated oligosaccharide is 3' sialyllactose (3' SL, Neu5Ac-α2,3-Gal-β1,4-Glc) and the acceptor is lactose.

9. The method according to any one of the preceding claims, wherein the 3' sialylated oligosaccharide is a sugar modified with KDO, preferably 3' KDO-lactose, and the acceptor is lactose.

10. A method according to any one of the preceding claims, wherein the 3' sialylated oligosaccharide is a mixture of 3' sialyllactose and 3' KDO-lactose and the acceptor is lactose.

11. The method according to any one of the preceding claims, wherein the sialyltransferase comprises: - an amino acid sequence that is at least 80.0%, at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to any of the full-length amino acid sequences shown in SEQ ID NOs 05, 04, 12, 01, 02, 03, 06, 07 or 08, or - the amino acid sequence shown in any one of SEQ ID NOs 05, 04, 12, 01, 02, 03, 06, 07 or 08.

12. A method according to any one of the preceding claims, comprising: i) using a culture or incubation medium comprising at least one precursor and / or receptor for producing said 3' sialylated oligosaccharides, and / or ii) adding to the culture or incubation medium at least one precursor and / or acceptor feed for producing said 3' sialylated oligosaccharides, Preferably, the precursor is selected from the list comprising sialic acid, CMP-sialic acid, CMP-Neu5Ac, CMP-KDO, glucose, galactose and UDP-galactose, Preferably, the acceptor is lactose.

13. The method according to claim 12, wherein the culture or incubation medium comprises - at least one carbon source selected from the group consisting of glucose, fructose, sucrose and glycerol, and / or - at least one compound selected from the group consisting of lactose, galactose, glucose, sialic acid, CMP-sialic acid, CMP-Neu5Ac and CMP-KDO.

14. A method according to any one of the preceding claims, wherein the 3' sialylated oligosaccharides are recovered from culture or incubation medium and / or cells.

15. The method according to any one of the preceding claims, wherein the method results in the production of 45 g / L or more, preferably 50 g / L or more, more preferably 60 g / L or more 3' sialylated oligosaccharides.

16. The method according to any one of the preceding claims, wherein the method results in the production of 10 g / L or less, preferably 5 g / L or less, more preferably 1 g / L or less, even more preferably 0.5 g / L or less, even more preferably 0.4 g / L or less, even more preferably 0.3 g / L or less, even more preferably 0.2 g / L or less, most preferably 0.1 g / L or less 3'-KDO-lactose.

17. The method according to any one of the preceding claims, wherein the method results in the production of a sugar mixture comprising 45 g / L or more, preferably 50 g / L or more, more preferably 60 g / L or more 3' sialylated oligosaccharides and 10 g / L or less, preferably 5 g / L or less, more preferably 1 g / L or less, even more preferably 0.5 g / L or less, even more preferably 0.4 g / L or less, even more preferably 0.3 g / L or less, even more preferably 0.2 g / L or less, most preferably 0.1 g / L or less of a KDO-modified sugar, wherein the 3' sialylated oligosaccharide is not 3'KDO-lactose, preferably the 3' sialylated oligosaccharide is 3'SL, and the KDO-modified sugar is preferably KDO-lactose, more preferably 3'-KDO-lactose.

18. A metabolically engineered cell for producing 3' sialylated oligosaccharides, wherein the cell has been metabolically engineered to have a sialyltransferase, preferably to express a sialyltransferase, wherein the sialyltransferase has α-2,3-sialyltransferase activity towards a galactose (Gal) residue of lactose and comprises an amino acid sequence that is at least 80.0% identical to any one of the full-length amino acid sequences shown in SEQ ID NO 05, 04, 12, 01, 02, 03, 06, 07 or 08.

19. The cell of claim 18, wherein the sialyltransferase comprises: - an amino acid sequence that is at least 80.0%, at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to any of the full-length amino acid sequences shown in SEQ ID NOs 05, 04, 12, 01, 02, 03, 06, 07 or 08, or - the amino acid sequence shown in any one of SEQ ID NOs 05, 04, 12, 01, 02, 03, 06, 07 or 08.

20. The cell according to any one of claims 18 or 19, wherein the cell is selected from the group consisting of prokaryotic cells and eukaryotic cells, preferably selected from the group consisting of yeast cells, bacterial cells, archaeal cells, algae cells and fungal cells.

21. The cell of any one of claims 18 to 20, wherein the cell comprises a nucleic acid molecule comprising a polynucleotide sequence encoding the sialyltransferase and operably linked to a control sequence recognized by the cell, wherein the sequence is foreign to the cell, the sequence further i) integrated in the genome of the cell and / or ii) presented to the cell on a vector.

22. The cell according to any one of claims 18 to 21, wherein the cell comprises an at least partially inactivated catabolic pathway for selected mono-, di- or oligosaccharides involved in and / or requiring the synthesis of 3' sialylated oligosaccharides.

23. An isolated nucleic acid molecule encoding a sialyltransferase, wherein the sialyltransferase has α-2,3-sialyltransferase activity towards a galactose (Gal) residue of lactose and comprises an amino acid sequence that is at least 80.0% identical to any one of the full-length amino acid sequences set forth in SEQ ID NOs 05, 04, 12, 01, 02, 03, 06, 07 or 08.

24. The isolated nucleic acid molecule of claim 23, wherein the sialyltransferase comprises: - an amino acid sequence that is at least 80.0%, at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to any of the full-length amino acid sequences shown in SEQ ID NOs 05, 04, 12, 01, 02, 03, 06, 07 or 08, or - the amino acid sequence shown in any one of SEQ ID NOs 05, 04, 12, 01, 02, 03, 06, 07 or 08.

25. A vector comprising the nucleic acid molecule of any one of claims 23 or 24.

26. Use of a sialyltransferase for producing 3' sialylated oligosaccharides, the sialyltransferase having α-2,3-sialyltransferase activity towards galactose (Gal) residues of lactose, and comprising: - an amino acid sequence that is at least 80.0%, at least 85.0%, at least 90.0%, at least 95.0%, at least 96.0%, at least 97.0%, at least 98.0%, at least 98.5% or at least 99.0% identical to any of the full-length amino acid sequences shown in SEQ ID NOs 05, 04, 12, 01, 02, 03, 06, 07 or 08, or - the amino acid sequence shown in any one of SEQ ID NOs 05, 04, 12, 01, 02, 03, 06, 07 or 08.

27. Use of a cell according to any one of claims 18 to 21 for producing 3' sialylated oligosaccharides.

28. Use of the method according to any one of claims 1 to 17 for producing 3' sialylated oligosaccharides.

29. Use of the isolated nucleic acid molecule according to any one of claims 23 or 24 for producing 3' sialylated oligosaccharides.

30. Use of the vector according to claim 25 for producing 3' sialylated oligosaccharides.

Citation Information

Patent Citations

  • Anodes for electrochemical purposes

    EP0002017A1

  • In vivo synthesis of sialylated compounds

    WO2018122225A1

  • Nutrient compositions and methods, kits, and cell compositions for producing the same

    WO2021067641A1

  • Live cell constructs for production of cultured milk product and methods using the same

    WO2021141762A1

  • Live cell constructs for biosynthetic milk production and related products and methods

    WO2021142241A1